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ZUSAMMENFASSUNG 
Insulinanaloga wurden entwickelt mit dem Ziel den Blutzuckerspiegel bei Diabetikern besser 
zu kontrollieren. Insulinanaloga haben im Vergleich zu Normalinsulin eine veränderte 
Aminosäuresequenz. Dies hat Veränderungen in relevanten biochemischen Eigenschaften zur 
Folge, z.B. in der Affinität für den Insulinrezeptor (IR) und den Typ-I Insulin-like Growth 
Factor Receptor (IGF-IR), sowie in der Dissoziationsgeschwindigkeit vom IR. Das Ergebnis 
kann eine erhöhte mitogene Aktivität der Insulinanaloga im Vergleich zu Normalinsulin sein. 
Normales Brustdrüsenepithel zeigt eine starke Expression von IR und IGF-IR, und 
Brustkrebszellen zeigen häufig sogar eine Überexpression beider Rezeptoren. Aus diesem 
Grund ist das Brustdrüsenepithel ein empfindliches Zielorgan für Insulinanaloga und deren 
proliferationssteigernde Wirkung. In der Tat resultierte die Behandlung weiblicher Sprague-
Dawley Ratten mit dem Insulinanalogon B10Asp in einer signifikanten Zunahme der Inzidenz 
von Mammakarzinomen im Vergleich zu Normalinsulin. Von allen Insulinanaloga, die 
heutzutage therapeutisch eingesetzt werden, wurde nur für Insulin Glargin (Lantus®) eine 
standardisierte zweijährige Karzinogenitätsstudie durchgeführt. In dieser Studie zeigten 
Insulin Glargin und Normalinsulin keine signifikanten Unterschiede in der Tumorinzidenz. 
Allerdings wurde eine extrem hohe Mortalitätsrate bei allen behandelten Tiergruppen 
berichtet, was die Schlussfolgerung, dass Insulin Glargin das Krebsrisiko nicht erhöht, infrage 
stellt. Es gibt nur wenige in vitro-Studien zur proliferativen Wirkung von Insulinanaloga auf 
Brustzelllinien und diese sind wenig aussagekräftig. Auch wurde der biochemische 
Mechanismus der proliferativen Wirkung von Insulinanaloga nicht geklärt. Die vorliegende 
Arbeit hatte das Ziel, die proliferative Potenz therapeutisch eingesetzter Insulinanaloga 
detailliert in insulinresponsiven epithelialen Brustzelllinien zu untersuchen und zu vergleichen 
und den molekularen und biochemischen Mechanismus der proliferativen Wirkung 
aufzuklären. Die Rolle des IR und des IGF-IR und der entsprechenden Signal-
transduktionswege wurde analysiert für Normalinsulin und das Insulinanalogon, das den 
stärksten proliferativen Effekt zeigte.  
Aus einer Gruppe von sieben Zelllinien zeigten MCF7 Zellen (eine Tumorzelllinie) und 
MCF10A Zellen (eine benigne Zelllinie) die stärkste proliferative Antwort auf Insulin. In 
Proliferationsassays mit MCF10A Zellen zeigten die vier untersuchten Insulinanaloga (Insulin 
Aspart, Insulin Lispro, Insulin Glargin und Insulin Detemir) gleich starke Wirkung wie 
Normalinsulin (menschliches Insulin und Rinderinsulin). In Proliferationsassays mit MCF7 
Zellen induzierte Insulin Glargin jedoch eine signifikant stärkere Proliferation als 
Normalinsulin und die anderen drei Insulinanaloga. Dieser Befund wurde durch BrdU-
Inkorporationstests an MCF7 Zellen bestätigt.  
Die Aktivierung der beiden durch Insulin stimulierten Signalwege – PI3K und MAPK 
Signalweg – wurde durch Bestimmung des Phosphorylierungsgrads wichtiger Signalmoleküle 
(Akt und GSK3α/β für den PI3K-Weg und Erk1/2 für den MAPK-Weg) untersucht. In 
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MCF10A Zellen war die Phosphorylierung von GSK3α/β und Erk1/2 nach Behandlung mit 
allen Insulinanaloga und Normalinsulin gleich stark. Interessanterweise war jedoch die 
Phosphorylierung von Akt nach Insulin Glargin - Behandlung signifikant stärker als nach 
Behandlung mit Normalinsulin. In MCF7 Zellen verursachte Insulin Glargin eine sehr starke 
Phosphorylierung aller drei Signalproteine. Diese war signifikant stärker als bei Normal-
insulin und den anderen Insulinanaloga. Die Verwendung spezifischer Inhibitoren in 
Proliferationsassays ergab, dass Insulin Glargin in MCF7 Zellen hauptsächlich den MAPK-
Weg aktiviert.  
Um die Rolle von IR und IGF-IR bei der starken mitogenen Aktivität von Insulin Glargin zu 
klären, wurden IR und IGF-IR durch RNAi-Technik jeweils spezifisch herunterreguliert. Die 
Aktivierung der Signalwege und Proliferation unter Knockdown-Bedingungen ergab 
eindeutig, dass Insulin Glargin den IGF-IR aktiviert, während die anderen Substanzen den IR 
aktivieren. Daraus folgt, dass die erhöhte proliferative Aktivität von Insulin Glargin auf der 
Aktivierung des IGF-IR beruht. Immunpräzipitation des IGF-IR und anschließende Analyse 
des Tyrosinphosphorylierungsgrades zeigten eine wesentlich stärkere Phosphorylierung in 
Zellen, die mit Insulin Glargin behandelt worden waren. Dies erhärtet die Befunde aus den 
Knockdown-Experimenten. Weiterhin wurden die Expressionsspiegel von Cyclin D1, eines 
IGF-I Zielgens, durch quantitative RT-PCR bestimmt. Sie ergaben eine höhere Expression 
von Cyclin D1 in Insulin Glargin - behandelten Zellen im Vergleich zu Normalinsulin. Dies 
bestätigt noch einmal die Aktivierung von IGF-IR durch Insulin Glargin. 
Um zu klären, ob Insulinanaloga möglicherweise den bekannten Cross-talk zwischen IR/IGF-
IR und Estrogenrezeptor-α (ERα) aktivieren, wurde sowohl die Zunahme des 
Phosphorylierungsgrads von ERα an Ser118 als auch die Induktion der ERE-abhängigen 
Luciferasegenexpression bestimmt. Im Vergleich zu Normalinsulin induzierte Insulin Glargin 
eine signifikant stärkere ERα-Phosphorylierung an Ser118, aber nur eine leichte Steigerung 
der Luciferase-Aktivität. Da der ERα durch Insulin Glargin nur schwach aktiviert wurde, ist 
es unwahrscheinlich, dass dieser Mechanismus wesentlich zur starken mitogenen Wirkung 
von Insulin Glargin beiträgt. Zum Schluss wurde durch Wundheilungs-, Transwell- und 
Matrigel- Assays geprüft, ob Insulin Glargin tumorpromovierendes Potential besitzt. Die 
Tests ergaben eine ähnliche migrationssteigernde Wirkung von Insulin Glargin und 
Normalinsulin in MCF7 Zellen.   
Zusammenfassend lässt sich sagen, dass Normalinsulin und drei der untersuchten 
Insulinanaloga den IR und den PI3K-Signalweg aktivieren. Insulin Glargin aktiviert 
außerdem den IGF-IR und den MAPK-Signalweg und stellt ein starkes Mitogen in 
Brustkrebszellen dar, welche eine hohe IGF-IR Expression aufweisen. Möglicherweise birgt 
deshalb die Behandlung mit Insulin Glargin ein Risiko für Brustkrebspatientinnen und für 
Frauen mit bisher nicht entdeckten Tumoren oder Tumorvorstufen.  
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1 SUMMARY 
Insulin analogues have been developed with the aim to provide better glycaemic control to 
diabetic patients. They are generated by modifying the insulin backbone which, however, may 
alter relevant biochemical characteristics such as the affinity to insulin receptor and type I 
insulin-like growth factor receptor (IGF-IR), and the insulin receptor dissociation rate. As a 
result insulin analogues may exhibit stronger mitogenic potency than regular insulin. Normal 
mammary epithelial cells show high expression of insulin receptor and IGF-IR and mammary 
cancer cells frequently even show overexpression of both receptors, thus suggesting 
mammary epithelial cells to be a sensitive target for insulin analogue - mediated proliferation. 
Indeed, treatment of female Sprague-Dawley rats with the insulin analogue B10Asp resulted 
in strong increase in the incidence of mammary tumours. Of all the insulin analogues 
available nowadays for therapeutical use, a standard two-year carcinogenicity study has been 
performed only for Insulin Glargine (Lantus®). The study showed similar incidence of 
mammary tumours in rats treated with Insulin Glargine or normal insulin. However, this study 
reported a very high mortality rate in all experimental groups thus raising questions on the 
conclusions drawn. In vitro studies on the effect of insulin analogues on mammary cell lines 
are scarce and lack comprehensiveness. In addition, the biochemical mechanism of the 
proliferative effect of the insulin analogues has not been clarified. This thesis aimed to study 
and compare in detail the proliferative potency of insulin analogues available for therapeutical 
use in insulin responsive mammary epithelial cell lines and to clarify the molecular and 
biochemical mechanism behind the proliferative potency. The role of insulin receptor, IGF-IR 
and related signalling pathways was analysed for the insulin analogue showing the strongest 
proliferative effect in comparison to regular insulin. 
Among a panel of seven mammary epithelial cell lines, MCF7 (a tumour cell line) and 
MCF10A (a benign cell line) showed the strongest insulin response. Proliferation assays on 
MCF10A cells demonstrated equipotency of four insulin analogues (Insulin Aspart, Insulin 
Lispro, Insulin Glargine and Insulin Detemir) to regular insulins (human and bovine insulin). 
However, proliferation assays performed in MCF7 cells revealed that Insulin Glargine 
induced significantly stronger proliferation than regular insulin and the other three insulin 
analogues. This finding was corroborated by BrdU incorporation studies in MCF7 cells.  
Activation of the two insulin-related signalling pathways - PI3K and MAPK pathway - was 
determined by studying the phosphorylation status of key signalling molecules (Akt and 
GSK3α/β for PI3K and Erk1/2 for MAPK pathway). In MCF10A cells, all insulin analogues 
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were equipotent to regular insulin in inducing phosphorylation of GSK3α/β and Erk1/2. 
Interestingly, Insulin Glargine induced significantly higher phosphorylation of Akt in 
comparison to regular insulin in MCF10A cells. On the contrary, in MCF7 cells, Insulin 
Glargine induced strong phosphorylation of the three signalling molecules studied. The 
signalling potency of Insulin Glargine was significantly stronger than that of regular insulin 
and all other insulin analogues. Use of specific inhibitors showed that MAPK is the major 
proliferation pathway activated by Insulin Glargin in MCF7 cells.   
In order to determine the contribution of insulin receptor and IGF-IR to the strong mitogenic 
potency of Insulin Glargine, the RNAi technique was utilized to specifically target insulin 
receptor and IGF-IR. Study of signalling pathways and proliferation under knockdown 
conditions clearly demonstrated the activation of IGF-IR by Insulin Glargine whereas the 
other compounds activated the insulin receptor. Thus, the increased proliferative ability of 
Insulin Glargine in comparison to regular insulin is the result of IGF-IR activation. IGF-IR 
immunoprecipitated from cells treated with Insulin Glargine or regular insulin showed much 
higher tyrosine phosphorylation levels in the Insulin Glargine - treated cells, which 
substantiates the findings from the knockdown experiments. Moreover, analysis of expression 
levels of cyclin D1, an IGF-I responsive gene, by quantitative RT-PCR showed higher 
expression levels in MCF7 cells treated with Insulin Glargine than in cells treated with regular 
insulin, again corroborating the strong activation of IGF-IR by Insulin Glargine. 
In order to clarify the potential activation of the established cross-talk between insulin 
receptor/IGF-IR and estrogen receptor-α (ERα) by insulin analogues, we determined the 
activation of ERα by analysing the phosphorylation status of Ser118 at ERα as well as ERE-
dependent luciferase gene expression. In comparison to regular insulin, Insulin Glargine 
induced significantly stronger phosphorylation of ERα at Ser118 and slightly higher luciferase 
activity. However, since ERα was only weakly activated by Insulin Glargine, modulation of 
ERα activity is unlikely to play a strong role in rendering high proliferative ability to Insulin 
Glargine. Finally, the possible tumour-promoting potential of Insulin Glargine was studied by 
wound healing, transwell and matrigel assays. The assays demonstrated similar migration-
inducing potential of Insulin Glargine and regular human insulin in MCF7 cells.   
In summary, this study shows that different from regular insulin and other insulin analogues 
studied, which activate the insulin receptor and the PI3K pathway, Insulin Glargine activates 
the IGF-IR and the MAPK pathway too, and is a strong mitogen in breast cancer cells 
showing high IGF-IR expression. Insulin Glargine may therefore be of risk for patients with 
breast cancer or as yet undetected (pre-) cancerous lesions.  
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2 INTRODUCTION 
2.1 Insulin  
2.1.1 Function  
Insulin is a ~ 6 kDa polypeptide hormone secreted by β-cells of the ‘islets of Langerhans’ in 
the pancreas. Together with glucagon, a hormone secreted by α-cells of pancreas, insulin 
maintains glucose homeostasis in the blood. Insulin has been demonstrated to have multiple 
biological effects in virtually all tissues. Its actions can be broadly categorised as metabolic 
actions and mitogenic actions. Metabolic actions of insulin comprise increased uptake of 
glucose, amino acids and fatty acids by target cells, increased expression and activity of 
enzymes involved in synthesis of glycogen (e.g., phosphofructokinase-2 and glycogen 
synthase), proteins and lipids, and decreased activity of enzymes involved in degradation of 
carbohydrates, proteins and lipids (Saltiel and Kahn, 2001). These varied metabolic effects 
make insulin the most potent anabolic hormone known. The main target tissues for metabolic 
actions of insulin are skeletal muscles, cardiac muscles, adipose tissue and liver. In muscles 
and adipose tissue, insulin induces translocation of the GLUT4, insulin-dependent glucose 
transporter, to the plasma membrane. Skeletal muscles are responsible for 75% of insulin-
dependent glucose disposal whereas adipose tissue account for only a small fraction (Klip and 
Paquet, 1990). In liver cells, glucose is taken up by the activity of GLUT2, the high Km 
insulin-independent glucose transporter (Mueckler, 1994). Furthermore, in the liver insulin 
regulates the expression of glycolytic and gluconeogenic enzymes.  
In addition to metabolic actions, insulin has also been demonstrated to elicit mitogenic 
response. In fact, results from knockout mice indicate that insulin receptor is not required for 
glucose metabolism in the embryo but rather for proper embryonic development. Insulin 
receptor knockout mice show 90% size of the control mice at birth. A few days after birth 
they die due to diabetic ketoacidosis indicating the importance of insulin in post-natal glucose 
metabolism (Accili et al., 1996; Joshi et al., 1996). Recent studies have additionally suggested 
a role of precursor insulin molecules (preproinsulin and proinsulin) along with insulin in 
emryonic development (Perez-Villamil, 1994; Hernandez-Sanchez, 2005). Furthermore, 
during early stages of retinal development, the physiological cell death is regulated by locally 
produced insulin/proinsulin, thus alluding a role for insulin as a survival factor (Diaz, 2000). 
Insulin is required for the optimal growth of several normal and cancer cell lines. Moreover, 
Introduction   6  
insulin has been demonstrated to be involved in proliferation and differentiation of B-
lymphocytes, T-lymphocytes and adipocytes (Spiegelman and Flier, 1996; Belfiore, 2007). 
The adipose tissue specific knockout mouse model of insulin receptor displays defective fat 
cell formation (Bluher et al., 2002). Interestingly, the recent study on fat cell-specific 
disruption of the insulin receptor gene demonstrated increased lifespan in these mice 
compared to control mice, suggesting a special role for insulin-signalling pathway of adipose 
tissue in longevity. Insulin and insulin receptor also play important roles in associative 
learning (Zhao and Alkon, 2001). Interruption of insulin production and insulin receptor 
activity results in learning and memory deficits. Hyperinsulinemia has been demonstrated to 
be one of the risk factors for Alzheimer's disease (Kidd, 2008). Insulin has been shown to be 
involved in modifying neurotransmitter release at synapses and in modulating the activities of 
both excitatory and inhibitory postsynaptic receptors such as NMDA and GABA receptors, 
respectively (Zhao and Alkon, 2001). In summary, insulin has pleiotropic effects on various 
tissues. This thesis is mainly concerned with the mitogenic effect of insulin.  
2.1.2 Insulin synthesis  
The primary product of the insulin gene is a 110 amino acid long preproinsulin molecule (Fig. 
2.1). Preproinsulin contains an amino-terminal signal sequence that is required for the 
precursor hormone to pass through the endoplasmic reticulum (ER). After entering the ER, 
the signal sequence is proteolytically removed to form proinsulin. Proinsulin is first processed 
by ‘protein disulfide isomerase’ to form three disulfide bonds in the molecule. This process 
has been demonstrated to occur in ER (Dodson, 1998). Thereafter, proinsulin is sequestered 
within Zn2+ and Ca2+ rich secretory vesicles of the Golgi apparatus, wherein proinsulin forms 
hexameric complexes with Zn2+ and Ca2+ ions (Dunn, 2005). Proteolytic enzymes like Ca2+ 
dependent prohormone convertases (PC1 and PC2; Bailyes, 1991) and exoprotease 
(carboxypeptidase E) act on proinsulin molecule to form the mature insulin molecule of 51 
amino acids. Like proinsulin, mature insulin is present in Golgi secretory vesicles as 
hexameric complexes containing Zn2+ and Ca2+ ions. These hexameric insulin complexes 
have very low solubility and are normally present as crystals within the mature secretory 
vesicles. Additionally, a catalytic activity of PC1 has been suggested to enhance targeting of 
processed insulin to the mature secretory granules (Kuliawat, 2000). The mature insulin 
molecule consists of 2 chains (A and B chain) linked together by two disulphide bonds 
(between A7 and B7, and A20 and B19). The A-chain consists of 21 amino acids including 
another disulfide bond (A6 and A11) and the B-chain consists of 31 amino acids.   
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Figure 2.1 Post translational processing of preproinsulin molecule to generate the mature 
insulin molecule.   (Taken from Beta Cell Biology Consortium website).   
2.1.3 Insulin secretion 
Insulin secretion from β-cells is a tightly regulated process (Fig. 2.2). The secretion of insulin 
can be induced by fatty acids, amino acids, and ionophores, but physiologically, the most 
important secretagogue is glucose (Hellman, 1975; McClenaghan et al., 1994; Henquin, 2000; 
Haber et al., 2003). After the meal, blood glucose level increases resulting in the entry of the 
glucose into the β-cells via GLUT2, an insulin-independent glucose transporter. Increased 
glycolysis and cellular respiration raises the level of ATP (or ATP/ADP ratio) in the cell. The 
high ATP/ADP ratio inactivates the ATP-dependent potassium channel.  Consequently, 
potassium ions accumulate inside the cell and this causes depolarization of the cell membrane. 
The calcium channels on β-cells are voltage-gated. Depolarization of the membrane opens up 
these channels and allows calcium ions entry in the cell. Finally, the increase in calcium levels 
triggers fusion of insulin storage granules to the plasma membrane and thus exocytotic release 
of insulin.  
Establishing the role of insulin itself in insulin secretion from β-cells has been a controversial 
issue. Insulin has either been shown to be not at all involved, or stated to be essential, or even 
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a negative regulator (Leibiger et al., 2008). However, recent conditional knockout mice 
models for proteins involved in insulin signalling pathway (like insulin receptor, IRS-1, IRS-2 
and PKB) show impaired glucose tolerance due to defective insulin secretion.  
 
Figure 2.2 Schematic diagram demonstrating insulin secretion from a typical β-cell (Taken from 
Beta Cell Biology Consortium website). 
Similar experiments on an established cell line of β-cell line, MIN6, yielded consistent results 
thus favouring the positive regulation of insulin secretion from β-cells by insulin (Da Silva-
Xavier et al., 2004). Finally, effect of insulin on its own release from β-cells has been 
suggested to be dependent on the insulin concentration (Jimenez-Feltstrom et al., 2004). Low 
dosage of insulin (0.05 to 0.1nM) stimulates insulin release, concentrations between 1nM and 
100nM have no effect on insulin release and higher concentrations result in inhibition of 
insulin exocytosis.  
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2.2 Insulin Receptor 
2.2.1 General information 
Insulin exerts its pleiotropic effects by binding to and activating its cognate receptor, insulin 
receptor (IR). Insulin receptor is a member of the tyrosine kinase receptor superfamily and is 
expressed by all tissues though the receptor numbers may widely differ. The insulin receptor 
has a heterotetrameric structure consisting of two α-subunits (MW of 110 kDa each) and two 
β-subunits (MW of 97 kDa each) and all subunits are held together by disulphide bonds (Fig. 
2.3). Alternate splicing of insulin receptor gene can produce two isoforms – IR-A lacking 
exon 11 and IR-B with full transcript. IR-A has been shown to be the predominant isoform of 
insulin receptor in fetal life and in many cancer cells (Frasca et al., 1999). The α-subunit of 
insulin receptor is an extracellular subunit and possesses the insulin binding domain. 
Although both α-subunits of a α2β2 holoreceptor may theoretically bind an insulin molecule, 
the receptor exhibits negative cooperativity and only one high affinity insulin binding site 
(Lee et al., 1993). Experiments have shown that the occupancy of one insulin binding domain 
decreases the affinity of the other insulin binding domain by 100-fold (Pang and Shafer, 
1984). 
 
 
 
 
 
 
 
 
 
 
Inactive IR Active IR
Insulin
Intracellular
Extracellular
Figure 2.3 Insulin induced autophosphorylation of insulin receptor.  Insulin (green circles) binds 
to the α-subunit of insulin receptor (IR) and activates it by inducing autophosphorylation at tyrosine 
residues in the β-subunit. The important tyrosine residues are at 950, 1158, 1162 and 1163 amino acid 
position.  
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The β-subunit consists of an extracellular part via which it is anchored to the α-subunit, a 
transmembrane region and an intracellular part which contains phosphorylation sites and 
intrinsic tyrosine kinase activity (Taylor, 1991). The α-subunit exerts inhibitory effect on the 
intrinsic kinase activity of the β-subunit. Proteolytic cleavage of the α-subunits or deletion 
mutants of α-subunits have been shown to relieve this inhibition (White and Kahn, 1994). 
Interestingly, a point mutation (Val664 → Glu) in the transmembrane segment of insulin 
receptor also partially relieves the inhibitory effect of the α-subunit on the β-subunit thus 
suggesting multiple regulation of the tyrosine kinase activity of the β-subunit (Longo et al., 
1992). The binding of insulin to the α-subunit causes a conformational change in the α-
subunit. Consequently, the inhibitory effect of the α-subunit on the tyrosine kinase activity of 
the β-subunit is relieved. The first event in tyrosine kinase activation is binding of ATP to the 
β-subunits and subsequent autophosphorylation of the receptor. 
The insulin receptor phosphorylates itself by a trans - mechanism. Structural studies reveal 
that the kinase domains of the two β-subunits are in juxtaposition so that one β-subunit can 
phosphorylate the other subunit (Lee et al., 1993). The most important autophosphorylation 
sites are tyrosine residues at positions 950 (intracellular juxtamembrane region of β-subunit), 
1158, 1162 and 1163 (tyrosine kinase domain). Autophosphorylation of these tyrosine 
residues stimulates tyrosine kinase activity by 10-20 fold (White et al., 1988). Once 
autophosphorylated, the binding of insulin to the insulin receptor is no longer required and the 
receptor can be inactivated only by dephosphorylation or internalization (Taylor, 1991).  
2.2.2 Insulin receptor signalling pathway 
The activation of the β-subunit results in the phosphorylation of several intracellular 
substrates like insulin receptor substrate family of proteins (IRS), Src-homology-2-containing 
protein (Shc), Grb2-associated binder-1 (Gab1), Cbl, and adaptor protein containing PH and 
SH2 domains (APS). The most important and well characterized intracellular substrates of 
insulin receptor are IRS family of proteins (IRS 1-4). These proteins are involved in important 
insulin receptor function like glycogen synthesis, lipid synthesis, glucose uptake, cell growth 
and differentitation. IRS-1 and IRS-2 proteins are approximately 180kDa, IRS-3 is 60kDa and 
IRS-4 is approximately 160kDa. IRS-1 and IRS-2 are the major signalling molecules in the 
insulin signalling pathway and are widely distributed (Taniguchi et al., 2006). Even though 
IRS-1 and IRS-2 are 43% identical in terms of amino acid sequence homology, their functions 
are not inter-changeable. IRS-1 knockout mice exhibit growth retardation, insulin resistance 
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and impaired glucose tolerance but do not develop overt diabetes (Araki et al., 1994; 
Tamemoto et al., 1994). IRS-2 knockout mice show defective growth in some tissues like 
certain regions of brain, retina and islets of Langerhans, insulin resistance, glucose intolerance 
and are severely diabetic (Sesti et al., 2001). IRS-1 and IRS-2 double knockout mice are non-
viable. In contrast to IRS-1 and IRS-2, IRS-3 and IRS-4 are redundant in function and in mice 
these proteins were found to be expressed only in adipocytes, brain and embryonic tissues. 
IRS-3 knockout mice showed normal growth, glucose homeostasis, and glucose transport in 
adipocytes (Liu et al., 1999). Interestingly, a functional copy of IRS-3 has not been reported 
in humans raising questions regarding its importance in humans (Bjornholm et al., 2002). 
Targeted disruption of IRS-4 gene in mice resulted in only mild defects in growth, 
reproduction, and glucose homeostasis (Fantin et al., 2000). IRS-1/2 interact with the insulin 
receptor via their PH (pleckstrin-homology) domain and PTB (phosphotyrosine-binding) 
domain. These proteins have up to 20 tyrosine residues which can undergo phosphorylation 
by insulin receptor. These phosphorylated tyrosines serve as docking site for other 
intracellular molecules that contain Src-homology-2-domains (SH2 domains) (Taniguchi et 
al., 2006).  
Other intracellular substrates of active insulin receptor perform diverse functions. Cbl 
protooncogene is involved in insulin-stimulated glucose uptake. Shc activation is involved in 
induction of cell proliferation (Saltiel and Pessin, 2002). The detailed description of important 
signalling pathways activated by insulin receptor is presented below. 
2.2.2.1 PI3K signalling pathway 
The PI3K signalling pathway is the major pathway activated by insulin. This pathway elicits 
both metabolic and mitogenic responses in the cells. PI3K is the most upstream signalling 
molecule of this pathway. It consists of two subunits – p85 (regulatory subunit) and p110 
(catalytic subunit). The regulatory subunit, p85, has been reported to have at least eight 
isoforms. The exact role of these different isoforms in the regulation of insulin action is not 
clear (Pons et al., 1995). The p85 subunit interacts via its two SH2 domains with the 
phosphotyrosine motifs of IRS proteins (Ogawa, 1998). Binding of the p85 subunit to IRS 
results in the recruitment of p110 subunit to p85 and thus in the activation of the catalytic 
activity of PI3K (Fig. 2.4). The p110 subunit catalyzes phosphorylation of 
phosphatidylinositol (4,5)-bisphosphate (PIP2) and generates  phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). Inhibitors against PI3K or transfection with dominant negative 
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constructs of the gene block insulin-mediated glucose transport, glycogen and lipid synthesis 
thus highlighting the importance of PI3K in the metabolic actions of insulin (Saltiel and Kahn, 
2001).  PIP3 binds to the pleckstrin homology (PH) domain of a variety of signalling 
molecules and thus influences glucose uptake, glycogen synthesis, and cell growth. The most 
important binding partner of PIP3 is phosphoinositide-dependent kinase 1and 2 (PDK1/2), for 
which PIP3 is an allosteric regulator. 
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Figure 2.4 PI3K pathway activation by active insulin receptor. PI3K pathway is the major pathway 
activated by insulin receptor (IR). It induces glucose uptake, glycogen synthesis, protein synthesis, cell 
growth and differentiation. In addition, it has anti-apoptotic effect. 
Akt, also known as protein kinase B (PKB), is a serine-threonine protein kinase. It has an 
amino-terminal PH domain, a central catalytic domain and a short regulatory domain at 
carboxy-terminus. The PIP3 recruits Akt to the plasma membrane by interacting with the PH 
domain of Akt protein. Once tethered to the membrane, Akt protein is phosphorylated at 
Thr308 and Ser473 by activated PDK1 and PDK2, respectively (Andjelkovic et al., 1997; 
Bellacosa et al., 1998). Activated Akt is another critical node in insulin signalling pathway. It 
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induces protein synthesis in the cell by interacting with mTOR (Nave et al., 1999). In 
addition, activated Akt has also been demonstrated to be associated with GLUT4 vesicles 
suggesting its role in glucose uptake (Kupriyanova et al., 1999). Furthermore, activated Akt 
directly phosphorylates FOXO1 at Ser256. FOXO1 are a class of transcription factors which 
upregulate expression of gluconeogenic genes. Phosphorylation of FOXO1 allows it to 
interact with 14-3-3, a cytoplasmic adapter protein. Consequently, it is sequestered to the 
cytoplasm, resulting in inhibition of gluconeogenesis (Tran et al., 2003). Activated Akt plays 
an important role in enhancing cell survival both directly and indirectly. Bad protein is a Bcl-
2 family member protein and in unphosphorylated state is bound to anti-apoptotic factors like 
Bcl-2 and Bcl-xl. Activated Akt directly phosphorylates Bad protein on Ser136 which results 
in the sequestration of Bad protein to 14-3-3 and release of anti-apoptotic factors (Datta et al., 
1997). Additionally, activated Akt has been demonstrated to enhance the degradation of IκB 
resulting in nuclear translocation of NF-κB and subsequent transcription of caspase inhibitors 
IAP1 and IAP2 and pro-survival Bcl-2 family members, Bcl-XL and Bfl-1/A1 (Dutta et al., 
2006). An important downstream target of Akt is GSK3α/β, a serine-threonine protein kinase 
which is a negative regulator of glycogen synthesis. Phosphorylation of GSK3α/β results in its 
inactivation. Inactivation of GSK3α/β restores the glycogen synthase activity which then 
catalyzes conversion of glucose to glycogen (Taniguchi et al., 2006).  
To summarise, PI3K pathway is the major mediator of the anabolic effects of insulin. Its 
activation results in increase in glucose uptake, glycogen synthesis, protein synthesis, cell 
proliferation and inhibition of gluconeogenesis and apoptosis.  
2.2.2.2 CAP-Cbl signalling pathway 
This signalling pathway is specifically involved in glucose uptake and collaborates with PI3K 
pathway for proper translocation of GLUT4 vesicles to the plasma membrane (Chiang et al., 
2003). The Cbl proto-oncogene is a direct intracellular substrate of the insulin receptor. 
Studies have shown that Cbl does not directly interact with insulin receptor and is recruited to 
insulin receptor by APS. APS binds to the phosphotyrosine residue of the activated insulin 
receptor via its SH2 domain. This results in its phosphorylation at tyrosine. Phosphorylated 
APS recruits Cbl to the insulin receptor where it is phosphorylated and activated. Activated 
Cbl forms a complex with CAP (Cbl Associated Protein) and activates TC10, a small GTPase. 
TC10 is activated specifically by insulin and disruption of its activation blocks insulin- 
stimulated glucose transport and GLUT4 translocation (Chiang et al., 2001). The signalling 
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events downstream of TC10 are not very clear but the net effect of TC10 activation is GLUT4 
translocation to the plasma membrane and thus increase in glucose uptake by the cell.  
2.2.2.3 MAPK signalling pathway 
MAPK pathway is another important pathway activated by insulin. This pathway is well-
known for its proliferative effect on cells. The first major event in activation of the MAPK 
signalling pathway is activation of Ras protein (Fig. 2.5). Ras proteins (H-Ras, N-Ras and K-
Ras) are 21 kDa GTPases that are attached to the cell membrane by prenylation. All the three 
isoforms are ubiquitously expressed. However, as all three isoforms have different lipid 
anchors, the cellular response can be modulated by selective targeting of the isoforms to 
different cellular compartments and signalling complexes (Hancock and Parton, 2005).  
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Figure 2.5 MAPK pathway activation by active insulin receptor. Insulin receptor (IR) can activate 
MAPK pathway by activation of Shc-Grb2-Sos complex. MAPK pathway induces cell proliferation.  
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Ras is active when it switches from the GDP-bound state to GTP-bound state (Lowy and 
Willumsen, 1993). Mutations in the Ras proteins resulting in constitutive activation of the Ras 
GTPase are found in 20% to 30% of human tumours.Activation of Ras involves activation of 
the Grb2-Sos complex. Grb2 (growth factor receptor bound protein 2) is an adapter protein 
and Sos (Son of sevenless) is a guanine nucleotide exchange factor which interacts with Grb2 
by its SH3 domain. Studies have shown that the Grb2-Sos complex can be activated by at 
least two pathways.The phosphorylated IRS-1 protein serves as a docking site for Grb2 which 
then recruits Sos to the plasma membrane for activation of Ras. Alternatively, Grb2 can bind 
to Shc protein (another direct intracellular substrate of insulin receptor) and this leads to the 
activation of Grb2-Sos complex. Once recruited to the plasma membrane, Sos activates Ras 
protein by exchanging GDP with GTP. To this activated Ras binds c-Raf, a serine-threonine 
protein kinase also called Raf-1. c-Raf phosphorylates and activates mitogen activated protein 
kinase kinase (MEK) (Kyriakis et al., 1992). Activated MEK catalyses phosphorylation of 
mitogen activated protein kinase (MAPK) at threonine and tyrosine residues (Ahn et al., 
1992). MAPK (also known as extracellular signal-regulated kinase, Erk) is a serine/threonine 
kinase and has two closely related isoforms, Erk1 and Erk2.The phosphorylated Erk1/2 enter 
the nucleus and has been demonstrated to activate transcription factors like FOS, MYC and 
JUN which are well known for their role in cell proliferation. Erk1/2 also increases expression 
of genes like Cyclin D1 that are required for cell cycle entry. Additionally, Erk1/2 are 
involved in a negative-feedback loop of insulin action by phosphorylating IRS-1 on serine 
residues (Bouzakri et al., 2003). In summary, MAPK pathway is primarily involved in 
mediating mitogenic actions of insulin. 
2.2.2.4 Inhibition of insulin receptor signalling 
Once insulin dissociates from insulin receptor, insulin signalling is rapidly attenuated by 
various mechanisms. The insulin receptor and its substrates like IRS proteins are rapidly 
dephosphorylated by protein tyrosine phosphatases (PTPases).  The most important PTPase in 
this regard is PTP1B. The disruption of PTP1B gene in mice results in increased insulin 
induced tyrosine phosphorylation of insulin receptor and IRS-1 and thus increased insulin 
receptor signalling (Drake and Posner, 1998). As a result, nowadays, PTP1B is being pursued 
as a drug target for the treatment of type II diabetes and obesity (Taylor and Hill, 2004). 
Another mechanism for attenuation of insulin signalling utilizes phosphorylation of serine and 
threonine residues of insulin receptor and IRS-1. Two serine/threonine kinases, ‘cAMP 
dependent protein kinase’ and ‘Protein kinase C’ have been implicated in this process 
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(Tanti et al., 1987; Karasik et al., 1990). Excessive serine phosphorylation of insulin receptor 
has been suggested as one of the reasons for insulin resistance. Additionally, insulin signalling 
is attenuated by internalization of the activated receptor. Studies have shown that after 5 min 
of insulin treatment approximately 30% of the insulin receptor is internalized (Marshall, 
1985). Mutation of the kinase domain resulting in the loss of tyrosine kinase activity inhibits 
internalization of the receptor thus implicating a role of the kinase domain in the attenuation 
of insulin signalling. Interestingly, internalized insulin receptors may remain catalytically 
active as protein kinase (Khan et al., 1989).  
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2.3 Diabetes mellitus  
Insulin being an important regulator of glucose homeostasis is highly required for healthy life. 
Impairment in insulin production or in insulin response causes a chronic disease called as 
‘Diabetes’. ‘Diabetes mellitus’ is characterized by sweet smelling urine due to excess of 
glucose in the urine. Its global incidence has been increasing sharply. According to WHO 
projection, the numbers of diabetic patients are expected to rise from current state of 170 
million diabetic patients to approximately 300 million patients by 2025. Two major types of 
diabetes mellitus have been described – type I and type II.  
Type I Diabetes 
It is also referred to as ‘insulin dependent diabetes’. This is an autoimmune disease in which 
the immune system targets the β-cells of the endocrine pancreas and results in the loss of 
insulin production.  This disturbs glucose homeostasis and is reflected as ‘hyperglycemia’. 
Excess glucose levels in the blood damages nerves (neuropathy), kidney (nephropathy) or 
eyes (retinopathy). For treating type I diabetic patients, efforts are being made to transplant 
pancreas or insulin producing β-cells. However, success has been limited as grafted tissues 
are rejected by the host immune system. Till date, the most reliable cure has been to take daily 
injections of insulin for controlling blood glucose level. Nowadays, insulin analogues have 
been developed which can mimic the insulin secretion profile of the body to a great extent and 
thus are proving to be of great help for diabetic patients. 
Type II Diabetes 
Type II diabetes or ‘non-insulin dependent diabetes’ comprises 90% of all cases. In this type, 
insulin target tissues do not respond to insulin. This is described as ‘insulin resistance’. The 
development of insulin resistance is a complex and progressive event. Research so far has 
demonstrated that various molecular events can lead to insulin resistance. Defects related to 
insulin receptor like incomplete processing of insulin receptor, decrease in insulin receptor 
numbers on the cell surface, auto-antibodies to the insulin receptor or decreased kinase 
activity of insulin receptor have been implicated in insulin resistance (Becker and Roth, 
1990). Other events like increased insulin degradation or defective downstream signalling 
from insulin receptor also result in insulin resistance. Furthermore, impairment in 
translocation of GLUT4 to the plasma membrane has been also shown to result in insulin 
resistance (James and Piper, 1994). Insulin resistance causes non-utilization of glucose and 
like in type I diabetes the patient suffers from ‘hyperglycemia’. Initial body response to 
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counter insulin resistance is increased insulin production (hyperinsulinemia) by β-cells. This, 
however, on long term results in the destruction of β-cells and as a result insulin production 
ceases. Obesity is considered one of the major risk factors for type II diabetes (55% of 
patients are obese). The patients with early stage type II diabetes can be treated by giving 
drugs which increase insulin secretion (like sulphonylurea), or decrease glucose release from 
liver (like metformin). In addition, drugs which can increase insulin sensitivity like 
thiazolidinediones are very useful. The patients with late stage type II diabetes do not produce 
insulin. Like patients with type I diabetes, these patients also have to take daily insulin 
injections.   
Gestational Diabetes 
Gestational diabetes mellitus develops in the pregnant women. It is very similar to type II 
diabetes in terms of inadequate insulin secretion and responsiveness. It is fully treatable but 
chances are that approximately 20%–50% of affected women may develop type II diabetes 
later in their life. 
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2.4 Insulin Analogues  
2.4.1 Basis for developing insulin analogues 
The treatment of diabetic patients with insulin started only from the 1920s. At that time 
animal insulins derived from pancreas of pigs or cows were used to treat diabetes. Though it 
was of great help to save the life of diabetic patients, many of them reported allergic response 
towards animal insulins. The production of human insulin became possible only after 
sufficient knowledge was gained to genetically manipulate microorganisms for producing 
proteins of interest. In the 1980s, first time human insulin was produced from genetically 
engineered bacteria (Chance et al., 1981). It was marketed as ‘humulin’ (insulin isophane) by 
Genentech and was a boon in treating diabetic patients. Additionally, unlike animal insulin it 
did not evoke immune response. 
The most effective way, till date, to give insulin is by injecting it subcutaneously from where 
insulin diffuses into the blood and acts on the target tissues. Insulin administered 
subcutaneouly reaches blood in 30-60 min (onset time), the blood level reaches maximum in 
2-3 h (peak time) and it stays in blood for total of 5-8 h (effective duration).  The onset time 
of normal insulin is 30-60 min and effective duration is only 5-8 h, a patient may have to take 
injections twice a day.  In order to reduce the dependency of diabetic patients on insulin 
injections, attempts were made to design insulin preparations with increased effective 
duration. 
Insulin forms hexamers in presence of zinc ions (Dunn, 2005). By increasing or decreasing 
zinc ion concentration insulin release from the site of injection can be varied. Protamines are 
added to the insulin preparations. They are highly basic proteins and their concentration in the 
insulin preparation determines the dissociation rate of insulin hexamers. In order to improve 
the effective duration of normal insulin, insulin preparations are modified by altering 
concentrations of zinc ions or protamines. NPH (neutral protamine Hagedorn), lente and 
ultralente are such insulin preparations which have delayed insulin action duration and have 
been shown to remain in the blood for 10-16 h (NPH) or 10-24 h (lente and ultralente). These 
preparations have improved the efficacy of insulin treatment but still they do not mimic 
optimal timing of insulin action. For example, by modifying insulin preparations the onset 
time of normal insulin cannot be decreased below 30-60 min. In addition, lente and ultralente 
insulin preparations do not provide constant basal insulin level for a longer duration.  
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To encounter these inadequacies, pharmaceutical companies are generating artificial insulin 
molecules, also called insulin analogues, by modifying the insulin backbone. Depending upon 
the modification, insulin analogues can be of two types : rapid-acting and long-acting insulin 
analogues. 
2.4.2 Rapid-acting insulin analogues  
Insulin molecules exhibit self-association property in the presence of zinc and form stable 
hexamers which dissociate slowly. Rapid-acting insulin analogues are artificial insulin 
molecules which have been modified in a way that they are present mostly in monomeric 
form. As a result, they have much lower onset time in comparison to normal insulins. At 
present there are three rapid acting insulin analogues that have been approved for 
therapeutical use –Insulin Aspart (Novorapid®, produced by Novo Nordisk), Insulin Lispro 
(Humalog®, produced by Eli Lilly) and Insulin Glulisine (Apidra®, produced by Sanofi-
Aventis).  
Insulin Aspart 
Regular human insulin has the amino acid proline at 28th position in the B-chain of insulin. 
Insulin Aspart is generated by introducing a mutation at this position which codes for aspartic 
acid (Fig. 2.6). Aspartic acid being a negatively charged amino acid increases the charge-
charge repulsion between two monomers and thus has reduced tendency to form hexamers.  
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Figure 2.6 Schematic presentation of modification made in the insulin backbone to generate 
Insulin Aspart. Proline at 28th position in B-chain of regular insulin molecule is replaced with aspartic 
acid to generate Insulin Aspart. 
It is thus more rapidly absorbed from the subcutaneous tissue at the site of injection compared 
to regular human insulin. Insulin Aspart is available for action within 5-15 min of taking the 
injection and the concentration peaks within 40-50 min. However, the total duration of action 
is less than 5 h (Rolla, 2008).  
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Insulin Lispro 
Insulin Lispro is generated by interchanging amino acids at 28th and 29th position of the B-
chain of insulin molecule to lysine and proline respectively (Fig. 2.7). It has been reported 
that because of this inversion Insulin Lispro does not form dimers and hexamers. As a result it 
is available within 5-15 min for the action. Like Insulin Aspart, its concentration also peaks 
within 30-90 min and it is eliminated from the body in less than 5 h (Rolla, 2008).  
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Figure 2.7 Schematic presentation of modifications made in the insulin backbone to produce 
Insulin Lispro. Proline at 28th position and Lysine at 29th position in B-chain of regular insulin 
molecule is interchanged to generate Insulin Lispro. 
Insulin Glulisine 
Insulin Glulisine differs from human insulin in that the amino acid asparagine at position B3 
is replaced by lysine and the lysine in position B29 is replaced by glutamic acid (Fig. 2.8). 
Insulin Glulisine acts fast and it can be found in the blood within 15-20 minutes after the 
injection. Its concentration peaks within 34-91 minutes (Rolla, 2008). 
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Figure 2.8 Schematic presentation of modifications made in the insulin backbone to produce 
Insulin Glulisine. Asparagine at 3rd position and lysine at 29th position in B-chain of regular insulin 
molecule are replaced by lysine and glutamic acid to generate Insulin Glulisine. 
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2.4.3 Long-acting insulin analogues  
Currently there are two long-acting insulin analogues approved for clinical use – Insulin 
Glargine (Lantus®, produced by Sanofi-Aventis) and Insulin Detemir (Levemir®, produced 
by Novo Nordisk).  
Insulin Glargine 
Insulin Glargine is generated by replacing asparatic acid at 21st position in the A-chain by 
glycine and introducing two additional arginine amino acids in the B-chain of insulin 
molecule (Fig. 2.9).  
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Figure 2.9 Schematic presentation of modifications in the insulin molecule to generate Insulin 
Glargine. A-chain of insulin Glargine has glycine instead of aspartic acid at 21st position and B-chain 
contains two extra amino acids (31st and 32nd position) which code for arginine.  
Due to these modifications, Insulin Glargine has low aqueous solubility at neutral pH. When 
injected into the subcutaneous tissue, it forms microprecipitates and slowly diffuses into the 
blood. The onset time is approximately two hours. In contrast to rapid acting insulin 
analogues, there is no pronounced peak and the concentration in the blood remains relatively 
constant over a period of 24 h (Gerich et al., 2006). 
Insulin Detemir 
Insulin Detemir is produced by deleting threonine at the 30th position of the B-chain and 
adding a 14-carbon fatty acid chain to lysine in the 29th position  (Fig. 2.10). The fatty acid 
chain enables insulin detemir to bind to albumin, the most prominent blood protein. This 
results in slow release of the insulin molecule and thus lengthens the time of action. Its action 
profile is similar to that of Insulin Glargine (Heise, 2007).  
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Figure 2.10 Schematic presentation of modifications in the insulin molecule to generate Insulin 
Detemir. Amino acid at the 30th position of the B-chain has been omitted and a 14-carbon fatty acid 
chain is added to the 29th position.   
These insulin analogues are gradually replacing the conventional insulin preparations. 
Nowadays, insulin-dependent diabetic patients are being prescribed rapid-acting insulin 
analogues to prevent blood glucose spikes after meal together with long-acting insulin 
analogues which can maintain basal insulin level (Garber, 2006).  
2.4.4 Mitogenic effects  of insulin analogues 
The modification of the insulin backbone to alter the pharmacodynamics (onset time, peak 
time and effective duration) of insulin has been a big step in improving the life-quality of 
diabetic patients. However, modification of the insulin molecule may alter its biochemical 
properties like affinity to insulin receptor and insulin-like growth factor – I receptor (IGF-IR) 
or insulin receptor dissociation rate contant (Kd) (Table 2.1). These factors may lead to higher 
proliferative potency of insulin analogues in comparison to normal insulin. For example, 
insulin receptor activation is predominantly related to metabolic control, but it also elicits a 
mitogenic response in the cell. The sustained activation of insulin receptor enhances its 
mitogenic effect. Hansen et al. (1996) showed that insulin analogues having lower insulin 
receptor dissociation rate constant (Kd) exhibited higher mitogenicity than regular insulin. 
This mitogenicity was disproportionately higher for insulin analogues that had a Kd value less 
than 40% of normal insulin (analogues H2 and X97, Table 2.1). IGF-IR is a growth factor 
receptor which shows a high degree of homology with insulin receptor. The activation of IGF-
IR induces strong proliferation in the cells (Sachdev and Yee, 2001). Due to modifications, 
insulin analogues may activate the IGF-IR resulting in higher proliferative potency compared 
to regular insulin and thus can pose a health hazard. Kurtzhals et al. (2000) demonstrated that 
in a human osteosarcoma cell line, B10Asp insulin induced six-fold higher proliferation in 
comparison to regular insulin. B10Asp is an insulin analogue generated by replacing glutamic 
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acid at 10th position of B-chain with asparatic acid. This modification increases its affinity for 
insulin receptor by two-fold and for IGF-IR by approximately six-fold in comparison to 
regular human insulin (Table 2.1). Slieker et al. (1997) reported that modifications of the 
carboxy-terminus of the B-chain in insulin may increase the affinity for IGF-IR. 
B31ArgB32Arg insulin was approximately 20-fold stronger than regular insulin in stimulating 
proliferation in human osteosarcoma cell line (Kurtzhals et al., 2000). 
Analogue 
Insulin Receptor 
affinity [%] 
Insulin Receptor 
off-rate or  relative 
Kd [%] 
IGF-I 
receptor 
affinity [%] 
Human insulin 100 100 100 
H2 (A8HisB4HisB10GluB27His) N.D. 1.5 ± 0.1* N.D. 
X97  (B10GluB30desThe) N.D. 24 ± 4* N.D. 
B10Asp 205 ± 20 14 ± 1 587 ± 50 
B31ArgB32Arg 120 ± 4 75 ± 8 2,049 ± 202 
Insulin Aspart (Novorapid) 92 ± 6 81 ± 8 81 ± 9 
Insulin Lispro (Humalog) 84 ± 6 100 ± 11 156 ± 16 
Insulin Glargine (Lantus) 86 ± 3 152 ± 13 641 ± 51 
Insulin Detemir (Levemir) 46 ± 5 204 ± 9 16 ± 1 
 
Table 2.1 Insulin analogues differ from regular human insulin. Modifications performed to 
generate insulin analogues may result in altered insulin receptor affinity, insulin receptor off-rate 
(lower values mean longer duration of occupancy) and IGF-I receptor affinity. Data shown here are 
means ± SE (adapted from Kurtzhals et al., 2000; * Hansen et al., 1996; N.D means ‘not determined’).  
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Another analogue similar to B31ArgB32Arg namely Insulin Glargine 
(A21GlyB31ArgB32Arg), showed up to eight-fold higher mitogenic potency compared to 
regular insulin. Insulin Glargine was also demonstrated to have higher mitogenicity in 
primary cultures of normal fibroblasts and smooth muscle cells which expressed high levels 
of IGF-IR and IRS-1 proteins (Eckardt et al., 2007).  
2.4.5 Effect of insulin analogues on human mammary epithelial cell lines 
Insulin receptor and IGF-IR show high expression levels in epithelial cells of the normal 
human mammary gland and have been shown to be significantly overexpressed in breast 
cancer and in malignant mammary cell lines (Papa et al., 1990; Milazzo et al., 1992; Schnarr 
et al., 2000; Sachdev and Yee, 2001; Frasca et al., 2008). Thus the mammary gland may 
represent a sensitive target for growth stimulation by insulin analogues. Indeed, treatment of 
MCF10A cells (a non-malignant human breast cell line) with B10Asp caused increased focus 
formation (Milazzo et al., 1997). B10Asp was also more potent than regular insulin in 
stimulating colony formation in MCF7 cells (a malignant human breast cell line). 
Furthermore, treatment of female Sprague-Dawley rats with B10Asp led to strong increase in 
the incidence of mammary tumours (Dideriksen et al., 1992). Studies on human mammary 
epithelial cells (HMEC) by Slieker et al. (1997) revealed that B31ArgB32Arg insulin 
stimulated proliferation ten-fold higher than regular insulin. Taken together, these studies 
demonstrate that insulin analogues may induce strong proliferation in mammary epithelial 
cells.   
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2.5 Breast Cancer  
2.5.1 General information 
The mammary gland is a unique organ in that it undergoes the majority of its development 
after birth and mostly during puberty. A female child has a rudimentary mammary gland. The 
onset of puberty results in increase of estrogen, progesterone and growth factors in blood. 
Under the effect of these hormones proper development of the mammary gland takes place 
(Sternlicht, 2006). In addition, during every menstrual cycle, estrogen and progesterone are 
secreted from ovary in a cyclical pattern. These hormones in combination with growth factors 
induce recurring rounds of proliferation and apoptosis of mammary cells (Ramakrishnan, 
2002). It is suggested that this cyclical proliferation of mammary cells can result in the 
gradual accumulation of genetic alterations which may ultimately culminate into a breast 
cancer (Fig. 2.11).  
 
Figure 2.11 Schematic presentation of the organisation of normal breast tissue and two major 
types of breast cancer. A. Anatomically, a mature breast tissue is organised in ducts and lobules. 
Lobules contain milk producing glands. These lobules are linked together by tiny tubes called 
ductules, which join to form ducts and transport milk to the nipple. The lobules and ducts are 
surrounded by connective tissue and adipose tissue. Whole breast tissue is attached to the chest wall 
by the help of pectoral muscles. B. Appoximately 80% of breast cancer develop from ducts. The 
ductal carcinoma in situ (DCIS) is a clinically pre-cancerous state characterized by rapidly dividing 
ductal cells located within the duct. When aberrantly dividing ductal cells gain invasive property and 
spread to adjoining areas it is called ‘invasive ductal carcinoma’. C. Nearly 10% of breast cancer 
originates from lobular cells. The uncontrolled division of lobular cells give rise to lobular carcinoma 
in situ (LCIS). When these cells become invasive they give rise to ‘Lobular carcinoma’ (adapted from 
National Cancer Institute website). 
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Breast cancer is the most frequently detected cancer in women and its incidence has been 
gradually increasing. Annually, about one million new breast cancer cases are detected with 
320,000 cases only in Europe. Breast cancer incidence rates increase with age, more rapidly 
among pre-menopausal and peri-menopausal women than among post-menopausal women 
(Bray et al., 2004). This pattern of flattening after menopause is observed only for breast 
cancer. These findings again suggest that hormones play an important role in the development 
of breast cancer. Indeed, events which are related with hormonal changes like onset of 
puberty, menopause, pregnancy, lactation and estrogen replacement therapy have been 
reported by various epidemiological studies to be associated with breast cancer risk. For 
example, women who have first pregnancy before the age of 30 years have only half of the 
risk to develop breast cancer than nulliparous women (Dumitrescu and Cotarla, 2005). Studies 
also suggest that breast feeding women have low breast cancer risk. For every 12 month of 
breast feeding there is approximately 4% reduction in the breast cancer risk (Dumitrescu and 
Cotarla, 2005).  
Besides influence of hormones, various other factors have been identified that increase the 
risk to develop breast cancer. Lifestyle choices can have strong impact on the development of 
breast cancer. For example, every 10 g increment in alcohol consumption increases breast 
cancer risk by 9% (Dumitrescu and Cotarla, 2005). Furthermore, diets which may result in the 
generation of high amounts of free oxygen radicals increase breast cancer risk. Anti-oxidant 
rich diet shows a negative correlation with breast cancer risk (Linos and Willett, 2007). In 
addition to lifestyle choices, the genetic background of women can also predispose her to 
develop breast cancer. The hereditary breast cancer comprises approximately 10% of total 
breast cancer cases (McPherson et al., 2000). The breast cancer susceptibility genes can be 
grouped into two categories: high-penetrance genes like BRCA1, BRCA2, PTEN, ATM or 
p53 and low-penetrance genes like ERα, alcohol dehydrogenase (ADH) and CYP1A1 (an 
enzyme that catalyses 2-hydroxylation of estradiol). Any deleterious mutation in high 
penetrance genes can increase breast cancer risk significantly. For example, women who are 
carriers of BRCA1 or BRCA2 mutations have approximately 80% increased risk for 
developing breast cancer (Oesterreich and Fuqua, 1999).  Likewise, PTEN germline mutation 
results in 25-50% lifetime breast cancer risk (Dumitrescu and Cotarla, 2005). However, 
polymorphisms in low penetrance genes do not increase breast cancer risk drastically but in 
combination with various environmental factors they can have significant effects. 
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 This thesis mainly aims to investigate and elucidate the mechanism behind the proliferative 
ability of insulin, insulin analogues and IGF-I on estrogen dependent and independent 
mammary cell lines. Therefore, the role of insulin, IGF-I and estrogen in breast cancer will be 
presented in detail in the following sections. 
2.5.2 Role of estrogen in breast cancer 
Epidemiological studies have shown that the prolonged exposure to estrogen increases breast 
cancer risk (Clemons and Goss, 2001). Estrogen exposure may be increased as a consequence 
of early onset of puberty, late menopause or estrogen replacement therapy. Girls who reach 
puberty before 12 years of age have 10-20% more risk to develop breast cancer than girls who 
reach puberty after the age of 14 years (Dumitrescu and Cotarla, 2005). Similarly, women 
with late onset of menopause show approximately 3% increase in breast cancer risk with 
every 1-year increase in the onset age of menopause (Collaborative Group on Hormonal 
Factors in Breast Cancer, 1996). In contrast, the breast cancer risk was 40% lower in women 
who underwent surgical operations to induce menopause ovariectomy at or below 35 years of 
age in comparison to women who had menopause at normal age (McPherson et al., 2000). 
Conversely, post-menopausal women who develop breast cancer have approximately 15% 
higher circulating estradiol level than post-menopausal women without breast cancer 
(Dumitrescu and Cotarla, 2005). Considering results of all these studies, it can be concluded 
that higher estrogen level increases breast cancer risk. A brief description of estrogen and its 
mode of action are presented below.    
Estrogens like other steroid hormones are derived from cholesterol. There are three major 
types of estrogens in females - estradiol (17β-estradiol), estrone and estriol (Fig. 2.12). 
Estradiol is the primary estrogen in females when they are reproductively active. After 
menopause, estradiol levels decrease and estrone becomes the major estrogen. Estriol is 
primarily produced during pregnancy by placental tissues.  
                                              
      A     B     C 
Figure 2.12 Chemical structure of three major estrogens – estradiol (A), estriol (B ) and estrone (C). 
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The major estrogen, estradiol, is pre-dominantly synthesised in the ovaries during follicular 
phase of the menstrual cycle.  It plays a key role in the development of normal breasts and is 
also involved in the sexual maturation of uterus. Studies show that it can also be synthesised 
at other sites like adipose tissue, brain and arterial walls where it may have localized effects 
(Simpson, 2003). 95% of estradiol circulating in the blood is bound to plasma carrier proteins 
like sex hormone-binding globulin (SHBG) thus seriously limiting bioavailability of estradiol. 
Epidemiological studies show that in few breast cancer cases, the expression of these carrier 
proteins are downregulated resulting in increased bioavailability of estradiol (Calle and 
Kaaks, 2004). The free estradiol, being a steroid hormone (hydrophobic property), passes 
through the cell membrane and nuclear membrane and binds to its cognate receptor, estrogen 
receptor (ER) which pre-dominantly resides in the nucleus (classical mechanism of estradiol 
actions). Additionally, estradiol may also interact with ER in the cytoplasm and this liganded 
ER enters the nucleus.  
Two subtypes of estrogen receptor have been reported: estrogen receptor – alpha (ERα) and 
estrogen receptor – β (ERβ). Both, ERα and ERβ, belong to the steroid/thyroid hormone 
superfamily of nuclear receptors and share similar structures and modes of action. They show 
modular structure with various functional domains. These are the NH2-terminal or A/B 
domain that modulates gene transcription in cell specific manner through its Activation 
Function-1 (AF-1); the C-or DNA-binding domain which contains two zinc fingers for 
interaction with DNA helix; a D domain or hinge region which contains the NLS; an E 
domain that contains ligand binding domain and ligand-dependent Activation Function-2 
(AF-2); and F domain which may distinguish between estrogen agonists and antagonists by 
interacting with other cell specific factors (Klinge, 2000; Ali and Coombes, 2002). ERα or 
ERβ knockout mice have life span equal to wild type mice but exhibit reproductive 
abnormalities (Couse and Korach, 1999). ERα is required for most of the estrogenic 
responses. Both, ERα or ERβ, are overexpressed in the majority of breast cancer cases. About 
70% of primary breast cancers are ERα positive. ERα has been found to be a valuable 
prognostic factor in the clinical management of breast cancer (Sommer and Fuqua, 2001). 
Numerous studies have shown that ERα positive breast tumours respond better to therapy than 
ERα negative breast tumours (Allred et al., 2004). 
In addition to the classical mechanism of estradiol actions, recent studies have demonstrated 
the existence of non-classical mechanisms. Estradiol has been suggested to be a ligand for 
GPR30, a membrane-associated ER localized to endoplasmic reticulum (Revankar et al., 
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2005; Prossnitz et al., 2008). Activation of GPR30 by estrogen has been shown to result in 
intracellular calcium mobilization and synthesis of PIP3 in the nucleus. GPR30 knockout in 
female mice resulted in hyperglycemia, impaired glucose tolerance, reduced body growth and 
inhibition of estradiol-induced insulin release from β-cells of the pancreas suggesting 
regulation of insulin function by estradiol (Martensson et al., 2008). Additionally, estradiol 
has been shown to initiate rapid activation of signalling molecules like Akt and Erk1/2 via 
interaction of estradiol-activated ERα with a scaffold protein, MNAR (modulator of 
nongenomic action of estrogen receptor) (Greger et al., 2007). Both Akt and Erk1/2 are 
downstream effectors of EGFR and IGF-IR. This implies cross-talk of ERα with growth 
factor activated signalling pathways (Smith, 1998; Levin and Pietras, 2008). The cross-talk 
between ERα and IGF-IR is introduced in the following section. 
2.5.3 Involvement of IGF signalling system in breast cancer 
2.5.3.1 IGF signalling system 
The IGF (insulin-like growth factor) system consists of IGF ligands (IGF-I and IGF-II), 
receptors (IGF-IR and IGF-IIR), IGF-binding proteins (IGFBPs; these bind to IGF ligands) 
and proteases of binding proteins (Sachdev and Yee, 2001). IGF-I and IGF-II are 79 and 60 
amino acid long single chain polypeptide growth factors. Earlier, it was assumed that all IGF-
I is produced by the liver under the tight control of GH (growth hormone) from pituitary 
gland and that the endocrine action of IGF-I is the major determinant for postnatal growth 
(Froesch et al., 1985; Daughaday and Rotwein, 1989). The liver specific knockout of the igf-1 
gene by cre-lox recombination sytem decreased the circulating IGF-I level by 75% but this 
did not effect the postnatal growth. This indicated that an autocrine/paracrine action of IGF-I 
is the major determinant for the tissue growth (Sjögren et al., 1999; Yakar et al., 1999). Later, 
it was shown that IGF-I can be produced by other organs as well. Similarly, IGF-II is also 
expressed both in the liver and in extrahepatic sites, but unlike the igf-1 gene which lacks any 
imprinting, the igf-2 gene is paternally imprinted (Sasaki et al., 1992). Both, IGF-I and IGF-II 
show a high degree of homology to the insulin molecule. For example, the positions 1 to 29 in 
IGF-I are homologous to insulin B-chain and positions 42 to 62 to insulin A-chain 
(Rinderknecht and Humbel, 1978). However, IGFs mainly have a mitogenic effect while 
insulin mainly exerts metabolic effect.  
Both IGF-I and IGF-II can bind to IGF-IR, which is a cell-surface tyrosine kinase receptor. It 
is expressed by all cell types with the exception of hepatocytes and T lymphocytes (Sachdev 
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and Yee, 2001). IGF-IR is highly homologous to insulin receptor, especially in the tyrosine 
kinase domain, in which they share 84% amino acid identities. Like insulin receptor, IGF-IR 
consists of two α-subunits and two β-subunits. The α-subunits are entirely extracellular and 
possess the ligand binding domain. The β-subunit has a small extracellular domain through 
which it is attached to the α-subunit by disulphide bonds, a membrane spanning domain and a 
large intracellular domain (Adams et al., 2000). The intracellular domain consists of the 
juxtamembrane domain, the tyrosine kinase domain and C-terminal domain. Under 
unstimulated condition, the catalytic activity of the IGF-IR is inhibited by the presence of an 
activation loop (a-loop; stretch of amino acids containing critical tyrosine residues 1131, 1135 
and 1136) which acts as a pseudosubstrate and prevents the substrate access and ATP binding 
(Larsson et al., 2005). The β-subunits possess trans-phosphorylation activity by which one 
subunit phosphorylates the tyrosine residues in the other subunit.  
The binding of ligand to the IGF-IR results in the trans-phosphorylation of the three critical 
tyrosine residues in the a-loop which changes the conformation of the a-loop. This 
conformational change releases the inhibitory effect of a-loop at the tyrosine kinase domain. 
Once activated, tyrosine kinase domain phosphorylates other tyrosine residues in the IGF-IR 
and exogenous substrates like IRS-1, IRS-2 and Shc which in turn result in the activation of 
PI3K, MAPK and 14-3-3 pathways (Baserga, 2000). Despite the high sequence homology, the 
functions of IGF-IR and insulin receptor are considerably different. The IGF-IR is mainly 
involved in regulation of cell proliferation, anti-apoptosis, differentiation and cell motility. 
Insulin receptor, as described in section 2.2 is mostly involved in control of glucose uptake 
and metabolism. Due to the high degree of homology, IGF-IR and insulin receptor are 
reported to form hybrids that basically behave as an IGF-IR (Frasca et al., 2003). IGF-IIR 
which is also referred to as mannose 6-phosphate receptor (M6PR), preferentially binds IGF-
II. It has no intracellular kinase domain and does not act as a signalling molecule (Hebert, 
2006). It is generally accepted that IGF-IIR functions as a sink for IGF-II and thus decreased 
expression of IGF-IIR can result in enhanced availability of IGF-II leading to increase in cell 
proliferation. 
The IGFBPs are a family of six homologous proteins (IGFBP 1-6) which have high binding 
affinity for IGF-I and IGF-II (Binoux et al., 1991). Their binding affinity for IGF-I and IGF-II 
is comparable to the binding affinity of IGF-IR. These proteins are present in the circulation 
as well as extravascular fluids and sequester IGFs from circulation. In human serum > 95% of 
IGFs are bound to IGFBPs and thus unavailable for action. Nowadays, there is increasing 
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evidence that the IGFBPs may have growth regulatory actions that are independent of their 
normally suggested IGF binding activity (Gucev et al., 1996). Cathepsins and matrix 
metalloproteinases cleave IGFBPs into smaller molecular forms that have reduced affinity for 
IGFs and this releases IGFs from the binding protein complex (Schmid et al., 1991; Fowlkes 
et al., 1994).  
 
2.5.3.2 Cross-talk between IGF-IR and ERα 
The IGF-IR signalling pathway has been reported to cross-talk with that of ERα (Fig. 2.13; 
Smith, 1998; Kato et al., 2000). Several studies suggested synergistic effects of IGF-I and 
estradiol on MCF7 cell proliferation (Dupont and Roith, 2001).  
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Figure 2.13 Proposed model of cross-talk between IGF-IR and ERα. Estradiol bound ERα 
interacts with Shc. This causes dephosphorylation and activation of c-Src. c-Src in turn phosphorylates 
IGF-IR, which phosphorylates and recruits Shc. The interaction of Shc to IGF-IR results in the 
translocation of ERα to the membrane. Activation of IGF-1R results in the activation of MAPK 
pathway (Song et al., 2004) and probably also of PI3K pathway, overall leading to cell proliferation. 
 
ERα has been shown to increase the expression of IGF-IR and IRS-1 (Mauro et al., 2001; 
Maor et al., 2006). Oesterreich et al., (2001) generated MCF7 sublines (C4 and C4-12) that 
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were negative for ERα by prolonged estrogen withdrawal. The lack of ERα in these cell lines 
resulted in decrease in mRNA and protein of IGF-IR and IRS-1. Re-expression of ERα in 
these cell lines resulted in the increased expression of IGF-IR and IRS-1, thus confirming the 
direct role of ERα in regulating IGF-IR and IRS-1 gene expression.  
Other studies have shown that ERα can directly interact with the signalling components of 
IGF-IR pathway. For example, ERα has been shown to interact with SH2 region of Src, the 
p85α regulatory subunit of PI3K, Shc and IGF-IR (Kahlert et al., 2000, Migliaccio et al., 
2000, Simoncini et al., 2000, Sun et al., 2001, Song et al., 2002). Recently, Song et al. (2004) 
demonstrated that estradiol can indirectly phosphorylate and activate IGF-IR. They suggested 
formation of a ternary complex between Shc, ERα, and IGF-IR in response to estradiol 
treatment. The downregulation of Shc, ERα, or IGF-IR with specific small inhibitory RNAs 
blocked E2-induced MAPK phosphorylation. In addition, our own study has shown that 
GSK3α/β, a downstream signalling molecule of PI3K pathway, is important for stabilization 
and full transcriptional activity of ERα (Grisouard et al., 2007).  
 
2.5.3.3 Role of IGF signalling system in breast cancer  
Several studies have implicated the IGF system with increased breast cancer risk. The 
comparative analysis of IGF-I level in serum of breast cancer patients and matched controls 
revealed increased IGF-I level in the breast cancer patients (Pollak, 1998). Epidemiological 
studies have demonstrated high plasma levels of IGF-I as a potential risk factor for breast 
cancer (Hankinson et al., 1998). Schernhammer et al. (2005) reported that circulating IGF-I 
level is modestly associated with breast cancer risk among premenopausal women (RR, 1.6; 
95% CI, 1.0-2.6), but not among postmenopausal women. The relative risk was higher for 
premenopausal women of age ≤ 50 years (RR, 2.5; 95% CI, 1.4-4.3). Studies implicate 
paracrine action of IGF-I in the development of breast cancer as in situ hybridization showed 
that IGF-I is mainly expressed in stromal cells and not in breast epithelium cells (Yee et al., 
1989). Interestingly, transgenic mice overexpressing IGF-I show increased ductal hypertrophy 
in the lactating mouse (Sachdev and Yee, 2001). IGF-II has also been demonstrated to be 
positively associated with breast cancer (Singer et al., 2004). Transgenic mice overexpressing 
IGF-II developed mammary tumours (Bates et al., 1995). In breast cancer patients, free IGF-II 
serum concentrations and free IGF-II/total IGF-II ratio correlates with tumour size. 
Furthermore, in situ hybridization and immunohistochemical analysis of breast tissues 
revealed that, as observed with IGF-I expression, stromal cells adjacent to malignant 
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epithelial cells have higher IGF-II expression than stromal cells around benign or normal 
breast epithelium, suggesting paracrine action of IGF-II in breast cancer (Giani et al., 1996; 
Giani et al., 1998).  
The analysis of primary breast tumours shows not only the increase in IGF-IR expression 
levels in comparison to benign tumours or normal breast epithelium (Pezzino et al., 1996), 
tyrosine kinase activity of the IGF-IR has also been reported to be enhanced in breast cancer 
(Resnik et al. 1998). Turner et al. (1997) demonstrated a positive association of IGF-IR levels 
and radioresistance of breast cancer cells. They also reported that tumours with elevated IGF-
IR had a higher incidence of recurrency at the primary site. However, tumours with high IGF-
IR levels have better prognosis than cancers with low level of IGF-IR (Yee et al., 1994). IGF-
IR has been shown to be overexpressed in breast epithelial tumour cell lines. Studies of the 
IGF-IIR locus report significant loss of heterozygosity in breast cancer suggesting IGF-IIR as 
a breast tumour suppressor gene (Hankins et al., 1996). Mutations in the IGF-II binding 
domain of IGF-IIR have been reported in breast cancer cells (Byrd et al., 1999). The stable 
transfection of MDA-MB231 breast cancer cells with IGF-IIR cDNA not only markedly 
reduced their ability to form tumours but also reduced growth rate in nude mice, suggesting 
the importance of low expression of IGF-IIR in tumour formation (Lee et al., 2003). Other 
members of the IGF system like IGFBPs have also been studied in relation to breast cancer 
risk. Recent epidemiological studies suggested positive association between lower levels of 
IGFBP3 and increased breast cancer risk in premenopausal women (Bruning et al., 1995; 
Hankinson et al., 1998; Allen et al., 2005). Reduced expression of IGFBPs may be a reason 
for the reported increase in circulating levels of IGF-I and IGF-II in premenopausal women.  
2.5.4 Involvement of insulin signalling pathway components in breast cancer 
Several studies have implicated insulin and its cognate receptor in the development of cancer. 
Earlier studies in animal models suggested a direct role of insulin in the development of 
cancer. For example, pharmacological doses of insulin were shown to stimulate carcinoma 
formation and DNA synthesis and affect the squamous neoplastic cell differentiation in Swiss 
male mice treated with the chemical carcinogen 3-methylcholanthrene thus suggesting insulin 
as a strong co-carcinogen (Lupulescu, 1985). Dombrowski et al. (2003) demonstrated that 
high local insulin concentration in liver of diabetic BB/Pfd rats results in the formation of 
hepatocellular neoplasms, demonstrating the role of insulin as a potential carcinogen. Another 
study demonstrated that breast cancer induced in rats by the chemical carcinogen 
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dimethylbenz(a)anthracene regresses under insulin deficient conditions (pancreatic β-cells 
were destroyed by treating with alloxan). Tumour growth was shown to resume when insulin 
was provided exogenously (Heuson et al., 1972). Interestingly, tumour growth did not resume 
upon administration of exogenous estrogen. Similarly, MCF-7 human breast cancer cells 
formed tumours in insulin treated diabetic nude mice but not in untreated diabetic nude mice, 
again suggesting a direct role of insulin in tumour development (Nandi et al., 1995). Taken 
together, all these animal experiments reveal direct role of insulin in cancer formation in 
general and breast cancer in particular.  
Epidemiological studies have linked increased insulin level with breast cancer. Circulating 
insulin levels were reported to be elevated in women with premenopausal breast cancer (Del 
Giudice et al., 1998). Data obtained from patients suffering from insulin resistance and/or 
hyperinsulinemia, two important characteristics of type II diabetes, show increased risk for 
breast cancer (Bruning et al., 1992; Yam et al., 1996; Gamayunova et al., 1997). The 
mechanism by which high insulin levels may result in breast cancer is presented in Fig. 2.14. 
Obesity which is an important risk factor for type II diabetes has been consistently shown to 
increase breast cancer rates in post-menopausal women by 30-50% (Carroll, 1998; Calle and 
Kaaks, 2004). 
Insulin receptor has been reported to be overexpressed in majority of the breast cancer cases 
(Belfiore et al., 1996; Papa et al., 1996). Breast tumours with high expression level of insulin 
receptor showed significantly reduced disease free survival (Mathieu et al., 1997).  Many 
well-established mammary epithelial tumourigenic cell lines like MCF7 and ZR75-1 also 
show increased expression of insulin receptor (Frasca et al., 2003). Interestingly, breast 
cancer cells predominantly overexpress the fetal isoform of insulin receptor, IR-A (Frasca et 
al., 1999). The IR-A isoform differs from the B-isoform of insulin receptor by the absence of 
a 12–amino acid segment in the carboxy-terminus of the α-subunit. IR-A can bind both 
insulin and IGF-II and has enhanced mitogenic signalling relative to the IR-B (Frasca et al., 
2003).  
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Figure 2.14 Diagram demonstrating the mechanism of breast tumour formation by high insulin 
levels. Elevated blood insulin levels result in activation of insulin receptor (IR) and in increase of 
mitogenic signal to mammary cells. In addition, elevated insulin levels lead to decrease in the 
synthesis of IGF-binding proteins (IGFBP) 1 and 2 and sex-hormone-binding globulins (SHBG) which 
results in increased bioavailability of IGF-I and estradiol (E2), respectively. Both, IGF-I and E2 are 
potent mitogens for mammary cells. The overall effect of all this may be breast tumour development 
(Calle and Kaaks, 2004).    
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2.6 Aims 
Modification of the insulin backbone may alter the biochemical properties of the resulting 
insulin analogues like affinity for insulin receptor, dissociation rate from insulin receptor, and 
affinity for IGF-IR (Table 2.1). Consequently, the signalling and proliferative potencies of 
insulin analogues may be altered. This may pose a serious health risk as proliferation of cells 
which express these receptors may be stimulated by such insulin analogues. The findings 
demonstrating strong proliferative ability of B10Asp relative to human insulin in a 
osteosarcoma cell line (Kurtzhals et al., 2000) and the high incidence of mammary tumours in 
B10Asp treated female Sprague-Dawley rats (Dideriksen et al., 1992) give credence to the 
health concern regarding insulin analogues. Normal breast tissue shows high expression of 
insulin receptor and IGF-IR and breast tumours show overexpression of both receptors (Papa 
et al., 1990; Schnarr et al., 2000; Frasca et al., 2008). Since insulin analogues may activate 
IGF-IR in addition to insulin receptor, it can be concluded that the mammary gland represents 
a sensitive target for growth stimulation by insulin analogues. 
The proliferative ability of insulin analogues that are currently approved for therapeutical use 
has been studied on various cell systems. However, there is lack of any comprehensive study 
in mammary epithelial cell lines. The few studies which have been published till date, are not 
comparable with each other as data has been acquired under dissimilar experimental 
conditions and estimated by different assay systems, thus leading to results which do not 
allow to draw general conclusions. In addition, all studies performed on mammary epithelial 
cell lines are limited in terms of the number of insulin analogues tested.   
The initial aim of this work is to compare the proliferative potency of various insulin 
analogues with regular insulin in mammary epithelial cell lines. For this, we will screen a 
panel of mammary epithelial cell lines for their insulin responsiveness and select the strongly 
insulin responsive cell lines for the comparative analysis of insulin analogues proliferative 
potency.  
Thereafter, we compare the signalling potency of insulin analogues with regular insulin. 
Specifically, we consider analysis of PI3K and MAPK pathways as these two pathways are 
activated by regular insulin and are involved in cell proliferation. The activation of these two 
pathways is studied by analysing the phosphorylation status of key signalling molecules after 
treatment with regular insulin or insulin analogues. For studying PI3K pathway activation, 
Akt and GSK3α/β phosphorylation status is studied. MAPK pathway activation is analysed by 
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studying phosphorylation status of Erk1/2. Specific inhibitors against both pathways are 
exploited to identify the pathway related to proliferation induced by insulin analogues.  
In addition, we aim to study the role of insulin receptor and IGF-IR in the proliferative 
potency of insulin analogues that show significantly higher proliferation than regular insulin. 
We utilize RNAi technique to specifically target insulin receptor and IGF-IR. This will enable 
us to identify the receptor that is mainly activated by insulin analogues. In addition, it will 
also permit comparative analysis of PI3K and MAPK pathways activated by treatment with 
insulin, IGF-I and insulin analogues. The receptor identified to play the more important role 
in proliferation is further analysed. Immunoprecipitation is used to gain understanding of 
receptor activation by studying the phosphorylation status of the receptor after treatment with 
insulin, IGF-I and insulin analogue. Furthermore, the activation of this receptor is eventually 
corroborated by studying the expression of a downstream target gene at the transcriptional 
level using quantitative RT-PCR.  
In order to clarify the potential activation of the cross-talk between insulin receptor/IGF-IR 
and ERα by insulin analogues, we determine the activation of ERα by analysing the 
phosphorylation status of Ser118 at ERα as well as ERE-dependent gene expression. 
Moreover, we aim to extend our study to the possible tumour-promoting potential of those 
insulin analogues that demonstrate significantly higher proliferative potency than regular 
insulin. We assess this by employing the ‘wound-healing assay’ for studying cell migration.  
To summarise, the objective of this study is to perform a detailed comparative analysis of 
proliferative and signalling potency of insulin analogues in insulin responsive mammary 
epithelial cell lines, and to elucidate the role of insulin receptor, IGF-IR and ERα in the 
mitogenic potency of insulin analogues. 
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3. RESULTS 
3.1 Screening of mammary epithelial cell lines 
In order to compare the mitogenic potency of insulin analogues with regular insulin we 
needed to identify ‘insulin responsive’ mammary epithelial cell lines. For this, we studied the 
proliferative response of a panel of mammary epithelial cell lines to treatment with regular 
insulin. In addition, we studied the expression pattern of insulin receptor, IGF-IR and ERα to 
gain more information about cell characteristics.  
3.1.1 Proliferative response to the insulin treatment  
To determine the insulin responsiveness of mammary epithelial cell lines, we treated cells 
with regular insulin (Actrapid or bovine insulin) for 72 hrs and measured proliferative 
response by colorimetric proliferation assay. Cells were treated with very high concentration 
(1.5µM) of regular insulin to stimulate maximum proliferation. Proliferation response 
(obtained as absorbance value) of insulin-treated cells was normalized with that of untreated 
cells so to obtain the ‘fold of control’. 
Cell line Tumor 
Type of normal 
insulin used 
Fold of Control 
MCF10A No* Actrapid 1.7 ± 0.20 
BT474 Yes* Bovine Insulin 0.9 ± 0.05 
MCF7 Yes* Actrapid 2.2 ± 0.28 
T47D Yes* Bovine Insulin 1.1  ± 0.04 
ZR75-1 Yes* Actrapid 1.4 ± 0.20 
MDA-MB231 Yes* Bovine Insulin 1.3 ± 0.12 
HCC1937 Yes* Bovine Insulin 1.1 ± 0.05 
 
Table 3.1 MCF10A and MCF7 exhibited highest insulin induced proliferation among the panel 
of cell lines tested. Cells were starved for 24 h in medium containing 2% charcoal-stripped serum and 
then were treated with 1.5µM insulin for 48 h (MCF10A) or for 72 h (all other cell lines). Thereafter, 
cells were fixed with 3% paraformaldehyde in PBS, stained with crystal violet and absorbance was 
read at 595nm. Fold of control was calculated by comparing the growth achieved in absence or 
presence of insulin. *, information regarding tumorigenicity of the cell lines was obtained from the 
ATCC website.  
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HCC1937, BT474 and T47D demonstrated poor proliferative response to the insulin treatment 
(Table 3.1). MDA-MB231 and ZR75-1 showed relatively moderate proliferation response to 
the insulin treatment, demonstrating approximately 1.3 to 1.4-fold increase in proliferation. In 
MCF10A cells, a benign mammary epithelial cell line, insulin treatment induced 
approximately 1.7-fold increase in proliferation. The strongest response to insulin treatment 
(approximately 2.2-fold) was observed in MCF7 cells, a malignant mammary epithelial cell 
line.  
As MCF10A and MCF7 showed the maximum proliferative response to the insulin treatment 
among the cell lines tested, we utilized these two cell lines for carrying out comparative 
analysis of proliferative and signalling potency of regular insulin and insulin analogues 
(Humalog, Novorapid, Lantus and Levemir) approved for therapeutical use.  
3.1.2 Expression pattern of Insulin Receptor, IGF-IR and ERα 
The above mentioned seven mammary epithelial cell lines  were studied for the expression 
pattern of insulin receptor, IGF-IR and ERα (Fig. 3.1). The MELN cells, a sub-cell line of 
MCF7 which are stably transfected with ERE-dependent firefly luciferase reporter gene, were 
also included in this analysis. All the cell lines analyzed, showed moderate  levels of insulin 
receptor. IGF-IR expression level varied among the cell lines. It was found to be strongly 
expressed in MCF7 and weakly expressed in HCC1937. T47D, BT474, MDA-MB231, ZR75-
1, and MCF10A cells showed comparatively moderate expression of IGF-IR. 
 
IRβ 
IGF-IRβ 
ERα 
Figure 3.1. Expression profile of insulin receptor, IGF-IR and ERα in mammary epithelial cell 
lines. Lysates from the mammary cells were resolved by SDS-PAGE and immunoblots were probed 
for the expression of insulin receptor and IGF-IR by antibodies against beta-subunit of insulin receptor 
(IR) and IGF-IR, respectively. Anti- ERα was used for detecting ERα. 
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Regarding ERα expression pattern, three cell lines, MCF10A, MDA-MB231 and HCC1937, 
did not show any expression of ERα protein. All other cell lines expressed ERα and like IGF-
IR, ERα was also found to be strongly expressed in MCF7 cells. 
3.2 Dose-dependent proliferative response to insulin and insulin analogues 
in MCF10A and MCF7 cells 
In order to study the dose-dependence of the proliferative response of MCF10A and MCF7 
cells to the regular insulins and insulin analogues, cells were treated with increasing 
concentrations (1.5nM, 15nM, 150nM and 1.5µM) of each compound and subjected to  
colorimetric proliferation assay. Fold of control was calculated for each dosage of treatment. 
For estimating the mitogenic potency of insulin analogues, the proliferation response obtained 
with insulin analogues was compared with the proliferation response obtained with regular 
insulin.  
3.2.1 Study of MCF10A cell proliferation using colorimetric method 
Actrapid treatment induced proliferation response in MCF10A cells at all concentrations 
tested (Fig. 3.2). At 1.5nM, proliferation response to Actrapid was merely 1.1-fold of 
untreated cells. Treatment of MCF10A cells with 15nM, 150nM or 1.5µM Actrapid resulted 
in approximately 1.7-fold increase in the proliferation response compared to untreated cells 
indicating a saturation in response at 15nM of Actrapid. 
 
Figure 3.2 Proliferative ability of insulin and insulin analogues are similar in MCF10A cells. 
MCF10A cells were starved for 24 h in growth medium without insulin and then were treated with 
increasing concentrations (1.5nM to 1.5µM) of insulin and insulin analogues for 48 h. Thereafter, cells 
were fixed and stained with crystal violet dye. After air drying, stain was dissolved in 10% acetic acid 
and the absorbance was measured at 595nm in the plate reader. The values presented are the 
mean ± SD of n = 16.  
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The proliferation levels observed in MCF10A cells treated with bovine insulin were similar to 
the proliferation levels obtained with Actrapid treatment thus suggesting similar mitogenic 
potency of the two regular insulins in MCF10A cells. Treatment of MCF10A cells with any of 
the four insulin analogues resulted in proliferation levels that were comparable to the 
proliferation levels observed with regular insulins. Thus, regarding stimulation of proliferation 
in MCF10A cells, insulin analogues are equipotent to regular insulins.  
 
3.2.2 Study of MCF7 cell proliferation using colorimetric method 
In contrast to MCF10A cells, the treatment of MCF7 cells with increasing concentrations of 
Actrapid led to gradual increase in proliferation (Fig. 3.3a). With 1.5nM Actrapid, 
approximately 1.2-fold increase in proliferation level was observed and this reached to the 
maximum value of 2.2-fold with 1.5µM Actrapid treatment. Bovine insulin yielded 
proliferation levels comparable to Actrapid treatment in MCF7 cells, which again suggests 
equipotency of two regular insulins.  
 
 
Figure 3.3a Lantus demonstrates highest proliferative ability in comparison to regular insulins 
and insulin analogues in MCF7 cells.  MCF7 cells were starved for 24 h in medium containing 2% 
DCC-FBS and then were treated with increasing concentrations of insulin and insulin analogues for 72 
h. Thereafter cells were fixed and stained with crystal violet dye. After air drying, the stain was 
dissolved in 10% acetic acid and the absorbance was measured at 595nm in a plate reader. Values 
presented are the mean ± SD of n = 20. The statistical analysis was done by using student’s t-test. 
Asterisks (*) show statistically significant (p < 0.05, t-test) difference between two data points.  
 
Humalog and Novorapid induced proliferation in MCF7 cells at all concentrations studied. 
The increase in proliferation observed with these two insulin analogues was similar to that 
obtained from regular insulins. In comparison to regular insulins, Novorapid induced slightly 
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stronger proliferation but the difference was not found to be statistically significant. 
Interestingly, MCF7 cell treatment with the two long-acting insulin analogues, Lantus and 
Levemir, yielded opposite effect. Treatment of MCF7 cells with 1.5nM and 15nM dosage of 
Levemir resulted in approximately 1.2-fold increase in proliferation which is comparable to 
the fold increase seen with Actrapid and bovine insulin at these concentrations. At higher 
concentrations (150nM and 1.5µM), Levemir was found to be slightly weaker in inducing 
MCF7 cell proliferation compared to the regular insulins. 
However, treatment with Lantus elicited strong proliferative response in MCF7 cells at or 
above 1.5nM. At 1.5nM Lantus concentration, approximately 1.5-fold increase in 
proliferation was observed in comparison to untreated cells and this proliferation response 
increased to 1.8-fold at 15nM concentration. At higher dosages of 150nM and 1.5µM,  Lantus 
induced even stronger proliferation of MCF7 cells, namely 2.7-fold and 3.1-fold in 
comparison to untreated cells, respectively. The statistical analysis showed that at 
concentrations ≥ 1.5nM, the fold of control obtained with Lantus are significantly higher 
compared to the fold of control obtained with Actrapid or bovine insulin.  
 
 
Figure 3.3b Lantus induces stronger proliferation at 1.5pM and 15pM and significantly higher 
proliferation at 150pM concentration compared to regular insulin in MCF7 cells.  MCF7 cells 
were starved for 24 h in medium containing 2% DCC-serum and then were treated with increasing 
concentrations of Actrapid or Lantus for 72 h. Thereafter, cells were fixed and stained with crystal 
violet dye. After air drying, the stain was dissolved in 10% acetic acid and the absorbance was 
measured at 595nm in a plate reader. The values presented are the mean ± SD of n = 20. The statistical 
analysis was done by using student’s t-test. Asterisk (*) shows statistically significant (p < 0.05, t-test) 
difference between two data points.  
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The observation that 1.5nM Lantus induces significantly stronger proliferative response of 
MCF7 cells than 1.5nM Actrapid motivated us to compare the proliferative ability of Lantus 
and Actrapid at lower concentrations (1.5pM, 15pM and 150pM). Our results show that even 
at 150pM concentration Lantus had significantly higher proliferative effect when compared to 
150pM Actrapid (Fig. 3.3b). Also, at 1.5pM and 15pM concentration, Lantus treatment 
yielded stronger proliferation than Actrapid, though the difference was not statistically 
significant. The dose-response model showed initial statistically significant growth response 
(given by the ED10 estimation) of MCF7 cells to Actrapid at 5.2 nM (95% confidence 
intervals, lower: -1.0571e-09 mol l-1, upper: 1.143e-08 mol l-1) and to Lantus at 0.31 nM (95% 
confidence intervals: lower: -7.8890e-11 mol l-1, upper: 7.059e-10 mol l-1) concentrations. 
To summarise, Humalog, Novorapid and Levemir had similar proliferative potency as normal 
insulins in MCF7 cells. Lantus, in comparison to the regular insulins, had significantly higher 
proliferative potency and was found to be approximately 1.5-fold stronger than Actrapid in 
eliciting proliferation of MCF7 cells at the concentrations ≥ 150pM.  
 
3.2.3 Study in MCF7 cells by FACS analysis of BrdU incorporation 
In order to gain more information regarding the proliferative ability of insulin and insulin 
analogues and to confirm our data regarding strong proliferative effect of Lantus in MCF7 
cells, we chose FACS analysis of BrdU incorporation as a second readout.  
 
 
Figure 3.4 Lantus demonstrates strongest increase in BrdU incorporation in MCF7 cells when 
compared with insulin and insulin analogues. MCF7 cells were starved in medium containing 2% 
charcoal stripped serum for 24 h and then were stimulated with regular insulins or insulin analogues 
for 16 h. Cells were then incubated in 10µM BrdU for 1 hr and submitted to FACS analysis. Fold of 
control was calculated by comparing the BrdU incorporation in the absence or presence of insulin 
treatment. The values presented are the mean and range of duplicates. 
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Herein, we studied BrdU incorporation in MCF7 cells stimulated with regular insulins or 
insulin analogues for 16 h at two low concentrations (1.5nM and 15nM). MCF7 cells treated 
with Actrapid or bovine insulin exhibited increased BrdU incorporation in comparison to the 
untreated cells (Fig. 3.4). Treatment of MCF7 cells with 1.5nM Humalog or 1.5nM Novorapid 
demonstrated similar levels of BrdU incorporation as was observed with 1.5nM of regular 
insulins. 15nM Humalog or 15nM Novorapid however were approximately 2-fold stronger 
than Actrapid in stimulating BrdU incorporation. Treatment of MCF7 cells with 1.5nM or 
15nM concentration of Levemir yielded slightly lower levels of BrdU incorporation in 
comparison to Actrapid. 
In agreement with the data obtained from colorimetric proliferation assay (Fig. 3.3A), Lantus 
induced highest increase in BrdU incorporation in comparison to both regular insulins and any 
of the other insulin analogues. The comparative analysis of BrdU incorporation at 1.5nM and 
15nM concentration of Lantus and Actrapid revealed that Lantus treatment led to 
approximately 1.5-fold (at 1.5nM) and 3-fold (at 15nM) higher BrdU incorporation than 
Actrapid. Taken together, the results from colorimetric proliferation assay (Section 3.2.2) and 
FACS analysis of BrdU incorporation clearly establish that in MCF7 cells Lantus has 
significantly higher proliferative potency than regular insulins or other insulin analogues 
studied. 
3.3 Study of PI3K and MAPK signalling pathways in MCF10A and MCF7 
cell lines 
As described in section 2.4.4, biochemical properties of insulin analogues differ from regular 
insulin with respect to insulin receptor and IGF-IR binding affinity. This may result in 
differential activation of PI3K and MAPK pathways, the two insulin-activated pathways that 
are involved in cell proliferation. In this regard, it will be interesting as well as important to 
study the effect of insulin analogues on stimulation of both PI3K and MAPK pathways. 
3.3.1 Activation of PI3K pathway by insulin and insulin analogues in MCF10A 
and MCF7 cells 
In order to investigate the effect of regular insulin and insulin analogues on PI3K pathway, 
cells were treated with the compounds and phosphorylation status of Akt and GSK3α/β 
proteins, two important signalling molecules of the PI3K pathway, was studied. As insulin 
analogues may show altered affinity for IGF-IR, MCF7 cells treated with IGF-I, the 
physiological ligand of IGF-IR, were also analyzed. To determine the signalling potency of 
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insulin analogues, the phosphorylation status of signalling molecules were compared in cells 
treated for 10 min with 15nM of insulin analogue and regular insulin. 
3.3.1.1 Study of Akt phosphorylation in MCF10A cells 
The MCF10A cells were either left untreated or were treated with regular insulins (Actrapid 
or bovine insulin), insulin analogues or IGF-I.  
 
Figure 3.5 Only Lantus induced significantly stronger Akt phosphorylation in MCF10A cells in 
comparison to regular insulins. 5 x 105 MCF10A cells were plated and starved for 24 h in medium 
without insulin. Then cells were either processed untreated (Un) or after 10 min incubation with 15nM 
insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – Lantus, Le – Levemir, H – 
Humalog and N – Novorapid). IGF-I (I; 15nM) was studied for comparison. The cell lysates were 
resolved by 10% SDS-PAGE and immunoblots were probed for phosphorylated Akt and total Akt.  
Fold of control was obtained by normalizing phosphorylated forms over the protein levels and then 
comparing with the untreated sample. Statistical analysis was done by using student’s t-test with at 
least three independent experiments and asterisk shows the significant difference (p<0.05) between 
Lantus and Actrapid.  
 
The basal Akt phosphorylation in untreated MCF10A cells was almost undetectable in the 
immunoblots suggesting that endogenous Akt activity is very low (Fig. 3.5 lane; ‘Un’). 
Treatment of MCF10A cells with bovine insulin (lane ‘B’) or Actrapid (lane ‘A’) increased 
phosphorylated Akt level substantially. However, the strongest increase in Akt 
phosphorylation level was observed after IGF-I treatment (lane ‘I’). It was approximately two 
times higher than that observed with regular insulin. The Akt phosphorylation levels after 
Humalog (lane ‘H’), Novorapid (lane ‘N’) or Levemir (lane ‘Le’) treatment was similar to the 
Akt phosphorylation level from regular insulin treatment. Treatment of MCF10A cells with 
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Lantus (lane ‘La’) showed strong phosphorylation of Akt. It was found to be approximately 
1.7-fold stronger than Actrapid. Statistical analysis revealed that Lantus-induced Akt 
phosphorylation levels were significantly higher compared to the levels observed with regular 
insulins.  
Thus, with respect to Akt phosphorylation, signalling potency of Humalog, Novorapid and 
Levemir was similar to regular insulin in MCF10A cells. However, Lantus was significantly 
stronger than regular insulins in inducing Akt phosphorylation.  
3.3.1.2 Study of GSK3α/β phosphorylation in MCF10A cells 
The phosphorylation levels of GSK3α/β in untreated MCF10A cells were very low (Fig. 3.6; 
lane ‘Un’). Short term incubation of cells with bovine insulin or Actrapid, resulted in strong 
increase of GSK3α/β phosphorylation levels (lanes ‘B’ and ‘A’).  
 
Figure 3.6 All insulin analogues are similar to regular insulins in inducing GSK3α/β 
phosphorylation in MCF10A cells. 5x105 MCF10A cells were plated and starved for 24 h in medium 
without insulin. Then cells were either processed untreated (Un) or after 10 min incubation with 15nM 
insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – Lantus, Le – Levemir, H – 
Humalog and N – Novorapid). IGF-I (I; 15nM) was studied for comparison. The cell lysates were 
resolved by 10% SDS-PAGE and immunoblots were probed for phosphorylated GSK3α/β and total 
GSK3α/β.  Fold of control was obtained by normalizing phosphorylated forms over the protein levels 
and then comparing with the untreated sample. Statistical analysis was done by using student’s t-test 
with at least three independent experiments. 
 
Surprisingly, IGF-I was equi-potent to regular insulins in inducing GSK3α/β phosphorylation 
(lane ‘I’) which is in contrast to the observed stronger effect of IGF-I in inducing Akt 
phosphorylation (refer to section 3.3.1.1). Treatment of MCF10A cells with Humalog, 
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Novorapid or Levemir caused similar increase in GSK3α/β phosphorylation levels as was 
obtained after treatment with regular insulins (compare lane ‘H’, ‘N’ and ‘Le’ with the lane 
‘A’ or ‘B’). Unexpectedly, Lantus treatment did not induce significantly higher 
phosphorylation levels of GSK3α/β in comparison to Actrapid treatment. To sum up, all 
insulin analogues were equi-potent to regular insulin in inducing GSK3α/β phosphorylation in 
MCF10A cells. Combining these results with the Akt phosphorylation results, it can be 
suggested that Humalog, Novorapid and Levemir are equi-potent to regular insulins in 
activating PI3K pathway. Lantus may be stronger than regular insulins in this regard. 
3.3.1.3 Study of Akt phosphorylation in MCF7 cells 
The endogenous Akt phosphorylation level in MCF7 cells was very low (Fig. 3.7 ; lane ‘Un’).  
Treatment with bovine insulin or Actrapid led to increase in Akt phosphorylation levels (lanes 
‘B’ and ‘A’). Actrapid had slightly stronger effect than bovine insulin but it was not found to 
be significantly higher.  
 
Figure 3.7 Of all insulin analogues studied, Lantus induces significantly stronger and Levemir 
induces significantly weaker phosphorylation of Akt in comparison to regular insulins in MCF7 
cells. 5x105 MCF7 cells were plated and starved for 24 h in serum free medium. Then cells were either 
processed untreated (Un) or after 10 min incubation with 15nM insulin (B – Bovine Insulin and A – 
Actrapid) or insulin analogues (La – Lantus, Le – Levemir, H – Humalog and N – Novorapid). IGF-I 
(I; 15nM) was studied for comparison. The cell lysates were resolved by 10% SDS-PAGE and 
immunoblots were probed for phosphorylated Akt and total Akt.  Fold of control was obtained by 
normalizing phosphorylated forms over the protein levels and then comparing with the untreated 
sample. Statistical analysis was done by using student’s t-test with at least three independent 
experiments and asterisk shows the significant differences (p<0.05) between Lantus and Actrapid or 
Levemir and Actrapid.  
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As was observed with MCF10A cells, IGF-I treatment to MCF7 cells induced strong 
phosphorylation of Akt (lane ‘I’). IGF-I was approximately 2.5 times stronger than regular 
insulins. Both Humalog and Novorapid induced similar Akt phosphorylation levels as was 
achieved with Actrapid treatment (refer to the lanes marked as ‘H’ and ‘N’ and compare with 
lane ‘A’). However, treatment of MCF7 cells with Levemir (lane ‘Le’) and Lantus (lane ‘La’) 
yielded contrasting results on Akt phosphorylation. Levemir was significantly  weaker than 
Actrapid in inducing Akt phosphorylation (approximately 2-fold). On the contrary, Lantus 
treated MCF7 cells exhibited significantly higher Akt phosphorylation levels (approximately 
2.2-fold) relative to Actrapid treated MCF7 cells (compare lanes ‘La’ and ‘A’). 
In summary, Humalog and Novorapid were equi-potent to regular insulin in inducing Akt 
phosphorylation in MCF7 cells. Levemir induced significantly weaker effect while Lantus 
induced significantly stronger effect than regular insulin in inducing Akt phosphorylation. 
3.3.1.4 Study of GSK3α/β phosphorylation in MCF7 cells 
Basal level of GSK3α/β phosphorylation in MCF7 cells was low (Fig. 3.8; refer to the lane 
marked as ‘Un’). Treatment with bovine insulin or Actrapid induced approximately 2.2-fold 
higher phosphorylation of GSK3α/β when compared with endogenous GSK3α/β 
phosphorylation levels (refer to the lanes marked as ‘B’ and ‘A’ for treatment with bovine 
insulin or Actrapid respectively and compare with lane marked as ‘Un’). IGF-I (lane ‘I’) 
treatment induced strongest increase in GSK3α/β phosphorylation levels (approximately 3.5-
fold of endogenous level). MCF7 cells treated with Humalog (lane marked as ‘H’) or 
Novorapid (lane marked as ‘N’) also showed approximately 2.2-fold increase in GSK3α/β 
phosphorylation levels as was observed with Actrapid treatment (compare lanes ‘H’ and ‘N’ 
with lane ‘A’). Treatment of MCF7 cells with Levemir (lane marked as ‘Le’) and Lantus (lane 
marked as ‘La’) showed opposite effect. Levemir, in comparison to Actrapid, was 
significantly weaker in inducing GSK3α/β phosphorylation (approximately 0.5-fold weaker). 
The treatment with Lantus, however, resulted in 1.5-fold increase in GSK3α/β 
phosphorylation levels in comparison to Actrapid (refer to the lane marked as ‘La’ and 
compare with lane ‘A’). Statistical analysis showed the difference to be significant. 
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Figure 3.8 Of all insulin analogues studied, Lantus induces significantly stronger and Levemir 
induces significantly weaker phosphorylation of GSK3α/β in comparison to regular insulins in 
MCF7 cells. 5 x 105 MCF7 cells were plated and after 24 h were starved for another 24 h in serum free 
medium. Then cells were either processed untreated (Un) or after 10 min incubation with 15nM 
insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – Lantus, Le – Levemir, H – 
Humalog and N – Novorapid). IGF-I (I; 15nM) was studied for comparison. The cell lysates were 
resolved by 10% SDS-PAGE and immunoblots were probed for phosphorylated GSK3α/β and total 
GSK3α/β.  Fold of control was obtained by normalizing phosphorylated forms over the protein levels 
and then comparing with the untreated sample. Statistical analysis was done by using student’s t-test 
with at least three independent experiments and asterisk shows the significant difference (p<0.05) 
between Lantus and Actrapid or Levemir and Actrapid. 
 
In summary, the two short acting insulin analogues, Humalog and Novorapid, were equi-
potent to normal insulins in inducing GSK3α/β phosphorylation. However, the two long 
acting insulin analogues were opposite in their effect. Levemir was weak and Lantus was 
strongest of all insulin analogues in stimulating GSK3α/β phosphorylation. From the results 
on GSK3α/β phosphorylation and Akt phosphorylation, it may be concluded that Humalog 
and Novorapid are similar to regular insulins in activating PI3K pathway. Levemir is weaker 
while Lantus is significantly stronger than regular insulin in activating PI3K pathway.   
3.3.2 Activation of MAPK pathway by insulin and insulin analogues in 
MCF10A and MCF7 cells 
Erk1/2 represent the down most effector molecules of the Mitogen Activated Protein Kinase 
(MAPK) pathway. The phosphorylation levels of these signalling molecules were compared 
in cells treated with insulin analogues and regular insulin in order to gain knowledge of the 
signalling potency of insulin analogues at the MAPK pathway level.  
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3.3.2.1 Study of Erk1/2 phosphorylation in MCF10A cells 
The untreated MCF10A cells showed low levels of Erk1/2 phosphorylation (Fig. 3.9; lane 
‘Un’). Short term incubation of MCF10A cells with regular insulin (bovine insulin - ‘B’ and 
Actrapid - ‘A’) resulted in 10 to 12-fold higher Erk1/2 phosphorylation in comparison to 
untreated cells. IGF-I being a strong mitogen induced highest increase in Erk1/2 
phosphorylation levels (about 35-fold of untreated sample; lane ‘I’). Treatment of MCF10A 
cells with Levemir (lane ‘Le’) and Humalog (lane ‘H’) yielded similar Erk1/2 
phosphorylation levels as observed after treatment with the regular insulins (compare ‘Le’ and 
‘H’ with lanes ‘A’ or ‘B’). 
 
Figure 3.9 All insulin analogues tested were equi-potent to regular insulins in inducing Erk1/2 
phosphorylation in MCF10A cells. 5 x 105 MCF10A cells were plated and after 24 h were starved for 
another 24 h in insulin deprived medium. Then cells were either processed untreated (Un) or after 10 
min incubation with 15nM insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – 
Lantus, Le – Levemir, H – Humalog and N – Novorapid). IGF-I (I; 15nM) was studied as a positive 
control. The cell lysates were resolved by 10% SDS-PAGE and immunoblots were probed for 
phosphorylated Erk1/2 and total Erk1/2.  Fold of control was obtained by normalizing phosphorylated 
forms over the protein levels and then comparing with the untreated sample. Statistical analysis was 
done by using student’s t-test with at least three independent experiments.  
 
Interestingly, short term treatment with Lantus (lane ‘La’) or Novorapid (lane ‘N’) led to 
slight increase in the Erk1/2 phosphorylation status in comparison to regular insulins but the 
differences observed were not significant (compare lanes ‘La’ and ‘N’ with ‘A’ or ‘B’). Thus, 
it can be concluded that in MCF10A cells all insulin analogues were equi-potent to regular 
insulin in inducing Erk1/2 phosphorylation. 
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3.3.2.2 Study of Erk1/2 phosphorylation in MCF7 cells 
The endogenous Erk1/2 phosphorylation levels in MCF7 cells were also very low (Fig. 3.10; 
lane ‘Un’). Treatment with regular insulins and IGF-I led to increase in Erk1/2 
phosphorylation levels (bovine insulin - ‘B’, Actrapid - ‘A’ or IGF-I - ‘I’). Bovine insulin and 
Actrapid induced approximately three fold increase over the endogenous levels. IGF-I being a 
strong mitogen, showed the strongest effect (approximately 12-fold increase in comparison to 
endogenous levels).  
 
Figure 3.10 Lantus induced significantly stronger Erk1/2 phosphorylation in comparison to 
Actrapid in MCF7 cells. 5 x 105 MCF7 cells were plated and after 24 h were starved for another 24 h 
in serum free medium. Then cells were either processed untreated (Un) or after 10 min incubation with 
15nM insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – Lantus, Le – Levemir, 
H – Humalog and N – Novorapid). IGF-I (I; 15nM) was studied as a positive control. The cell lysates 
were resolved by 10% SDS-PAGE and immunoblots were probed for phosphorylated Erk1/2 and total 
Erk1/2. Fold of control was obtained by normalizing phosphorylated forms over the protein levels and 
then comparing with the untreated sample. Statistical analysis was done by using student’s t-test with 
at least three independent experiments and asterisk shows the significant difference (p<0.05) between 
Lantus and Actrapid. 
 
Treatment of MCF7 cells with either Humalog (lane ‘H’) or Novorapid (lane ‘N’) induced 
slightly but not significantly stronger phosphorylation of Erk1/2 compared to Actrapid or 
bovine insulin (compare lanes ‘H’ and ‘N’ with ‘A’ or ‘B’). Again, as observed with the 
phosphorylation of Akt and GSK3α/β, treatment of MCF7 cells with Levemir or Lantus 
yielded opposite results on induction of Erk1/2 phosphorylation. In comparison to Actrapid, 
Levemir was approximately 1.5-fold weaker in inducing Erk1/2 phosphorylation (compare 
‘Le’ with ‘A’). On the contrary, Lantus induced very strong phosphorylation of Erk1/2 and 
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showed approximately 2-fold stronger effect than Actrapid. The statistical analysis showed 
that phosphorylation is significantly stronger than with regular insulins (compare lane ‘La’ 
with lane ‘A’ and ‘B’).  
To summarise, in MCF7 cells, Humalog and Novorapid were equi-potent to the regular 
insulins in inducing Erk1/2 phosphorylation. Levemir was weaker than regular insulins and 
Lantus strongly induced Erk1/2 phosphorylation thus suggesting strong activation of MAPK 
pathway by Lantus.  
3.3.2.3 Study of p38 phosphorylation in MCF7 cells 
The p38 MAPK when activated by phosphorylation leads to inhibition of proliferation (Zhang 
and Liu, 2002). Phosphorylated p38 has been reported to negatively regulate expression of 
cyclin D1 gene which is important for cell cycle progression. Thus, its effect is opposite to 
that of Erk1/2 MAPK. To gain further insights into the activation of MAPK pathway by 
insulin analogues in MCF7 cells, we studied phosphorylation status of p38 protein.  
 
Figure 3.11 Insulin analogues did not differ from regular insulins regarding their effect on p38 
phosphorylation in MCF7 cells. 5x105 MCF7 cells were plated and after 24 h were starved for 
another 24 h in serum free medium. Then cells were either processed untreated (Un) or after 10 min 
incubation with 15nM insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – 
Lantus, Le – Levemir, H – Humalog and N – Novorapid). IGF-I (I; 15nM) was studied as a positive 
control. The cell lysates were resolved by 10% SDS-PAGE and immunoblots were probed for 
phosphorylated p38 and total p38.  Fold of control was obtained by normalizing phosphorylated forms 
over the protein levels and then comparing with the untreated sample. The figure represents mean ± 
SD of datapoints from at least three independent experiments. 
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Interestingly, the basal phosphorylation level of p38 was very high suggesting growth 
inhibiting experimental conditions (Fig. 3.11; lane ‘Un’).  The treatment with normal insulin 
did not lead to any significant alteration in the phosphorylation levels of p38 (refer to the 
lanes marked as ‘B’ and ‘A’ for treatment with bovine insulin or Actrapid respectively). 
However, IGF-I treatment resulted in clear although not significant increase in p38 
phosphorylation (refer to the lane marked as ‘I’ and compare with ‘Un’). This is at variance 
with the anti-proliferative effect of phospho-p38 and suggests other roles of phospho-p38 in 
cell functions.  Treatment of MCF7 cells with insulin analogues did not show any significant 
change in the p38 phosphorylation levels in comparison to regular insulin (refer to the lanes 
marked as ‘H’, ‘N’, ‘Le’ and ‘La’ for Humalog, Novorapid, Levemir and Lantus respectively 
and compare with lane ‘A’ and ‘B’). Thus, unlike Erk1/2 MAPK pathway, p38 MAPK 
pathway remains unaffected by insulin analogues in comparison to regular insulins. 
3.3.2.4 Role of MAPK in Lantus induced MCF7 cell proliferation 
The Erk1/2 MAPK pathway is a well established mitogenic pathway in MCF7 cells (Lu and 
Campisi, 1992; Jhun et al., 1994). However, some studies show that the PI3K signalling 
pathway can also transduce proliferation signals in MCF7 cells (Dufourny et al., 1997).  
 
Figure 3.12 MAPK pathway is the major proliferation pathway in Lantus-induced MCF7 cell 
proliferation. 1 x 104 MCF7 cells were plated per well of a 96-well plate. After 24 h, cells were 
starved for another 24 h in growth medium containing 2% DCC stripped serum. The specific inhibitors 
for PI3K pathway (Wortmannin) and MAPK pathway (U0126) were added in combination with 
150nM Actrapid or 150nM Lantus for another 72 h. The medium was changed every 24 h. After 72 h 
of incubation cells were PBS washed and fixed by 3% PFA and stained with crystal violet dye. The 
dye was dissolved in 10% acetic acid and absorbance was measured at 595nm in the plate reader. 
Values presented are the mean ± SD of n = 8. The statistical analysis was done by using student’s t-
test. Asterisk (*) shows statistically significant (p < 0.05, t-test) difference between Lantus and 
Actrapid data points.  
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Our proliferation assays demonstrated that Lantus induced MCF7 cell proliferation 
significantly stronger than regular insulins. As Lantus stimulated both PI3K and MAPK 
pathways strongly (Section 3.3.1 and Section 3.3.2) it remained to be determined which 
pathway was related to the strong proliferation of MCF7 cells in our experiments. To achieve 
this, MCF7 cells were treated with specific inhibitors of PI3K or MAPK pathways and 
stimulated with Actrapid or Lantus. The proliferation levels were assessed by colorimetric 
proliferation assays. Wortmannin, which inhibits the catalytic subunit of PI3K (p110), was 
used for inhibiting PI3K pathway. For inhibition of MAPK pathway, U0126 was used which 
binds to MAPKK, an upstream effector of Erk1/2. The colorimetric proliferation assay was 
performed on MCF7 cells treated with Actrapid or Lantus in combination with either 
Wortmannin or U0126. As both inhibitors were dissolved in DMSO, proliferation levels were 
analysed in cells treated only with DMSO or treated with DMSO in combination with 
Actrapid or Lantus for proper comparison. 
Lantus induced stronger proliferation than Actrapid in presence of DMSO indicating 
negligible effect of DMSO (Fig. 3.12). Wortmannin treatment slightly diminished Actrapid 
and Lantus-induced proliferation. Nevertheless, Lantus induced proliferation was still stronger 
in comparison to Actrapid. Interestingly, U0126 treated MCF7 cells did not proliferate in 
response to Actrapid and Lantus treatment. Thus, the above inhibitor experiment clearly 
demonstrates that in MCF7 cells the MAPK pathway is the major proliferation pathway 
activated by Actrapid and Lantus.  
3.4 Understanding the molecular mechanism behind increased 
proliferative effect of Lantus in MCF cells 
Sections 3.3.1.3, 3.3.1.4 and 3.3.2.2 clearly demonstrated that Lantus has significantly higher 
signalling potency in comparison to all other insulin analogues tested and, most importantly, 
to regular insulin in MCF7 cells. This higher signalling potency is reflected in stronger 
proliferative potency of Lantus in comparison to regular insulin and other insulin analogues 
tested in MCF7 cells. The strong proliferative potency of Lantus may be due to strong 
activation of insulin receptor or may involve IGF-IR. ERα activation also induces 
proliferation of MCF7 cells and as described in section 2.5.3.2, ERα can cross-talk with IGF-
IR. As ERα is abundantly expressed by MCF7 cells, there is a possibility that it may 
contribute to the proliferative potency of Lantus in MCF7 cells. Therefore, we investigated 
the role of insulin receptor, IGF-IR and ERα in the proliferative ability of Lantus.  
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3.4.1 Investigating the role of insulin receptor in the strong proliferative potency 
of Lantus  
MELN cells are MCF7 cells stably transfected with ERE dependent firefly luciferase reporter 
gene. We utilised MELN cells for siRNA studies as MELN cells are easier to transfect than 
MCF7 cells. In order to study the involvement of insulin receptor in the strong signalling 
potency of Lantus, MELN cells were transfected with non-targeting siRNA (CT2 siRNA) or 
insulin receptor targeting siRNA. Thereafter, cells were stimulated for short term (10 min) 
with 15nM Actrapid, Lantus or IGF-I and phosphorylation status of Akt and Erk1/2 
(important molecules of PI3K and MAPK signalling pathways, respectively) was studied.  
 
Figure 3.13a Insulin receptor knockdown in MELN cells. 3 x 105 MELN cells were plated per well 
of a 6-well plate. After 12 h, cells were transfected with either 25nM of non-taregting siRNA (CT2 
siRNA) or 25nM of insulin receptor targeting siRNA. After 48 h of transfection, cells were starved for 
next 24 h in serum-free medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 
15nM Actrapid (‘A’), 15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium 
was aspirated, cells were washed with PBS and cell lysates were prepared as mentioned in the 
Methods section. Equal amount of cell lysate was loaded and samples were resolved by 10% SDS-
PAGE. After membrane transfer, blots were probed first for insulin receptor (IR) and then stripped and 
probed for IGF-IR.  
MELN cells treated with siRNA targeting insulin receptor showed 70% decrease in the insulin 
receptor protein level (Fig. 3.13a; compare insulin receptor protein levels in samples treated 
with non-targeting siRNA or with insulin receptor targeting siRNA). The siRNA against 
insulin receptor did not target IGF-IR (refer to the immunoblot probed with antibody against 
the beta-subunit of IGF-IR) thus demonstrating the specificity of the siRNA.  
3.4.1.1 Study of Akt phosphorylation under insulin receptor knockdown conditions 
Under non-targeting conditions, MELN cells treated with 15nM Actrapid demonstrated 
increased Akt phosphorylation levels in comparison to untreated cells (Fig. 3.13b; compare 
lanes ‘Un’ and ‘A’ under CT2 siRNA label). Lantus treatment induced even higher Akt 
phosphorylation levels (compare lanes ‘La’ and ‘A’). The highest Akt phosphorylation levels 
were obtained after treatment with IGF-I (compare lane ‘I’ with lanes ‘A’ and ‘La’). This is in 
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agreement with the Akt phosphorylation data obtained under untransfected conditions in 
MCF7 cells (Sec 3.3.1.3). 
 
Figure 3.13b Actrapid, Lantus or IGF-I induced Akt phosphorylation level in MELN cells 
transfected with insulin receptor siRNA. 3 x105 MELN cells were plated per well of a 6-well plate. 
After 12 h, cells were transfected with either 25nM of non-targeting siRNA (CT2 siRNA) or 25nM of 
insulin receptor targeting siRNA. After 48 h of transfection, cells were starved for next 24 h in serum-
free medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 15nM Actrapid 
(‘A’), 15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium was aspirated,  
cells were washed with PBS and cell lysates were prepared as mentioned in Method section. Equal 
amount of cell lysate was loaded and samples were resolved by 10% SDS-PAGE. After membrane 
transfer, blots were probed first for phospho-Akt and then stripped and probed for total Akt protein. 
Insulin receptor knockdown diminished Actrapid potency in inducing Akt phosphorylation by 
approximately 70%, thus confirming the well established fact that normal insulin at 15nM  
concentration acts mostly via insulin receptor (compare lanes marked as ‘A’ under the two 
transfection conditions). In comparison to Actrapid treatment, knockdown of insulin receptor 
did not significantly compromise Lantus ability to induce Akt phosphorylation suggesting the 
involvement of other receptors for Lantus induced signalling. Furthermore, IGF-I ability to 
induce Akt phosphorylation was also not compromised under insulin receptor knockdown 
conditions. In fact, it seemed to be increased under insulin receptor knockdown conditions. 
This is an interesting observation and indicates a ‘quenching’ effect of insulin receptor on 
IGF-IR which is abolished after silencing of the insulin receptor.  
3.4.1.2 Study of Erk1/2 phosphorylation under insulin receptor knockdown conditions 
Treatment of CT2siRNA transfected MELN cells with Actrapid induced phosphorylation of 
Erk1/2 (Fig. 3.13c; compare lanes marked as ‘Un’ and ‘A’). This effect corresponds to the 
effect of Actrapid on untransfected MCF7 cells (Section 3.3.2.2). In addition, similar to the 
results obtained on untransfected MCF7 cells, Lantus and IGF-I treatment induced stronger 
phosphorylation of Erk1/2 than Actrapid in CT2siRNA transfected cells.   
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Figure 3.13c Actrapid, Lantus or IGF-I induced Erk1/2 phosphorylation level in insulin receptor 
siRNA transfected MELN cells. 3 x 105 MELN cells were plated per well of a 6-well plate. After 12 
h, cells were transfected with either 25nM of non-taregting siRNA (CT2 siRNA) or 25nM of insulin 
receptor targeting siRNA. After 48 h of transfection, cells were starved for next 24 h in serum-free 
medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 15nM Actrapid (‘A’), 
15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium was aspirated, cells 
were washed with PBS and cell lysates were prepared as described in the Methods section. Equal 
amount of cell lysate was loaded and samples were resolved by 10% SDS-PAGE. After membrane 
transfer, blots were probed first for phosphorylated forms of Erk1/2 and after stripping for total 
Erk1/2.  
Under insulin receptor knockdown conditions, the ability of Actrapid to induce Erk1/2 
phosphorylation was decreased by approximately 80%. However, under these conditions, 
Lantus ability to induce Erk1/2 phosphorylation was not decreased to the same extent 
(compare lanes marked as ‘La’ under both transfection conditions). Furthermore, as reported 
for Akt phosphorylation, insulin receptor knockdown resulted in increased IGF-I ability to 
induce Erk1/2 phosphorylation (compare lanes marked as ‘I’ under two transfection 
conditions). This again suggests a quenching effect of insulin receptor on IGF-IR. 
3.4.2 Investigating the role IGF-IR in the strong proliferative potency of Lantus  
In order to determine the involvement of IGF-IR in the stronger signalling and proliferative 
potency of Lantus in comparison to Actrapid, a similar approach was used as described in the 
above section. MELN cells were either treated with non-targeting siRNA (CT2 siRNA) or 
with siRNA targeting the IGF-IR and then signalling and proliferative potencies of Lantus 
were compared to Actrapid. IGF-I treatment was used as positive control for IGF-IR 
activation.  
MELN cells transfected with IGF-IR targeting siRNA showed approximately 90% decrease in 
IGF-IR protein level when compared with the cells transfected with non-targeting siRNA 
(Fig. 3.14a; compare IGF-IR protein levels in samples treated with non-targeting siRNA or 
with IGF-IR targeting siRNA). The downregulation of the IGF-IR did not lead to decrease in 
the insulin receptor protein content, demonstrating the specificity of siRNA (refer to the 
immunoblot probed with antibody against beta subunit of insulin receptor). 
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Figure 3.14a  IGF-IR knockdown in MELN cells. 3 x 105 MELN cells were plated per well of a 6-
well plate. After 12 h, cells were transfected with either 25nM of non-taregting siRNA (CT2 siRNA) 
or 25nM of insulin receptor targeting siRNA. After 48 h of transfection, cells were starved for next 24 
h in serum-free medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 15nM 
Actrapid (‘A’), 15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium was 
aspirated, cells were washed with PBS and cell lysates were prepared as mentioned in the Methods 
section. Equal amount of cell lysate was loaded and samples were resolved by 10% SDS-PAGE. After 
membrane transfer, blots were probed first for IGF-IR and then stripped and probed for insulin 
receptor. 
3.4.2.1 Study of Akt phosphorylation under IGF-IR knockdown conditions 
Under non-targeting conditions, treatment of MELN cells with IGF-I induced strong 
phosphorylation of Akt (Fig. 3.14b, compare lanes marked as ‘Un’ and ‘I’ under non-
targeting conditions). Furthermore, treatment with Actrapid and Lantus induced Akt 
phosphorylation with Lantus showing a significantly stronger effect than Actrapid (compare 
lanes marked as ‘A’ and ‘La’ under non-targeting conditions). This is in agreement with the 
Actrapid and Lantus induced Akt phosphorylation levels obtained in untransfected cells (refer 
to Fig. 3.7).  
 
Figure 3.14b Actrapid, Lantus or IGF-I induced Akt phosphorylation level in MELN cells 
transfected with IGF-IR siRNA. 3 x 105 MELN cells were plated per well of a 6-well plate. After 12 
h, cells were transfected with either 25nM of non-targeting siRNA (CT2 siRNA) or 25nM of insulin 
receptor targeting siRNA. After 48 h of transfection, cells were starved for next 24 h in serum-free 
medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 15nM Actrapid (‘A’), 
15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium was aspirated, cells 
were washed with PBS and cell lysate were prepared as mentioned in the Methods section. Equal 
amount of cell lysate was loaded and samples were resolved by 10% SDS-PAGE. After membrane 
transfer, blots were probed first for phospho-Akt and then stripped and probed for total Akt protein. 
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Knockdown of IGF-IR decreased IGF-I ability to induce Akt phosphorylation by 
approximately 60% (compare lanes marked as ‘I’ under the two transfection conditions).  
Interestingly, IGF-IR knockdown also decreased Lantus ability to induce Akt phosphorylation 
(compare lanes marked as ‘La’ under the two transfection conditions). On the contrary, 
Actrapid was observed to be slightly more potent in inducing Akt phosphorylation after IGF-
IR knockdown (compare lanes marked as ‘A’ under the two transfection conditions). This 
suggests that IGF-IR also exerts a ‘quenching’ effect on insulin receptor activity, which is 
abolished after knockdown of the IGF-IR. Thus, from the results on the receptor signalling 
after insulin receptor knockdown or IGF-IR knockdown it may be concluded that both 
receptors regulate each others activity. 
3.4.2.2 Study of Erk1/2 phosphorylation under IGF-IR knockdown conditions 
In MELN cells transfected with non-targeting siRNA, the phosphorylation status of Erk1/2 in 
response to the treatment with Actrapid, Lantus or IGF-I was comparable to the results 
obtained under untransfected conditions (compare Fig. 3.14c with Fig. 3.10). IGF-I induced 
strongest phosphorylation of Erk1/2 compared to Actrapid and Lantus. Lantus induced Erk1/2 
phosphorylation level was significantly higher than the level induced by Actrapid.  
 
Figure 3.14c Actrapid, Lantus or IGF-I induced Erk1/2 phosphorylation level in MELN cells 
transfected with IGF-IR siRNA. 3 x 105 MELN cells were plated per well of a 6-well plate. After 12 
h, cells were transfected with either 25nM of non-taregting siRNA (CT2 siRNA) or 25nM of insulin 
receptor targeting siRNA. After 48 h of transfection, cells were starved for next 24 h in serum-free 
medium. Cells were then left untreated (‘Un’) or were treated for 10 min with 15nM Actrapid (‘A’), 
15nM Lantus (‘La’) or 15nM IGF-I (‘I’). At the end of the experiment, medium was aspirated, cells 
were washed with PBS and cell lysates were prepared as described in the Methods section. Equal 
amount of cell lysate was loaded and samples were resolved by 10% SDS-PAGE. After membrane 
transfer, blots were probed first for phosphorylated forms of Erk1/2 and after stripping for total 
Erk1/2.  
In MELN cells transfected with IGF-IR-targeting siRNA, IGF-I ability to induce Erk1/2 
phosphorylation was compromised and was reduced to approximately 60% (compare lane ‘I’ 
under the two transfection conditions). The knockdown of IGF-IR severely decreased Lantus 
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ability to induce Erk1/2 phosphorylation thus suggesting that Lantus-induced strong 
activation of MAPK pathway involves IGF-IR activation (compare lanes marked as ‘La’ 
under the two transfection conditions). In the absence of IGF-IR, Actrapid was more potent in 
inducing Erk1/2 phosphorylation compared to non-targeting conditions (compare lanes 
marked as ‘A’ under two types of transfections). This observation demonstrates again that 
IGF-IR has a ‘quenching’ effect on insulin receptor.  
The results demonstrate that IGF-IR plays an important role in Lantus induced strong 
phosphorylation of Akt and Erk1/2. In addition, IGF-IR exerts a quenching effect on insulin 
receptor as was evident from increased signalling potency of Actrapid under IGF-IR 
knockdown conditions.  
3.4.2.3 Study of the proliferative potency of Lantus under IGF-IR knockdown conditions 
Finally, in order to ascertain the involvement of IGF-IR in the strong proliferative ability of 
Lantus, the proliferation assay was performed under knockdown conditions. For this, MELN 
cells were transfected with non-targeting siRNA or IGF-IR targeting siRNA and cells were 
treated with Actrapid, Lantus or IGF-I.  
 
 
Figure 3.15 Lantus mediated strong proliferation in MELN cells is due to the activation of IGF-
IR.  1 x 104 MELN cells were plated per well of a 96-well plate. After 12 h, cells were transfected 
using oligofectamine (2µl/well) with 25nM CT2 siRNA or 25nM IGF-IR targeting siRNA. After 48 h 
of transfection cells were starved for next 24 h in medium containing 2% DCC-FBS. Thereafter, cells 
were treated with 150nM Actrapid, 150nM Lantus or 15nM IGF-I for 72 h. At the end of the 
experiment, cells were fixed and stained with crystal violet dye. After air drying, the stain was 
dissolved in 10% acetic acid and the absorbance was measured at 595nm in a plate reader. Fold of 
control was determined with reference to Actrapid. Statistical analysis (student’s t-test) was performed 
with at least 8 data points. Asterisks mean statistical significance at p < 0.05. 
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Under non-targeting conditions, treatment of MELN cells with both, Lantus or IGF-I yielded 
significantly higher proliferation of MELN cells compared to Actrapid (Fig. 3.15). As 
expected, IGF-IR knockdown decreased IGF-I ability to stimulate proliferation. Under IGF-IR 
knockdown conditions, proliferation levels achieved with Lantus treatment were similar to 
that of Actrapid treatment. This is a direct confirmation that the high proliferative potency of 
Lantus involves IGF-IR activation. Thus, it can be concluded that increased signalling and 
proliferative potency of Lantus compared to Actrapid involves activation of IGF-IR. 
3.4.2.4 Study of Lantus induced IGF-IR phosphorylation  
IGF-IR activation is characterized by the phosphorylation of specific tyrosine residues in the 
kinase domain of IGF-IR. Thus, Lantus induced activation of IGF-IR should result in 
increased phosphorylation of IGF-IR. To study this, we performed immunoprecipitation of 
IGF-IR followed by detection of phospho-tyrosine in the immunoprecipitates. Cell lysates 
from untreated MCF7 cells or MCF7 cells treated with Actrapid, Lantus or IGF-I were 
subjected to immunoprecipitation using a polyclonal antibody against the beta-subunit of IGF-
IR (Fig. 3.16).  
 
Figure 3.16 Lantus in comparison to Actrapid strongly phosphorylates IGF-IR in MCF7 cells.  
MCF7 cells were starved in medium containing 2% DCC-FBS for 24 h and then were treated with 
15nM Actrapid (A), 15nM Lantus (La) or 15nM IGF-I (I) for 10 min or were left untreated (Un). Cell 
lysates obtained were subjected to immunoprecipitation with antibody against IGF-IR. Precipitation 
with non-immune IgG was included to study the specificity of the immunoprecipitation. 
Immunoprecipitates obtained were resolved by 10% SDS-PAGE and the blot was first probed for the 
phosphorylated form of IGF-IR then stripped and probed for IGF-IR.  
The IGF-IR could not be detected in the lysate subjected to immunoprecipitation using non-
immune IgG thus confirming the specificity of the immunoprecipitation procedure (refer to 
lane marked ‘IgG’ and compare with other lanes of the immunoblot).  The basal 
phosphorylation of IGF-IR was very low and almost undetectable in the immunoblot (refer to 
lane labeled ‘Un’). IGF-I being a cognate ligand of IGF-IR induced strong phosphorylation of 
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IGF-IR (refer to lane labeled ‘I’). Importantly, treatment of MELN cells with Actrapid did not 
increase IGF-IR phosphorylation levels in comparison to untreated cells (refer to lane labeled 
‘A’). On the contrary, high phosphorylation levels of IGF-IR were detected in MELN cells 
treated with Lantus thus confirming the activation of IGF-IR by Lantus (refer to the lane 
labeled ‘La’). 
3.4.2.5 Study of induction of a IGF-IR responsive gene by Lantus treatment 
The activation of IGF-IR results in increased expression of genes involved in cell proliferation 
like cyclin D1 (Sachdev and Yee 2001, Furlanetto et al.,1994). In order to investigate if IGF-
IR activation by Lantus results in increase of cyclin D1 gene expression, we utilised 
quantitative RT-PCR and studied the cyclin D1 expression level in Lantus treated MCF7 cells 
after 1 h, 3 h or 6 h of treatment. The cyclin D1 gene expression level observed in Lantus 
treated MCF7 cells was compared with Actrapid treated MCF7 cells to determine the relative 
strength of the two compounds. IGF-I treatment was used as a positive control. At 1 h of 
treatment, no significant difference in cyclin D1 expression level was observed between any 
of the treatments (Fig. 3.17). 
 
Figure 3.17 Lantus in comparison to Actrapid induced significantly higher expression of Cyclin 
D1 gene in MCF7 cells.   MCF7 cells were serum-starved for 24 h and were either left untreated or 
were treated for 1 h, 3 h and 6 h with 15nM Actrapid or 15nM Lantus or 15nM IGF-I. Total RNA was 
extracted and reverse transcribed to obtain cDNA. Real time PCR was performed by using specific 
primers for cyclin D1. GAPDH was used as internal control. Standard curve for Ct values was 
obtained by plotting the number of molecules in serially diluted cDNA against their Ct value. This 
standard curve was then used to determine from each sample the number of molecules at the end of the 
experiment. After normalizing the cyclin D1 value against GAPDH, fold of control was calculated for 
each time point. Statistical analysis was done with at least two independent experiments and asterisks 
show data significantly different from Actrapid (p<0.05).  
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At the 3 h timepoint, Actrapid treatment induced approximately 1.8-fold higher cyclin D1 
gene expression in comparison to untreated cells, thus confirming insulin to be a mitogen. 
Treatment of MCF7 cells with Lantus for 3 h resulted in approximately 2.6-fold increase in 
cyclin D1 gene expression. The increase was found to be significantly higher than with 
Actrapid treatment. Similarly, at the 3 h timepoint, IGF-I treatment induced approximately 2.4 
fold increase in cyclin D1 gene expression and this increase was also significantly higher in 
comparison to Actrapid treatment. After 6 h of treatment, cyclin D1 gene expression was 
decreased in all samples, the Actrapid treated sample demonstrating basal levels of cyclin D1 
gene expression and Lantus and IGF-I treated cells showing slightly higher than basal levels. 
This reduction may be explained by the cyclical expression pattern of cyclin D1 gene (Stacey, 
2003). 
To sum up, Lantus induced expression levels of cyclin D1, an IGF-I regulated gene. The 
expression levels are comparable with the expression levels obtained with IGF-I treatment. 
This experiment thus confirms that Lantus activates IGF-IR.  
3.4.3 Investigating the role of ERα in the strong proliferative potency of Lantus  
Several studies have suggested a cross-talk between IGF-IR and ERα signalling (Smith, 1998; 
Kato et al., 2000). IGF-I induces stronger proliferation in MCF7 cells which expressed ERα 
compared to MCF7 cells which do not express ERα, suggesting an important role of ERα in 
IGF-IR mediated cell proliferation (Oesterreich et al., 2001). Results shown above clearly 
establish that Lantus induces strong proliferation in MCF7 cells via activation of IGF-IR. As 
MCF7 cells show a high expression level of ERα (Fig. 3.1), it was hypothesised that Lantus-
induced high proliferation involves ERα activation. In order to investigate the potential role of 
ERα regarding the proliferative potency of Lantus, the following two approaches were used –  
1. ERα activation involves phosphorylation of the Ser118 residue in ERα (Lannigan, 
2003). This serine residue has been demonstrated to be phosphorylated by GSK3β and 
MAPK, two protein kinases related to IGF-I signalling pathway (Grisouard et al., 
2007; Kato et al., 2000). Thus, to assess activation of ERα by Lantus, the 
phosphorylation status of Ser118 residue of ERα was studied in Lantus treated MCF7 
cells. Regular insulin and IGF-I were studied for comparison. Other insulin analogues 
were also studied.  
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2. The potential ERα activation by regular insulin, Lantus and IGF-I was directly 
assessed by luciferase reporter assay system. Estradiol treated cells were the positive 
control. 
3.4.3.1 Study of ERα phosphorylation and activation in MCF7 cells  
MCF7 cells were treated with regular insulin, insulin analogue and IGF-I for 10 min and 
phosphorylation status of ERα at Ser118 residue was compared. 
 
Figure 3.18 Lantus induced significantly higher phosphorylation of ERα in comparison to 
regular insulin and other insulin analogues in MCF7 cells. 5 x 105 MCF7 cells were serum starved 
for 24 h and then were processed without any treatment (Un) or after 10 min treatment with 15nM 
insulin (B – Bovine Insulin and A – Actrapid) or insulin analogues (La – Lantus, Le – Levemir, H – 
Humalog and N – Novorapid). 15nM IGF-I  was studied for comparison. The cell lysates were 
resolved by 10% SDS-PAGE and immunoblots were probed for ERα phosphorylated at Ser118 residue 
and total ERα protein.  Fold of control was obtained by normalizing phosphorylated forms over the 
protein levels and then comparing with the untreated sample. Statistical analysis was done with at least 
three independent experiments and asterisk shows the significant difference (p<0.05) between Lantus 
and Actrapid effects. 
MCF7 cells exhibited a weak basal phosphorylation level of ERα (Fig. 3.18; lane ‘Un’). 
Treatment with bovine insulin or Actrapid did not result in significant increase in 
phosphorylated ERα levels (compare lanes marked ‘A’ or ‘B’ with lane ‘Un’). However, IGF-
I treatment resulted in 2.5-fold increase in ERα phosphorylation levels in comparison to 
endogenous levels (compare lane ‘I’ with ‘Un’). Interestingly, in comparison to regular 
insulin, Lantus treatment resulted in 1.5-fold increase in ERα phosphorylation levels. 
Statistical analysis revealed that the effect of Lantus is significantly stronger than that of 
Actrapid. There was no observable difference in ERα phosphorylation level in cells treated 
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with regular insulin and other insulin analogues (Levemir, ‘Le’; Humalog, ‘H’ or Novorapid, 
‘N’). Thus, Lantus, like IGF-I, induces stronger phosphorylation of ERα at Ser118 residue in 
comparison to regular insulin and other insulin analogues tested, suggesting stronger 
activation of ERα by Lantus and IGF-I.  
3.4.3.2 Study of ERα activation by Lantus using reporter assay system  
Activated ERα dimerises and acts as a transcription factor. As a transcription factor it binds to 
estrogen response elements (ERE) in the promoter region of estrogen responsive genes and 
induces their transcription (McDonnell and Norris, 2002). In order to directly study the 
activation of ERα by Lantus, an ERE dependent luciferase reporter assay system was utilized. 
MELN cells (MCF7 cells stably transfected with ERE-luc reporter system) were treated with 
Actrapid, Lantus or IGF-I and the luciferase activity was measured.  
 
 
Figure 3.19 Lantus was slightly stronger than Actrapid in inducing luciferase activity in MELN 
cells. 3 x 105 MELN cells were plated and after 24 h cells were processed untreated (Un) or were 
processed after treatment with 15nM Actrapid (A), 15nM Lantus (La) or 15nM IGF-I for 6 h. MELN 
cells treated with 10nM or 100nM estradiol (E10, E100) were used as positive control. Specific 
luciferase activity was determined by normalizing the luminescence with the protein concentration. 
Fold of control was calculated by normalizing specific activity from treated cells with the specific 
activity of untreated cells. Values presented are the mean and range of four values. The statistical 
analysis was done by using student’s t-test. Asterisks (*) show statistical significance (p < 0.05, t-test) 
in comparison to untreated cells. 
Untreated MELN cells showed very low luciferase activity (Fig. 3.19). Treatment with 10nM 
and 100nM estradiol led to 8.5-fold and 6.8-fold increase over untreated cells, respectively. 
MELN cells treated with Actrapid, Lantus or IGF-I showed only little increase in luciferase 
activity compared to the untreated cells. Lantus and IGF-I treated cells demonstrated slightly 
higher luciferase activity than Actrapid treated cells, reflecting the ERα phosphorylation 
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described in section (3.4.3.1). Taken together, this suggests that Lantus modulates ERα 
activity slightly stronger than Actrapid. However, combining the results from ERα 
phosphorylation and luciferase assays, it can be concluded that ERα is only weakly activated 
by Lantus and thus ERα is unlikely to play a strong role in rendering high proliferative ability 
to Lantus.     
3.5 Study of Lantus induced cell migration by wound healing assay in 
MCF7 cells  
Cancer is characterised by metastasis which involves cell migration and cell invasion. We 
investigated the potency of Lantus in comparison to Actrapid in inducing migration in MCF7 
cells. For this, cell monolayer was wounded and cells were treated with Actrapid or Lantus for 
21 h (Fig. 3.20). At specific timepoints (3 h, 6 h, 12 h and 21 h), wound width was determined 
and wound healing was calculated as percentage of initial wound width. IGF-I, the cognate 
ligand of IGF-IR, is known to stimulate cell migration. As Lantus also activates IGF-IR 
(section 3.4), IGF-I was included in the study as a control.    
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Figure 3.20 Lantus and Actrapid induced comparable MCF7 cell migration. Confluent monolayer 
of MCF7 cells was wounded using a yellow tip. Cells were treated with 2µg/ml mitomycin C for 1 hr. 
Thereafter, cells were either left untreated or treated with Actrapid (15nM or 150nM), Lantus (15nM 
or 150nM) or IGF-I (15nM) for 3 h, 6 h, 12 h or 21 h. At each timepoint wounds were photographed 
and percentage of wound healing was calculated. The picture presented here is a representative image 
from two independent wounds. 
 
Untreated MCF7 cells demonstrated approximately 60% of wound healing by 21 h (Fig. 
3.21). Treatment with 15nM IGF-I increased MCF7 cell migration as ~ 88% wound closure 
was observed at the 21 h timepoint in comparison to ~ 60% observed in untreated cells. At 
this timepoint, 15nM and 150nM Actrapid were also found to induce cell migration as 
reflected by ~ 75% of initial wound closure. Similarly, Lantus treatm ent (15nM and 150nM) 
of MCF7 cells resulted in ~ 80% closure of initial wound after 21 h which was 1.3-fold of 
wound closure observed in untreated cells at this timepoint. Comparison of Lantus and 
Actrapid-induced MCF7 cell migration reveals that both compounds stimulate migration to a 
similar extent.  
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Figure 3.21 Graphical presentation of MCF7 cell migration under different treatments after 
21 h. Distance between the two edges of the wound was measured at 0 h (initial wound) and 21 h. The 
extent of wound healing at 21 h was calculated by subtracting the distance between the two edges at 
21 h and 0 h. These values were utilised to calculate ‘wound healing [%]’ by dividing wound width at 
21h by the initial wound width. The data presented here are mean ± SD of two independent wounds.  
In summary, the wound healing experiment demonstrates that the migration-inducing 
potential of Lantus and Actrapid in MCF7 cells are similar.  
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4 DISCUSSION 
Insulin analogues have been a great achievement in maintaining normal glucose serum levels 
in diabetic patients. However, as insulin analogues are generated by modifying the insulin 
backbone which alters binding properties to insulin receptor and IGF-IR, serious concerns 
have been raised regarding the possible increase of mitogenic potential of insulin analogues. 
These concerns have been augmented by studies demonstrating high potential of B10Asp, an 
insulin analogue generated by replacing amino acid at 10th position with asparagine, in 
causing proliferation, focus formation and colony formation in osteosarcoma cells, MCF10A 
cells and MCF7 cells, respectively. In addition to in vitro studies, B10Asp administration to 
female Sprague-Dawley rats resulted in increased mammary tumour incidence compared to 
regular insulin. The observation that insulin receptor and IGF-IR are highly expressed in 
normal mammary epithelial cells and even overexpressed in tumorigenic mammary epithelial 
cells, suggests high susceptibility of mammary epithelial cells toward the mitogenic effect of 
insulin analogues. Thus, a comprehensive and detailed study of the mitogenic potency of 
therapeutically available insulin analogues on mammary epithelial cells is strongly warranted.  
In this regard, in vitro experiments reported till date, studying the mitogenic effects of 
therapeutically used insulin analogues on mammary epithelial cells, have been largely 
inconclusive owing to the experimental assays used and inconsistencies in the results. 
Furthermore, a standard two-year carcinogenicity test has not been performed for 
therapeutically used insulin analogues except for Insulin Glargine. In this study, the rats 
treated with Insulin Glargine and regular insulin showed equal incidence of mammary 
tumours. However, the study also reported a very high mortality rate in all treated animal 
groups thus raising questions on the experimental design and conclusions drawn. The aim of 
the present work was to compare the proliferative and signalling ability of insulin analogues 
that are currently therapeutically used, with the regular insulin in human mammary epithelial 
cells. In addition, we also aimed to unravel the molecular and biochemical mechanism behind 
the proliferative potency of those insulin analogue(s) which demonstrated higher proliferative 
ability than regular insulin. 
Our study showed that in comparison to regular insulin, only Insulin Glargine (Lantus), of all 
four insulin analogues tested, elicited significantly higher proliferation in MCF7 cells, a cell 
line with high IGF-IR/IR ratio. In MCF10A cells, an insulin responsive mammary epithelial 
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cell line exhibiting low IGF-IR/IR ratio, Insulin Glargine had similar proliferative potency as 
other insulin analogues and regular insulin. At the molecular level, we observed that Insulin 
Glargine treatment resulted in strong activation of PI3K and MAPK signalling pathways in 
MCF7 cells. The strong activation of MAPK pathway by Insulin Glargine is reflected in the 
significantly increased proliferative ability of Insulin Glargine compared to regular insulin. 
Insulin Glargine exerts its strong mitogenic potency by strongly activating IGF-IR besides 
insulin receptor. ERα, by virtue of its cross-talk with IGF-IR, is also activated by Insulin 
Glargine but its overall contribution into the mitogenic potency of Insulin Glargine may be 
low. Finally, our preliminary experiments on stimulation of the migratory and invasive 
potential of the cells by Insulin Glargine revealed no significant difference from regular 
insulin.   
We postulate that Insulin Glargine may rather be a tumour promoter than a tumour inducer 
and exerts a significantly stronger proliferative effect in comparison to regular insulin 
(Actrapid) in cells that demonstrate high IGF-IR/IR ratio. The findings presented in this work 
may be of clinical relevance for those diabetic patients who have breast cancer or as yet 
undetected (pre-) cancerous lesions. 
4.1 Insulin responsiveness of mammary epithelial cell lines 
It is well established that insulin is a mitogen. In order to find a suitable model to study the 
mitogenic effect of insulin and insulin analogues on mammary epithelial cells, a panel of 
tumorigenic and non-tumorigenic cell lines was screened for their responsiveness toward 
insulin treatment (Table 3.1). Although all cell lines analysed expressed insulin receptor 
moderately, only MCF7 and MCF10A cells showed a clear proliferative response to the 
insulin treatment. The other mammary epithelial cell lines, though expressing similar levels of 
insulin receptor as MCF10A and MCF7, exhibited weak or lack of proliferative response 
indicating the importance of signalling molecules downstream of insulin receptor for 
transduction of the mitogenic effect of insulin. For example, the lack of IRS-1 protein 
expression in ZR75-1 cells (Gliozzo et al., 1998) may be the reason for ZR75-1 cells to 
demonstrate merely 1.4-fold increase in proliferation after insulin treatment. The poor 
proliferative response of BT474 cells to insulin treatment may also be explained by the low 
expression level of IRS-1 protein (Mayer et al., 2008). Bartucci et al. (2001) showed that 
absence of sustained activation of the PI3K pathway results in the lack of mitogenic response 
to IGF-I treatment in MDA-MB231 cells. This may also be true for the weak mitogenic 
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response to insulin observed in our study, where MDA-MB231 cells show barely a 1.3-fold 
increase after insulin treatment. Two other cell lines, T47D and HCC1937, respond poorly to 
the insulin treatment. Although the reason for this is unclear, it may be hypothesized that 
signalling pathways leading to proliferative response after insulin treatment are interrupted in 
these long-term established cell lines.  
Thus, our study suggests that insulin responsiveness of a cell line is not only dependent on the 
insulin receptor expression level but also on the expression and functional integrity of 
downstream signalling molecules. 
4.2 Characterisation of proliferative and signalling potency of insulin 
analogues  
Insulin analogues are commercially available as pharmaceutical preparations but not as the 
pure compounds from the companies. Since the pure compounds should be preferentially used 
for research purposes, we tried to obtain the pure insulin analogues from the respective 
companies. Unfortunately, formal agreement could not be made because they were either not 
willing to provide us the compounds or the requested conditions for signing the Material 
Transfer Agreement were not acceptable to us. Therefore, insulin analogues (Lantus, Levemir, 
Novorapid, Humalog) as well as regular human insulin (Actrapid), used in the present work, 
were bought from the pharmacy. We consider this justifiable, since in the end these 
pharmaceutical preparations are used for injection in diabetic patients. 
MCF10A and MCF7, the two most insulin-responsive cell lines, were employed to 
characterize the proliferative and signalling potency of the insulin analogues in comparison 
with regular insulin. In order to analyse the possible mitogenic potency of the additives in the 
pharmaceutical preparations, we first inactivated regular insulin and insulin analogues in the 
pharmaceutical preparation by chemical reduction of S-S bridges and heating. Thereafter, we 
performed proliferation assays with the resultant solutions. There was no difference in the 
proliferative rate of untreated cells or cells treated with carrier solvents of pharmaceutical 
preparations after inactivation of regular insulin or insulin analogues. This indicates that 
additives did not have mitogenic potency (data not shown).  
Purified bovine insulin is commercially available as zinc insulin while Actrapid is a 
pharmaceutical preparation of regular human insulin. Of importance is the fact that in all our 
experiments bovine insulin was studied for comparison and demonstrated similar proliferative 
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and signalling ability as Actrapid. This permits the conclusion that the pharmaceutical 
formulation does not alter the efficiency of insulin action significantly. In addition, similar 
proliferative potency of bovine insulin and Actrapid demonstrates that human insulin can be 
replaced with animal insulin without any safety concerns with regard to mitogenicity of the 
compound. Out of four insulin analogues studied, three insulin analogues (Insulin Lispro 
[Humalog], Insulin Aspart [Novorapid] and Insulin Detemir [Levemir]) demonstrated similar 
proliferative ability in both MCF10A and MCF7 cells. Only Insulin Glargine clearly induced 
significantly higher proliferation in MCF7 cells in comparison to Actrapid. However, in 
MCF10A cells, the proliferative effect of Insulin Glargine was similar to that of Actrapid. The 
proliferation and signalling potency of each analogue will be discussed in detail below.  
4.2.1 Proliferative and signalling potency of Insulin Glargine 
Several studies have attributed higher mitogenic potency to Insulin Glargine in comparison to 
regular insulin. Kurtzhals et al. (2000) by thymidine incorporation assay reported six-fold 
higher proliferative potency of Insulin Glargine than regular insulin in osteosarcoma cells 
while Eckardt et al. (2007) by measuring BrdU incorporation demonstrated three-fold higher 
proliferative potency of Insulin Glargine than regular insulin in fibroblasts and coronary 
artery smooth muscle cells. In agreement with the above mentioned studies, we found that in 
MCF7 cells, Lantus treatment led to approximately 1.5-fold (at 1.5nM) and 3-fold (at 15nM) 
higher BrdU incorporation than regular insulin. Furthermore, proper proliferation assay 
involving three days of treatment of MCF7 cells with Insulin Glargine or regular insulin, 
revealed that at concentrations ≥ 150pM, Insulin Glargine induced significantly stronger 
proliferation than regular insulin. Even at concentrations as low as 1.5pM and 15pM, which 
reflect lower than physiological insulin concentrations after overnight fasting, the Insulin 
Glargine effect was stronger than Actrapid though the difference was not statistically 
significant. The difference between Insulin Glargine and Actrapid was approximately 1.3-fold 
at most of the concentrations studied with the 1.5-fold difference at higher concentrations 
(150nM and 1.5µM). The difference between the data obtained by the BrdU incorporation 
assay and the colorimetric proliferation assay may be on the one hand due to the difference in 
the sensitivity of the two assays. On the other hand, BrdU incorporation detects only S-phase 
cells whereas the colorimetric assay represents the cells in all phases of the cell cycle. 
The physiological insulin concentration in serum of healthy people varies between ~15pM 
and ~200pM after overnight fasting (Labor Lademannbogen, Labor Limbach). Postprandial 
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levels are about 500pM. The fact that within this concentration range, we did not find regular 
insulin to induce significant proliferation of MCF7 cells suggests that at low concentrations 
(1.5pM, 15 pM and 150pM) regular insulin is unlikely to be a strong mitogen. Regarding 
serum concentrations of Insulin Glargine only few data are available. Free insulin serum 
levels of healthy volunteers and of patients with type-1 diabetes who received Insulin 
Glargine injections for 1 to 11 days varied between 70pM and 90pM, with peak levels of 
about 220pM after injection (Heise et al., 2002; Heise et al., 2004; Gerich et al., 2006; Becker 
et al., 2008). However, at concentrations of 1.5pM and 15pM, Lantus clearly induced stronger 
proliferation than Actrapid and at 150pM the proliferation levels obtained with Lantus were 
significantly higher (approximately 1.3-fold) than with regular insulin. Our findings 
demonstrating higher proliferative ability of Insulin Glargine in comparison to regular insulin 
in MCF7 cells at physiological concentrations raise safety concerns regarding treating diabetic 
patients who have or are at risk to have breast cancer with Lantus.  
However, in contrast to our data on MCF7 cells, Staiger et al. (2007) and Liefvendahl and 
Arnqvist (2008) did not observe higher mitogenic potency of Insulin Glargine compared to 
regular insulin in MCF7 cells. The dissimilarity in the results may be due to differences in the 
cell handling procedure or due to methodical differences. Additionally, proliferation values 
presented by Staiger et al. (2007) had very high error bars (in some cases SEM was 25% of 
the value) thus making these data difficult for reasonable analysis.  
Our investigation of the molecular mechanism behind the strong proliferative potency of 
Insulin Glargine revealed that Insulin Glargine strongly activates both PI3K and MAPK 
pathways. We observed that Insulin Glargine compared to insulin and other insulin analogues, 
induced significantly higher phosphorylation of Akt and GSK3α/β proteins, two important 
downstream targets in the PI3K pathway. Likewise, Insulin Glargine also strongly activated 
the MAPK pathway in MCF7 cells as reflected by high Erk1/2 phosphorylation levels. 
Quantitative evaluation of the phosphorylation signals followed by the statistical analysis 
revealed that Insulin Glargine was approximately two times stronger than regular insulin in 
activating PI3K and MAPK pathways. There are contradictory reports regarding the major 
proliferation pathway in MCF7 cells. Lu and Campisi (1992) and Jhun et al. (1994) 
demonstrate MAPK to be the major proliferation-linked pathway. On the contrary, Dufourny 
et al. (1997) demonstrate PI3K to be the major proliferation-linked pathway. The results from 
our proliferation experiments in presence of specific inhibitors of PI3K and MAPK pathways, 
favours MAPK pathway as the major proliferation pathway in MCF7 cells. In addition to 
Discussion     74 
 
activation of the signalling pathways, we also studied the role of IR, IGF-IR and ERα in 
Lantus-induced proliferation. These findings are elaborately discussed in Sections 4.4 and 4.5.  
In contrast to MCF7 cells, the proliferative potency of Insulin Glargine was similar to regular 
insulin in MCF10A cells. This finding agrees with other reports demonstrating equi-potency 
of Insulin Glargine and regular insulin on benign rat-1-fibroblasts (Berti et al., 1998), human 
coronary artery cells (Staiger et al., 2005), muscle cells (Bähr et al., 1997), and human 
skeletal muscle cells (Ciaraldi et al., 2001). The molecular background for the differential 
proliferative ability of Lantus in MCF7 and MCF10A cells is due to differences in the IGF-
IR/IR ratio in these cells (Section 4.4). The equi-potency of both Insulin Glargine and regular 
insulin in MCF10A cells is reflected in the comparable activation of the MAPK pathway as 
suggested by the similar levels of phosphorylated Erk1/2. Interestingly, analysis of PI3K 
pathway activation revealed that in comparison to regular insulin, Insulin Glargine induced 
significantly higher phosphorylation of Akt protein. Slightly higher levels of phosphorylated 
GSK3α/β, a downstream effector of Akt, were also observed with Insulin Glargine treatment 
compared to regular insulin treatment but the difference was not statistically significant. 
Surprisingly, treatment of the cells with IGF-I caused similar phosphorylation of GSK3α/β as 
seen with Insulin Glargine. The reason of this result is unclear. It may be hypothesised that in 
MCF10A cells, the signal downstream of Akt level diverges and GSK3α/β is not the main 
target of Akt. Conversely, it can be argued that signal transduction from Akt to GSK3α/β is so 
strong in MCF10A cells that differences between the two treatments cannot be detected by 
immunoblotting. To prove this, the specific kinase activity of Akt needs to be determined. 
However, the complexity of the findings requires a more detailed analysis. We did not study 
which signalling pathway is responsible for proliferation in MCF10A cells. Nevertheless, the 
similar proliferative ability of Insulin Glargine and Actrapid and similar activation of MAPK 
pathway but not PI3K pathway by Insulin Glargine and Actrapid indicate that like in MCF7 
cells, in MCF10A cells MAPK pathway is the major proliferation pathway too. 
Another interesting observation is that the ratio of phosphorylated to total proteins of 
signalling molecules (Akt, GSK3α/β and Erk1/2) in MCF10A cells treated with regular 
insulin or insulin analogue is much higher than the ratios observed in similarly treated MCF7 
cells. However, the proliferation levels observed in MCF7 treated cells were significantly 
higher than in MCF10A treated cells. This suggests that care should be taken to present high 
phosphorylation levels of key signalling molecules as primary readout for proliferative 
potency of any compound.  
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4.2.2 Proliferative and signalling potency of Insulin Detemir 
Addition of a 14-carbon fatty-acid chain to the amino acid at 29th position of the B-chain of 
insulin renders Insulin Detemir to have higher affinity for albumin and increased lipophilicity 
compared to human insulin. It binds to BSA with an affinity of ~ 4x105 l/mol (Kurtzhals et 
al., 1996). Insulin Detemir also exhibits 50% lower binding affinity for the insulin receptor 
and 80% lower affinity for the IGF-IR than human insulin and dissociates almost two times 
faster than human insulin from insulin receptor (Kurtzhals et al., 2000). These differences in 
biochemical properties were shown by Kurtzhals et al. (2000) to be reponsible for the merely 
11% (corrected for albumin binding) mitogenic potency of Insulin Detemir relative to human 
insulin.  
However, under our experimental conditions, we observed that only at high concentrations 
(150nM and 1.5µM), Insulin Detemir-stimulated proliferation levels in MCF7 cells are lower 
than with regular insulins. At lower concentrations (1.5nM and 15nM) Insulin Detemir 
treatment of MCF7 cells yielded similar proliferation levels as obtained with regular insulin. 
This difference may be explained by the 80% lower affinity of Insulin Detemir for IGF-IR 
compared to regular insulin. At high concentrations, regular insulin can activate IGF-IR to 
some extent. On the contrary, Insulin Detemir with its 80% lower binding affinity for IGF-IR 
may not activate IGF-IR even at higher concentrations. Therefore, at high concentrations of 
regular insulin the proliferation levels achieved are higher than that achieved by Insulin 
Detemir treatment. However, at lower concentrations, regular insulin does not or only very 
weakly activate IGF-IR. Thus, under these conditions both, Insulin Detemir and regular 
insulin, are observed to induce similar levels of proliferation in MCF7 cells. Interestingly, 
although Insulin Detemir shows ~ 50% reduced binding affinity for insulin receptor and in 
comparison to regular insulin dissociates two times faster from insulin receptor (Kurtzhals et 
al., 2000), its proliferative ability is similar to regular insulin at low concentrations in MCF7 
cells. These results strongly suggest that the binding affinity for insulin receptor is not a major 
determinant for the proliferative potency of insulin. This also explains the finding, that in 
MCF10A cells, a cell line with low IGF-IR/IR ratio (0.8:1), Insulin Detemir exhibited similar 
proliferative ability as regular insulin at all the concentrations studied. 
At the molecular level, in MCF7 cells, the signalling potency of 15nM Insulin Detemir was 
approximately 50 % lower than 15nM regular insulin as demonstrated by the phosphorylation 
levels of Akt, GSK3α/β and Erk1/2. These experiments were performed under serum-free 
conditions, thus the results are solely based on the biochemical properties of Insulin Detemir 
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and not affected by the serum binding properties of Insulin Detemir. As at 15nM 
concentration, regular insulin only weakly activates IGF-IR, the relative difference in the 
phosphorylation levels of key signalling molecules induced by Insulin Detemir and regular 
insulin is most probably due to reduced insulin receptor affinity of Insulin Detemir and not to 
reduced affinity for IGF-IR. Interestingly, the ~ 50 % lower activation of the MAPK pathway 
(as reflected by the phosphorylation status of Erk1/2 proteins) by 15nM Insulin Detemir 
compared to 15nM regular insulin did not lead to corresponding decrease in the proliferative 
ability of Insulin Detemir vis-à-vis regular insulin. Most probably, the stronger Erk1/2 
phosphorylation by 15nM Actrapid in comparison to 15nM Insulin Detemir is a transient 
effect and consequently there is no difference in proliferative potence between the two 
compounds. This assumption is supported by the study from Hansen et al. (1996) in which it 
was demonstrated that the sustained activation of insulin receptor is required for its mitogenic 
effect. However, the precise interpretation of this observation demands a more detailed study. 
In MCF10A cells, signalling potency of Insulin Detemir was similar to regular insulin. The 
difference in the signalling potency of Insulin Detemir between MCF7 cells and MCF10A 
cells is most likely due to differences in the cell characteristics. 
Altogether, it can be concluded that Insulin Detemir does not exhibit higher mitogenic 
potency than human insulin and therefore can be assumed to have low safety risks. In fact, 
studies have associated Insulin Detemir therapy with positive effects in diabetic patients like 
loss of weight (Tibaldi, 2007). The weight loss is attributed to the increased concentration of 
Insulin Detemir in the brain, which results in elevated insulin signalling and thus lowering of 
the ‘hunger signal’. The higher lipophilicity of Insulin Detemir in comparison to human 
insulin allows Insulin Detemir to cross the blood-brain barrier easily which results in higher 
concentration in brain (Rossetti et al., 2007). As the albumin concentration in brain is 200-
fold lower than in the blood (Seyfert et al., 2002), there is a higher percentage of free Insulin 
Detemir in brain than in the blood. Hennige et al. (2005) determined the tyrosine 
phosphorylation status of the insulin receptor and IRS-2 protein in hypothalamic and 
cerebrocortical tissues of C57B1/6 mice and demonstrated that insulin signalling is faster and 
stronger in the mice subjected to Insulin Detemir treatment compared to those treated with 
regular insulin. 
4.2.3 Proliferative and signalling potency of Insulin Aspart 
Insulin Aspart is generated by replacing proline at the 28th position of B-chain with aspartic 
acid. Literature survey reveals that mitogenic response to Insulin Aspart is highly dependent 
Discussion     77 
 
on the cell types under study and the mitogenic potency of Insulin Aspart can be weaker, 
similar or stronger than that of regular insulin. In Saos/B10 cells, Insulin Aspart showed only 
58 ± 22 [%] of the potency of Actrapid in inducing thymidine incorporation (Kurtzhals et al., 
2000). However, in CHO-K1 cells Insulin Aspart induced thymidine incorporation to a 
similar level as regular insulin (Hansen et al., 1996). Recently, Eckardt et al. (2007) also 
demonstrated equal potency of Insulin Aspart and regular insulin by studying BrdU 
incorporation into the DNA of human primary smooth muscle cells from different donors. 
Trüb et al. (1999) showed a slight increase in the percentage of S-phase cells (1.2-fold of 
regular insulin) after Insulin Aspart treatment in MCF7 cells.  
We also observed a differential mitogenic response to Insulin Aspart in the two insulin-
responsive mammary epithelial cell lines, MCF10A and MCF7. In agreement with the studies 
from Hansen et al. (1996) and Eckardt et al. (2007), Insulin Aspart - treated MCF10A cells 
demonstrated similar proliferation levels as Actrapid - treated MCF10A cells. This was 
reflected also at the signalling pathway level, where MCF10A cells treated with Insulin 
Aspart and Actrapid showed similar phosphorylation levels of Akt, GSK3α/β and Erk1/2. 
However, in contrast to MCF10A cells and in agreement with Trüb et al. (1999), treatment of 
MCF7 cells with 15nM Insulin Aspart resulted in ~ 1.5-fold higher BrdU incorporation in 
comparison to regular insulin. This higher potency of Insulin Aspart vis-à-vis regular insulin 
to stimulate BrdU incorporation was also reflected in the slightly higher proliferative effect of 
Insulin Aspart compared to Actrapid at all concentrations studied though the differences were 
not statistically significant. This trend was further corroborated by our results on Erk1/2 
phosphorylation levels which were somewhat higher in Insulin Aspart - treated MCF7 cells 
than in Actrapid - treated MCF7 cells whereas the PI3K pathway was similarly activated by 
both Insulin Aspart and Actrapid in MCF7 cells. 
The slightly higher proliferative potency of Insulin Aspart in MCF7 cells may be explained by 
the fact that Insulin Aspart has a lower insulin receptor dissociation rate and therefore stays 
for longer duration on the insulin receptor than regular insulin, which results in a stronger 
proliferative effect (Hansen et al., 1996). However, it is interesting that the altered 
biochemical property of Insulin Aspart does not result in stronger proliferative ability in 
comparison to regular insulin in MCF10A cells. It may be argued that the high number of 
insulin receptors relative to IGF-IR in MCF10A cells (low IGF-IR/IR ratio) compensates the 
differences in the biochemical properties of Insulin Aspart and regular insulin, resulting in 
equipotency of the two compounds with respect to proliferative ability. Nevertheless, this 
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observation merits further analysis. In summary, our study demonstrates that under low IGF-
IR/IR condition, Insulin Aspart may not pose a safety risk with regard to proliferation. 
However, the slightly increased mitogenic potency of Insulin Aspart in comparison to regular 
insulin in MCF7 cells demands further studies, preferably using animal models.  
4.2.4 Proliferative and signalling potency of Insulin Lispro 
Insulin Lispro is generated by interchanging the aminoacids at position 28 and 29 of the B-
chain of insulin molecule to lysine and proline respectively. This modification results in 
slightly lower affinity for insulin receptor (0.8-fold of human insulin) and slightly higher 
affinity for IGF-IR (1.5-fold of human insulin). However, these altered binding properties of 
Insulin Lispro did not result in altered proliferative ability in comparison to regular insulin 
(Kurtzhals et al., 2000; Slieker et al., 1997; Eckardt et al., 2007). In agreement with these 
studies, our results from the proliferation experiments on MCF10A and MCF7 cells also 
demonstrate similar proliferative potency of Insulin Lispro and regular insulin. Furthermore, 
at the molecular level, Insulin Lispro-induced phosphorylation levels of Akt, GSK3α/β and 
Erk1/2 were similar to regular insulin - induced levels in both cell lines. Taken together, we 
can conclude that the slightly higher IGF-IR affinity of Insulin Lispro does not result in higher 
proliferative potency in comparison to Actrapid and thus may have limited safety risks 
regarding mitogenicity.  
4.3 Insulin receptor and IGF-IR quench each other 
Our knockdown experiments yielded interesting results regarding the influences insulin 
receptor and IGF-IR exercise on each other. Surprisingly. under IGF-IR knockdown 
conditions, we observed an increase in the signalling and proliferative potency of regular 
insulin. Specifically, regular insulin clearly induced stronger Akt and Erk1/2 phosphorylation 
in MELN cells which exhibited low levels of IGF-IR compared to MELN cells exhibiting 
normal levels. The increased signalling potency of regular insulin also resulted in increased 
proliferative potency in MELN cells exhibiting low IGF-IR levels. Similarly, signalling and 
proliferative potency of IGF-I was observed to increase under insulin receptor knockdown 
conditions. IGF-I treatment of normal MELN cells yielded high phosphorylation levels of Akt 
and Erk1/2. These phosphorylation levels were found to increase strongly in MELN cells 
expressing low levels of insulin receptor. 
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These findings suggest that both IGF-IR and insulin receptor have inhibitory effect on each 
others ligand. Recent studies have shown that insulin receptor and IGF-IR, being highly 
homologous to each other, may form hybrid receptors (Frasca et al., 1999). As insulin 
receptor has two splice variants, IR-A (lacks exon 11) and IR-B (with full transcript), there 
can be two types of hybrid receptors - HR-A and HR-B. Regular insulin, compared to its 
binding affinity for the insulin receptor homodimer, demonstrates decreased binding affinity 
for HR-A, and has been suggested not to bind to HR-B (Frasca et al, 2003). Under conditions 
with reduced IGF-IR levels more homodimers of insulin receptors are present, which results 
in increased binding of regular insulin and in increased MAPK activation and proliferative 
potency of regular insulin. IGF-I does not exhibit strong differences in the binding affinities to 
HR-A or IGF-IR and binds to HR-B with lower affinity than to HR-A. The marked increase in 
signalling potency of IGF-I in cells which have elevated IGF-IR homodimer (due to reduction 
in insulin receptor) suggests towards the higher level of HR-B than HR-A in these cells. This 
is contradictory to the studies demonstrating higher levels of IR-A in mammary tumorigenic 
cells and thus higher levels of HR-A. This interesting observation will certainly need further 
investigations.  
4.4 Proliferative ability of Insulin Glargine is due to the strong activation 
of IGF-IR  
In comparison to regular insulin, Insulin Glargine induced significantly stronger proliferation 
at concentrations ≥ 150pM in MCF7 cells. By using RNA interference, we found that the 
higher signalling and proliferative potency of Insulin Glargine in comparison to regular 
insulin is due to its ability to activate IGF-IR besides the insulin receptor. Insulin did not 
induce phosphorylation of Akt and Erk1/2 when the level of its cognate receptor was 
significantly reduced. However, under these conditions, Insulin Glargine did induce 
phosphorylation of Akt and Erk1/2 suggesting involvement of IGF-IR. Futhermore, in MELN 
cells with significantly reduced IGF-IR expression level, the signalling and proliferative 
potency of Insulin Glargine and regular insulin were similar, which again suggests IGF-IR 
activation by Insulin Glargine and renders an explanation for the high proliferative ability of 
Insulin Glargine. The strong activation of IGF-IR by Insulin Glargine can be explained by the 
fact that Insulin Glargine possesses six-fold higher IGF-IR binding affinity than regular 
insulin (Kurtzhals et al., 2000). Insulin Glargine most probably activates IGF-IR by directly 
binding to it as the immunoprecipitation analysis showed that Insulin Glargine treatment 
results in strong phosphorylation of IGF-IR. The activation of IGF-IR was also reflected in 
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the transcription of the IGF-I responsive gene cyclin D1 in Insulin Glargine-treated MCF7 
cells.  
The differences in the proliferative potency of Insulin Glargine and regular insulin in 
MCF10A and MCF7 cells can be explained by taking into consideration the nature of two cell 
lines and the biochemical properties of Insulin Glargine. MCF10A cells exhibit low IGF-
IR/IR ratio (0.8:1; Gammeltoft et al. [1999]) in contrast to high IGF-IR/IR ratio (7:1; 
Liefvendahl et al. [2008] to 4:1; Gammeltoft et al. [1999]) observed in MCF7 cells. We 
postulate that in MCF7 cells, the IGF-IR plays the more important role in determining the 
proliferative potency of Insulin Glargine. However, in MCF10A cells, the insulin receptor 
probably plays a more important role in determining the proliferation response to Insulin 
Glargine. This may explain why Insulin Glargine with its slightly decreased affinity for 
insulin receptor and nearly 1.5 fold faster dissociation rate from insulin receptor does not 
elicit stronger proliferative response than Actrapid in MCF10A cells.  
4.5 ERα does not play a major role in the proliferative potency of Insulin 
Glargine  
ERα is a well established nuclear receptor and transcription factor and plays an important role 
in breast cancer development. About 70% of primary breast cancers are ERα-positive. In 
breast cancer cell lines like MCF7 and ZR75-1, ERα is abundantly expressed. Insulin 
Glargine induced strong proliferation in ERα-positive MCF7 cells but not in ERα-negative 
MCF10A cells. We described in the above section that IGF-IR activation plays an important 
role in the strong proliferative effect of Insulin Glargine. The IGF-IR signalling pathway has 
been reported to cross-talk with ERα signalling (Kato et al., 2000; Dupont and Le Roith, 
2001; Zhang et al., 2005) in a way that IGF treatment of cells results in phosphorylation of 
ERα in the AF-1 domain. This phosphorylation modulates ERα activity in a positive manner. 
Therefore, there is a possibility that activation of ERα contributes to the growth stimulatory 
role of IGF-IR. In order to assess the involvement of ERα in IGF-IR signalling, we first tried 
to express ERα in MCF10A cells. This would have enabled us to compare the influence of 
IGF-IR activation on proliferation of ERα positive and ERα negative MCF10A cells. 
However, this approach was not successful as MCF10A cells are very resistant to transfection 
(transfection efficiency was less than 5% with any method chosen). Alternatively we 
attempted to knockdown ERα in MCF7 cells. ERα knockdown resulted in decrease of IGF-IR 
protein levels (data not shown). This can be explained by the positive regulation of IGF-IR 
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expression by ERα in MCF-7 cells (Maor et al., 2006). Finally, we studied activation of ERα 
by IGF-I and Insulin Glargine in MCF7 cells. Previous findings from our laboratory show that 
phosphorylation of ERα at Ser118 residue located in the AF-1 domain is required for full 
activation of ERα (Medunjanin et al., 2005). The Ser118 residue can be phosphorylated by 
GSK3α/β (Medunjanin et al., 2005) and by MAPK (Kato et al., 1995). Both enzymes are 
important components of signalling pathways activated by IGF-IR. Our results show that 
Insulin Glargine induced significantly higher phosphorylation of ERα at Ser118 residue in 
comparison to regular insulin and all other insulin analogues. However, Insulin Glargine 
increased ERα activity only slightly stronger than regular insulin as was evident from the 
results of ERE-dependent luciferase activity studies. Taken together, these results suggest that 
activation of ERα contributes only weakly to the Insulin Glargine mediated MCF7 cell 
proliferation.  
4.6 Model for Insulin Glargine action in MCF7 cells  
The results on Insulin Glargine-induced signalling are summarized in a model to explain the 
high proliferative ability of Insulin Glargine in MCF7 cells (Fig. 5.1 a, b). Under normal 
conditions (Fig 5.1a), regular insulin via insulin receptor activates mainly PI3K/Akt pathway 
and to low extent MAPK pathway. IGF-I, through the IGF-IR, activates both PI3K/Akt and 
MAPK pathways strongly. 
Active IGF-IR
PI3K pathway
Akt/PKB
GSK3α/β
MAPK pathway
Ras
Raf
Erk1/Erk2
Inactive IR Inactive IGF-IR
MITOGENIC EFFECT
Active IR
Insulin Lantus IGF-I
Glycogen synthase
 
 
 
 
 
 
 
 
Figure 5.1a Illustration of the mode of action of Insulin Glargine in MCF7 cells under normal 
conditions. Insulin (green solid circle) under physiological conditions binds to the insulin receptor 
(IR; shown in green) and activates mainly PI3K pathway (shown by thick green arrow at Akt) and to 
low extent MAPK pathway (shown by thin green arrow at Erk1/2). IGF-I (blue solid circle) binds to 
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IGF-IR (shown in blue) and activates both PI3K and MAPK pathways strongly (shown by the thick 
blue arrows at Akt and Erk1/2). Insulin Glargine (depicted as Lantus in red solid circle) can bind to 
both receptors and activates PI3K and MAPK pathways equally strongly (shown by red arrows at Akt 
and Erk1/2). 
Insulin Glargine stimulates both insulin receptor and IGF-IR resulting in activation of both 
PI3K and MAPK pathways at levels higher than observed with insulin. The strong activation 
of IGF-IR by Insulin Glargine is responsible for the strong proliferative potency of Insulin 
Glargine. This mechanism of action applies to cell lines characterized by a high IGF-IR/IR 
ratio such as MCF7. 
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Figure 5.1b Illustration of the mode of action of Insulin Glargine in MCF7 cells under IGF-IR 
knockdown conditions. Under IGF-IR knockdown conditions, IGF-I mediated PI3K and MAPK 
activation decreases significantly (compare the blue arrows thickness under both the conditions) while 
insulin mediated activation of PI3K and MAPK pathway increases compared to normal condition 
(compare the thickness of green arrows). IGF-IR knockdown decreases Insulin Glargine mediated 
PI3K and MAPK pathway activation to the level stimulated by insulin (compare the thickness of green 
and red arrow). 
Under IGF-IR knockdown conditions (Fig. 5.1b), the ability of IGF-I to activate PI3K and 
MAPK pathway is severely compromised. Insulin Glargine treatment elicits similar 
phosphorylation levels of Akt and Erk1/2 as obtained with regular insulin. Thus, under IGF-
IR knockdown conditions Insulin Glargine behaves like normal insulin. This explains the 
observation that in cell lines with low IGF-IR/IR ratio, the proliferative ability of Insulin 
Glargine is similar to that of Actrapid. Interestingly, under IGF-IR knockdown conditions 
insulin treatment causes stronger stimulation of insulin receptor accompanied by stronger 
phosphorylation of Akt and more importantly of Erk1/2 compared to control siRNA 
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conditions. This shows that insulin receptor is a mitogenic receptor, but under normal 
conditions its mitogenic ability is impaired due to presence of IGF-IR.   
 
4.7 Migratory and invasive potency of Insulin Glargine  
IGF-I via activation of IGF-IR has been shown to stimulate not only proliferative but also 
motile cell responses (Leventhal and Feldman, 1997; Bredin et al., 1999; Meyer et al., 2001). 
In MCF7 cells contrasting data has been reported regarding the role of IGF-I in cell migration. 
Guvakova et al. (2002) showed that the release of cell-cell adhesion (cell separation) was 
enhanced in MCF7 cells overexpressing the IGF-IR and blocked in cells expressing a kinase-
dead mutant of this receptor. Furthermore, IGF-IR mediated cell separation was demonstrated 
to be due to the activation of α-actinin through the PI3K pathway which results in the rapid 
organization of actin into microspikes at the cell-cell junctions. On the contrary, Mauro et al. 
(2001) showed that IGF-I treatment of MCF7 cells results in increase in cell-cell adhesion via 
activation of E-cadherin protein.  
We studied MCF7 cell migration in the presence of regular insulin, Insulin Glargine or IGF-I 
by using wound healing assay. Our results show that there was no significant difference in the 
wound healing rate between the cells treated with insulin, Insulin Glargine and IGF-I. As 
IGF-I treatment of MCF7 cells did not induce significant migration under our experimental 
conditions, it may be suggsted that IGF-I has weak potency in stimulating cell migration in 
our system. In addition to the wound healing experiment, we also studied the effect of Insulin 
Glargine on MCF7 cell invasion by matrigel assay (data not shown). Control experiments 
showed increased migration through the matrigel layer by treatment of the cells with 
10%DCC-FCS as compared with 2%DCC-FCS, but there was no effect of IGF-I, Insulin 
Glargine or regular insulin on invasion. In summary, insulin, Insulin Glargine and IGF-I 
demonstrate poor migratory and invasive potency in MCF7 cells. It is important to point out 
that the validity of these data is limited in the terms of time-points and concentrations of the 
compounds studied. Further investigations are required to make a conclusive statement. 
4.8 Outlook 
Our findings show that at concentrations ≥ 150pM, Insulin Glargine exerted significantly 
higher proliferation relative to regular insulin in MCF7 cells. At lower concentrations (1.5pM 
and 15pM) a stronger proliferative effect of Insulin Glargine compared to regular insulin was 
clearly visible although not statistically significant. The question is whether this stronger 
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proliferative effect of Insulin Glargine is of relevance to diabetic patients undergoing Insulin 
Glargine therapy. Only few data are available on serum concentrations of Insulin Glargine. 
Free serum insulin levels of healthy volunteers and of patients with type I diabetes who 
received Insulin Glargine injections for 1 to 11 days varied between 70pM and90pM, with 
peak levels of about 220pM after injection (Gerich et al., 2006; Heise et al., 2002; Heise et 
al., 2004; Becker et al., 2008). Considering these studies in the light of our results, we 
postulate that at these Insulin Glargine serum levels, cell proliferation may be significantly 
stimulated in diabetic patients. We found that the difference in proliferation between Insulin 
Glargine and Actrapid treated MCF7 cells was approximately 1.5-fold. Although this 
difference seems not to be very high, it must be considered that insulin therapy is prescribed 
lifelong. The higher proliferative ability of Insulin Glargine must therefore be considered a 
matter of concern. Nevertheless, proliferation assays must be performed at Insulin Glargine 
concentrations between 15pM and 150pM to achieve precise data for concentrations that are 
found in serum of patients treated with Insulin Glargine.  
Normal breast epithelial cells do not exhibit very high IGF-IR/IR ratio, whereas, importantly, 
a high IGF-IR/IR ratio is observed in many breast tumours (Frasca et al., 2003). In the present 
study, we observed that Insulin Glargine induced stronger proliferation than regular insulin 
only in MCF7 cells which are characterized by a high IGF-IR/IR ratio. The mammary 
epithelial cells exhibiting lower IGF-IR/IR ratio responded to Insulin Glargine and regular 
insulin to a similar extent. These observations may explain why the two-year carcinogenicity 
experiment on normal mice and rats reported by Stammberger et al. (2002) did not show a 
significant difference in the incidence of mammary tumors between groups treated with 
Insulin Glargine or regular insulin. As high IGF-IR/IR ratio is observed mostly in tumour 
cells, we assume that Insulin Glargine may act as a tumour promoter rather than a tumour 
initiator. We also hypothesize that Insulin Glargine may be of risk for diabetic patients with 
breast cancer or as yet undetected (pre-) cancerous lesions. In the future, animal studies must 
be carried out to gain more information on the potential tumour promoting effects of Insulin 
Glargine in the mammary gland. Attempts can be made to initiate breast cancer in rats or mice 
by chemical carcinogens and then compare the effect of Insulin Glargine and regular insulin 
on tumour progression. In addition, transgenic mouse models of breast cancer should be 
analysed.  
We reported preliminary experiments to study the migratory and invasive potency of Insulin 
Glargine in comparison to regular insulin. Our results show slightly higher migratory potency 
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of Insulin Glargine relative to regular insulin. As a diabetic patient is on insulin therapy for 
lifelong even a slight increase can compromise the health of the diabetic patient. A detailed 
and comprehensive study of migratory and invasive potency of Insulin Glargine must be 
performed.   
Our study reveals that Insulin Lispro and Insulin Detemir where equipotent to regular insulin 
regarding mitogenicity. However, in comparison to regular insulin, Insulin Aspart had slightly 
increased proliferative effect at all concentrations in MCF7 cells. Nowadays, doctors 
prescribe one short acting insulin analogue together with one long acting insulin analogue for 
better control of glycaemia and there are reports that Insulin Glargine and Insulin Aspart are 
prescribed together (Garber, 2006). Our results suggest that this particular combination 
(Insulin Glargine + Insulin Aspart) may pose a higher safety risk compared to any of them 
administered alone. There is no information about the proliferative potency of such 
combinations. Thus, there is urgent need to compare the proliferative ability of regular insulin 
with the combination of Insulin Aspart and Insulin Glargine.  
Last but not least, type II diabetes, which is characterized by hyperinsulinemia has been 
reported to be positively associated with the risk to develop not only breast cancer but also 
cancer in other organs such as colon, pancreas and prostate (Key, 2001; Silverman, 2001; 
Giovannucci, 2007; Venkateswaran et al., 2007). A similar study as presented in this thesis 
must also be carried out with respect to the proliferative potency of insulin analogues on 
colon, pancreas and prostate cell lines.  
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5 MATERIALS 
5.1. Equipment 
Name of the Equipment  Name of the Company 
General Equipments 
Analytical balance 2002 MP1  Sartorius, Göttingen, Germany 
Blotting chamber for wet blotting  Sigma, Deisenhofen, Germany 
Centrifuge GPK  Beckman Instruments, München , Germany 
Centrifuge for Eppendorf tubes Biofuge  Heraeus, Hanau, Germany 
CHROMO4 System for Real-Time PCR Detection MJ Research, Miami, USA 
Heating block Dri Block DB3  Thermo-Dux, Wertheim, Germany 
Luminometer Biolumat LB9505    Berthold, Bad Wildbad, Germany 
Magnetic stirrer MR 2002 Heidolph, Kelheim, Germany 
Microscope camera DFC 480 Leica Microsystems, Solms, Germany 
Microwave Micromat 135 AEG, Nürnberg, Germany 
Multiplate ® PCR plates Bio-Rad, Hercules, CA, USA 
Multiskan Ex (Plate Reader) Thermo Fisher Scientific, Dreieich, Germany 
Nanodrop Peqlab, Erlangen, Germany 
PCR Primus96 Plus machine MWG Biotech, Martinsried, Germany 
PTC-200 Peltier Thermal Cycler MJ Research, Miami, USA 
pH electrode InLab 410 Mettler Toledo, Steinbach, Germany 
pH meter 535 Multical WTW, Weilheim, Germany 
Photometer Ultrospec III Amersham Pharmacia Biotech, Freiburg, 
Germany 
Pipetboy acu Integra, Hamburg, Germany 
Powersupply EPS 300 Amersham Pharmacia Biotech, Freiburg, 
Germany 
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Refrigerated centrifuge “fresco” Heraeus, Hanau, Germany 
SDS-PAGE Mini Protean II and III Bio-Rad, München, Germany 
Spin-over rotator Bioblock Novodirect, Kehl, Germany 
Thermomixer compact Eppendorf, Hamburg, Germany 
Water-purification system Milli-Q  Millipore, Eschwege, Germany 
Vortex mixer Bender u. Hobein AG, Zürich, Switzerland 
X-ray film developer Hyperprocessor Amersham Pharmacia Biotech, Freiburg,  
Germany 
Cell Culture Equipments 
Humidified CO2 incubator Forma Scientific, Labotech Göttingen, 
Germany 
Microscope (phase contrast) Leica Microsystems, Solms, Germany  
Neubauer hemacytometer Schott, Hofheim, Germany 
Sterile bench Heraeus, Hanau, Germany 
 
5.2. Chemicals  
If not otherwise mentioned, all chemicals used in the present study were of analytical grade and 
sourced from following companies: Merck (Darmstadt, Germany), Roche (Mannheim, Germany), and 
Sigma (Deisenhofen, Germany). All consumables for cell culture work were of cell culture grade and 
sourced mainly from Becton and Dickenson Labware (Heidelberg, Germany), Eppendorf (Hamburg, 
Germany) and Greiner Bio-One (Frickenhausen, Germany).  
Name of the chemical Name of the company 
General Chemicals 
Acrylamide/bis-acrylamide, 30% solution Sigma, Deisenhofen, Germany 
Ammonium persulfate Merck, Darmstadt, Germany 
Bovine serum albumin, 30% solution Bio Rad, München, Germany 
Bromophenol blue Serva, Heidelberg, Germany 
Complete mini EDTA-free protease inhibitor cocktail tablet Roche, Mannheim, Germany 
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DC protein assay kit Bio Rad, München, Germany 
Dimethyl sulphoxide (DMSO)   Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Sigma, Deisenhofen, Germany 
dNTPs mix  Stratagene, Amsterdam, The 
Netherlands 
ECL-plus reagent Amersham Pharmacia Biotech, 
Freiburg, Germany 
Luciferase assay reagent (LAR)   Promega, Mannheim, Germany 
Luciferase cell culture lysis 5 x reagent Promega, Mannheim, Germany 
β-Mercaptoethanol Sigma, Deisenhofen, Germany 
Milk powder Fluka, Buchs, Switzerland 
Oligonucleotide PCR primers Operon, Köln, Germany 
Paraformaldehyde (PFA) Merck, Darmstadt, Germany 
Protein A agarose beads Roche Diagnostics, Mannheim, 
Germany 
PVDF-membrane Immobilon-P Millipore, Eschwege, Germany 
SYBR green supermix Bio Rad, München, Germany 
N,N,N’,N’-tetramethyl ethylenediamine (TEMED) Serva, Heidelberg, Germany 
Tris-base Sigma, Deisenhofen, Germany 
Tris-HCl Roth, Karlsruhe, Germany 
Triton X-100 Serva, Heidelberg, Germany 
Tween-20   GERBU, Gaiberg, Germany 
X-ray film Konica, Tokyo, Japan 
Cell Culture Chemicals 
Charcoal (Norrit A) Serva, Heidelberg, Germany 
Dextran 60 Serva, Heidelberg, Germany 
EDTA 1 % (w/v) in PBS  Biochrom, Berlin, Germany 
Fetal calf serum (FCS)  Biochrom, Berlin, Germany 
L-glutamine, 200 mM  Biochrom, Berlin, Germany 
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Matrigel R & D Systems, Minneapolis, USA 
Oligofectamine  Invitrogen, Karlsruhe, Germany 
Penicillin/streptomycin (10.000 U/10.000 μg/ml)  Biochrom, Berlin, Germany 
Transwell plates Corning, NY, USA 
Trypsin/EDTA, 0,05 %/0,02 % (w/v) in PBS  Biochrom, Berlin, Germany 
U0126  Calbiochem, Darmstadt, Germany 
Wortmannin Calbiochem, Darmstadt, Germany 
    
5.3. Hormones/Growth factors used 
Name of the compound Name of the company 
17β-estradiol (E2) Sigma, Deisenhofen, Germany 
Actrapid® Novo Nordisk, Bagsvard, Denmark 
Bovine insulin Sigma, München, Germany 
IGF-I R & D Systems, Minneapolis, USA 
Humalog® Lilly Deutschland GmbH, Bad 
Homburg, Germany 
Lantus® Sanofi Aventis 
Levemir® Novo Nordisk, Bagsvard, Denmark 
Novorapid® Novo Nordisk, Bagsvard, Denmark 
     
5.4. Disposable materials 
All disposable laboratory plastic and reaction tubes were sourced from Becton Dickinson (Heidelberg, 
Germany), Bio-Rad (München, Germany), Eppendorf AG (Hamburg, Germany), Greiner 
(Frickenhausen, Germany) and Sarstedt (Nümbrecht, Germany). 
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5.5. Growth Medium 
Name of the medium Name of the company 
Dulbecco’s MEM, 3.7 g/l NaHCO3, 4.5 g/l D-glucose, 
phenol-red free, glutamine-free, pyruvate-free (DMEM) 
Invitrogen, Karlsruhe, Germany 
Mammary Epithelial Growth Medium (MEGM) Provitro, Berlin, Germany 
RPMI 1640, phenol-red free, glutamine-free, pyruvate-
free (RPMI)  
PAA, Cölbe, Germany 
5.6. Cell lines studied 
Cell line 
Growth 
Medium 
Source-Description 
MCF7 DMEM Human (ER+) breast epithelial adenocarcinoma cell line derived from metastatic pleural effusion (DSMZ, Germany) 
MELN DMEM MCF-7 cells (ER+) stably transfected with ERE-controlled luciferase reporter plasmid (Balaguer et al. 2001)  
MDA-MB231 DMEM Human (ER-) breast epithelial adenocarcinoma cell line derived from pleural effusion (ATCC, Wesel) 
HCC1937 DMEM A near-tetraploid  human (ER-) breast epithelial adenocarcinoma cell line (ATCC, Wesel) 
BT474 RPMI-1640 Human (ER+) breast epithelial ductal carcinoma cells isolated from solid invasive tumour (ATCC, Wesel)  
T47D RPMI-1640 Human (ER+) breast epithelial ductal carcinoma cells derived from metastatic pleural effusion (ATCC, Wesel)  
ZR75-1 RPMI-1640 Human (ER+) breast epithelial ductal carcinoma cells derived from ascites (ATCC, Wesel).  
MCF10A MEGM 
Human non-tumorigenic epithelial cell line (ER-) produced by 
long term culture in serum free medium with low Ca++ 
concentration (ATCC, Wesel).  
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5.7. Solutions and media for cell culture work 
M2 
phenol-red free DMEM or RPMI  
Penicillin/Streptomycin 100 U/ml resp. 100 µg/ml 
FCS 10 % 
sodium pyruvate 1 mM 
L-glutamine 2 mM 
DCC solution 
Tris-HCl (pH 8.0) 0.01 M 
Charcoal Norrit A 0.25 % (w/v) 
Dextran 60 0.0025 % (w/v) in distilled H2O 
M3 
phenol-red free DMEM or RPMI 
Penicillin/Streptomycin 100 U/ml resp. 100 µg/ml 
dextran-coated charcoal-treated FCS (DCC-FCS) 10 % 
sodium pyruvate 1 mM 
L-glutamine 2 mM 
M4  
phenol-red free DMEM or RPMI 
Penicillin/Streptomycin 100 U/ml resp. 100 µg/ml 
sodium pyruvate 1 mM 
L-glutamine 2 mM 
MEGM   
serum-free MEGM  
Human recombinant EGF  10 ng 
Hydrocortisone 0.5 µg 
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Insulin  5.0 µg 
BPE 26 mg Protein/2 ml 4.0 µl 
Gentamicin 50.0 µg 
Amphotericin B  50.0 ng 
 
5.8. Description of kits used 
Kit Description Company 
Bio-Rad DC Protein Assay kit For determining protein concentration in cell 
lysates 
Bio Rad, München, 
Germany 
FITC BrdU Flow Kit For BrdU incorporation in proliferating cells  BD Biosciences, 
HD, Germany 
QIAquick gel extraction Extraction of nucleotide fragments from 
agarose gels 
Qiagen,Hilden, 
Germany 
QIAquick PCR purification 
and nucleotide removal 
To purify DNA fragments from enzymatic 
reactions 
Qiagen, Hilden, 
Germany 
RevertAidTMH Minus First 
Strand cDNA Synthesis 
For the synthesis of cDNA from total RNA Fermentas, St.Leon-
Rot, Germany 
RNeasy Extraction of total RNA from cells or tissues Qiagen, Hilden, 
Germany 
 
5.9. siRNA sequences 
Name siRNA references and/or sequences Company 
CT2  Non-targeting siRNA sequence  
(ON-TARGETplus Non-targeting siRNA #2; 
Cat # D-001810-02-05) 
Dharmacon, Lafayette, CO, USA 
IGF-IR IGF-IR targeting sequence (ON-TARGET 
plus SMART pool; Cat # L-003012-00-0005) 
Dharmacon, Lafayette, CO, USA 
 
Materials   93 
IR IR targeting sequence (ON-TARGET plus 
SMART pool; Cat # L-003014-00-0005) 
Dharmacon, Lafayette, CO, USA 
ERα ERα targeting sequence (Cat # N2010) New England Biolabs, Frankfurt, 
Germany 
5.10. Quantitative real time PCR primers 
Name Specificity Organism Length (N) Sequence (5’ → 3’)   Tm (°C) 
SYBR GAPDHfwd GAPDH H.Sapiens 18 AGCCACATCGCTCAGACA 59.9 
SYBR GAPDHrev GAPDH H.Sapiens 19 GCCCAATACGACCAAATCC 60.1 
SYBR CCND1fwd Cyclin D1 H.Sapiens 20 CCTGTCCTACTACCGCCTCA 64.5 
SYBR CCND1rev Cyclin D1 H.Sapiens 18 TGGGGTCCATGTTCTGCT 59.9 
5.11. Buffers and Solutions 
Specification Composition 
Acrylamide solution 
acrylamide/bisacrylamide 30:0.8 in distilled H2O 
APS 
Ammonium Persulfate 10 % (w/v) 
Cell lysis buffer (made in distilled H2O) 
HEPES (pH 7.6) 50 mM 
NaCl 150 mM 
MgCl2 1.5 mM 
Na4P2O7 x 10 H2O 10 mM 
EDTA 2 mM 
Glycerol 10 % (v/v) 
Triton X-100 1.5 % (v/v) 
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Na-Fluoride 100 mM 
Na-Orthovanadate (Na3VO4) 2.7 mM 
Protease Inhibitor Cocktail Tablet 1 (/10 ml)  
LiCl buffer  (made in distilled H2O) 
 
LiCl 1M 
Tris-HCl, pH 8.0 100mM 
Na-Azide 0.1% 
PBS (10 x)  
NaCl 0.86M 
Na2HPO4 0.58M 
NaH2PO4xddH2O 0.17M 
Sample buffer (5 x)  
Tris-HCl (pH 6.7) 50 mM 
DTT 200 mM 
SDS 2 % 
Glycerol 2.5 % 
Bromophenol blue 0.1 % 
β-Mercaptoethanol 1.75 M 
SDS  
10 % made in distilled H2O 
TBS (10 x)  
Tris-HCl (pH 7.6) 0.1 M 
NaCl 1.5 M 
TBS-T  
TBS 1 x 
Tween 0.1 % 
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TE buffer (pH 8.0)  
Tris-HCl 10mM 
EDTA 1M 
Tris-HCl  
Tris solution which pH is adjusted with HCl   
SDS-PAGE gel (10 %, 2 mini gels) 
H2O 4.02 ml 
30 % acrylamide solution 3.3 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10 % SDS 100 µl 
10 % Ammonium Persulfat 50 µl 
Temed 30 µl 
Stacking gel (5 %, 2 mini gels)  
H2O 3 ml 
30 % acrylamide solution 0.66 ml 
1 M Tris (pH 6.8) 1.26 ml 
10 % SDS 50 µl 
10 % Ammonium Persulfat 38 µl  
Temed 30 µl 
Running buffer (1 x) 
Tris-HCl (pH 8.3) 25 mM 
Glycine 250 mM  
SDS 0.1 % 
Protein Standard  
Protein All Blue precision plus standard (Bio- Rad) 
Transfer buffer 
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Tris-base 50 mM  
Glycine 380 mM  
Methanol 20 % 
Blocking buffer  
Non-fat dry milk in TBS/T 5 % 
Stripping buffer 
Tris-HCl (pH 6.7) 62 mM 
β-Mercaptoethanol 7.18 ml 
10 % SDS 200 ml 
5.12. Antibodies 
Primary antibodies 
Name Species Dilution Company 
α IGF-IRβ rabbit (P)     1:1000 Santa Cruz, Heidelberg, Germany 
α IGF- IRβ mouse (M)  1:1000 Upstate, Millipore, Eschwege, 
Germany 
α IR-β rabbit (P)    1:1000 Santa Cruz, Heidelberg, Germany 
α IR-β rabbit  (M)  1:1000 Cell Signaling, NEB, Frankfurt, 
Germany 
α phospho Akt 
(Ser 473) 
mouse (M) 1:1000 Cell Signaling, NEB, Frankfurt, 
Germany 
α phospho GSK3α/β 
(Ser 21/9) 
rabbit (P)    1:800 Cell Signaling, NEB, Frankfurt, 
Germany 
α phospho Erk1/2 mouse (M) 1:1000 
Cell Signaling, NEB, Frankfurt, 
Germany 
α phospho p38 mouse (M) 1:1000 
Cell Signaling, NEB, Frankfurt, 
Germany 
 α Akt-1/2 rabbit (P) 1:1000 Santa Cruz, Heidelberg, Germany 
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α GSK3α/β mouse (M) 1:50,000 BioSource, Solingen, Germany 
α Erk1/2 rabbit(P) 1:1000 
Cell Signaling, NEB, Frankfurt, 
Germany 
α p38 rabbit (P) 1:1000 
Cell Signaling, NEB, Frankfurt, 
Germany 
α phospho Tyr 4G10 mouse (M) 1:1000 
Upstate, Millipore, Eschwege, 
Germany 
IgG rabbit  (P) 1:1000 
Upstate, Millipore, Eschwege, 
Germany 
α β-actin mouse (M) 1:200,000 Abcam, Cambridge, UK 
α ERα rabbit  (P) 1:1000 Santa Cruz, Heidelberg, Germany 
α ERα mouse (M) 1:1000 Novocastra, Newcastle, UK 
α phospho ERα     
(Ser 118) 
mouse (M) 1:5000 
Cell Signaling, NEB, Frankfurt, 
Germany 
P denotes polyclonal and M denotes monoclonal in the above list. 
 
Secondary antibodies 
The secondary antibodies used were tagged with HRP. 
Specificity Species Dilution Company 
α mouse goat 1:20,000 Dianova, Hamburg, Germany 
α rabbit goat 1:1000 Dianova, Hamburg, Germany 
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6 METHODS 
6.1 Cell culture 
6.1.1 Maintenance of various cell lines 
MCF7, MELN (a sub cell line of MCF7 cell line [Balaguer et al., 2001]), MDA-MB231 and 
HCC1937 cells were all maintained in phenol red-free DMEM (4.5 g/liter glucose) containing 
10% FBS and penicillin/streptomycin (100 U/ml / 100 µg/ml, respectively). BT474, T47D 
and ZR75-1 were maintained in RPMI-1640. Three days before the experiment, cells were 
grown in medium supplemented with 10% dextran-coated charcoal-treated FBS (DCC-FBS) 
(prepared as described by Migliaccio et al. (1993)). MCF10A cells were maintained in 
mammary epithelial growth medium (MEGM) supplemented with growth factor cocktail and 
antibiotics. Three days before the experiment, MCF10A cells were cultured in MEGM 
without insulin.  
6.1.2 Cell harvesting 
The growth medium was aspirated from the culture dish. Cells were washed with 3 ml of 
EDTA for 3-4 minutes. Thereafter, cells were incubated with 3-4 ml of Trypsin/EDTA 
solution for 5 minutes except MCF10A cells which detached only after 10 min of 
trypsinisation. Reaction was stopped by adding equal volume of M3 medium into the dish. 
The cells were collected in 15ml/50ml Falcon tubes and then spun at 1000 rpm for 5 minutes. 
The medium was aspirated and cell pellet was resuspended in growth medium. The cell 
number in the cell suspension was determined by counting with Neubauer hemacytometer. 
Cells were plated as per the requirement of the experiment. 
6.1.3 Proliferation assays 
a. Colorimetric method using crystal violet dye 
1 x104 cells/well were plated in a 96-well plate in 10% DCC-FBS medium (M3). After 24 h, 
cells were starved for next 24 h in medium containing 2% DCC-FBS except MCF10A cells 
which were starved in MEGM without insulin. Thereafter, cells were stimulated with insulin 
or insulin analogues every 24 h for total of 72 h, MCF10A cells were stimulated for 48 h. 
Controls remained untreated. At the end of incubation time, cells were washed with 100µl of 
PBS, fixed for 5 min with 100µl of 3% paraformaldehyde in PBS and stained for 10 min with 
100µl of 1% crystal violet dye dissolved in 10% ethanol. Excess crystal violet dye was 
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removed and plates were extensively washed with water to remove traces of unbound crystal 
violet dye. After air drying, the bound dye was dissolved in 100µl of 10% acetic acid. Optical 
density was read at 595 nm using a plate reader (Multiscan MX, Thermo, Dreieich, Germany). 
b. Colorimetric method using XTT 
T47D cells were plated and treated with insulin or insulin analogue as described above. After 
68 h of treatment, tetrazolium salt XTT was added to the cells. Four hours after the XTT 
addition, the optical density of the plate was read at 450nm using a plate reader.     
c. FACS analysis of BrdU incorporation 
MCF7 cells were starved in medium containing 2% DCC-FBS for 24 h and then were 
stimulated with regular insulins and insulin analogues for 16 h. BrdU incorporation was 
allowed by incubating cells with 10µM BrdU for 1 h and the whole process was carried out as 
suggested in the Manual of the Becton Dickinson kit (FITC BrdU Flow Kit). Thereafter, cells 
were submitted to FACS analysis and BrdU incorporation was measured using FACS Calibur 
equipment from Becton Dickinson. BrdU incorporation of insulin treated cells was compared 
with BrdU incorporation in untreated cells. Fold of control was determined by normalizing 
data from treated cells over untreated cells. 
6.1.4 Migration assays 
a. Wound healing assay 
MCF7 cells were plated in a 6-well plate containing M3 medium and allowed to grow till they 
reach confluency. Then, cells were treated for 1 h with 2µg/ml mitomycin C to inhibit cell 
proliferation. The monolayers were scratched using a 200 µl pipette tip, washed with PBS and 
incubated with different concentrations of Actrapid or Lantus (15nM, 150nM or 1.5µM). IGF-
I (15nM) was used as a positive control. Wound was photographed first at the beginning of 
the experiment and then after 3 h, 6 h, 12 h and 21 h. Healing was determined at every 
timepoint by measuring distance between two wound margins. Migration was calculated by 
comparing the healing at the particular timepoint with the initial wound.  
b. Transwell assay 
MCF7 cells were harvested from the culture dish and washed with PBS twice to get rid of the 
serum traces. Cell pellet was resuspended in medium containing 2%DCC-FBS. 1 x 105 cells 
were seeded in the upper chamber of the transwell plate (diameter 6.4mm, pore size 8µm) 
which was inserted in the 24-well plate. Medium containing 2%DCC-FBS (control) or 
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2%DCC-FBS in combination with 15nM Actrapid, 15nM Lantus or 15nM IGF-I was added to 
the lower chamber. Compounds were added freshly every 24 h for 2 days. M4 medium or M2 
medium in the lower chamber acted as negative and positive control, respectively, in this 
experiment. After 48 h, cells from the upper surface of the membrane were removed by cotton 
swab. Cells which had migrated to the lower surface of the membrane were washed with PBS 
twice, fixed with 3% PFA and stained with haematoxylin dye. Membrane was cut out and 
mounted with moviol on microscopic slides. Thereafter, cells were counted by light 
microscopy.    
c. Invasion assay using matrigel 
Basement Membrane Extract (BME) was aliquoted and stored at -80 oC. Before starting the 
experiment, BME was thawed at 4oC and reconstituted with medium containing 2%DCC-FBS 
to prepare a working dilution of 0.8µg/µl. Care was taken not to introduce any bubbles during 
reconstitution. 66µl of this dilution (200 µl/cm2) was added to the transwell insert and left for 
30 minutes at 37oC to gel. The gel was rehydrated by adding 100µl of medium containing 
2%DCC-FBS to the upper chamber and 600µl of medium containing 2%DCC-FBS to the 
lower chamber for at least one hour. Thereafter, medium was removed from the upper 
chamber and 1 x 105 MCF7 cells, resuspended in medium containing 2%DCC-FBS, were 
seeded on it. The lower chamber contained either medium containing 2%DCC-FBS (control) 
or medium containing 2%DCC-FBS in combination with 15nM Actrapid, 15nM Lantus or 
15nM IGF-I. Compounds were added freshly every 24 h for 3 days. M4 medium or M2 
medium in the lower chamber acted as negative and positive control, respectively, in this 
experiment. The transwell plates were incubated for 72 h at 37oC.  
At the end of the experiment, cells were removed from the upper chamber by cotton swab. 
Invaded cells at the lower surface of the membrane were washed with PBS twice, fixed with 
3% PFA and stained with haematoxylin dye. Membrane was cut out and mounted with moviol 
on microscopic slides. Thereafter, cells  were observed and counted by light microscopy.  
6.1.5 Silencing of IGF-IR or IR by transient transfection of MELN cells with 
siRNA 
a. Effect on signalling pathways 
3 x 105 MELN cells were plated in M3 in each well of a 6-well plate. After 24 h, cells were 
transfected with 25nM siRNA either targeting IGF-IR or IR using oligofectamine (10µl/well). 
For control, cells were transfected with 25nM non-targeting siRNA. After 48 h of 
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transfection, cells were starved in M4 for 24 h. At the end of the starvation period, cells were 
left unstimulated or stimulated with 15nM Actrapid, 15nM Lantus or 15nM IGF-I for 10 min. 
To stop the experiment, cells were washed with ice-cold PBS and cell lysate was made by 
standard lysis method. 
b. Effect on cell proliferation 
1 x 104 MELN cells were plated in M3 in each well of a 96-well plate. After 24 h, cells were 
transfected with 25nM siRNA targeting IGF-IR using oligofectamine (2µl/well). For control, 
cells were transfected with 25nM non-targeting siRNA. After 48 h of transfection, cells were 
starved in medium containing 2% DCC-FBS for 24 h. Cells were then treated for next 72 h 
with fresh medium containing 2% DCC-FBS (control) or medium containing 2% DCC-FBS 
supplemented with 150nM Actrapid or 150nM Lantus or 150nM IGF-I. At the end of the 
experiment, medium was aspirated, cells were washed, fixed and stained with crystal violet as 
described in section 6.1.3.a.  
6.2 Biochemistry 
6.2.1 Cell lysis 
a. Standard lysis protocol 
Medium was aspirated and cells were washed with PBS. 500µl – 750µl of ice-cold PBS was 
added to the cells and cells were scraped with a disposable cell scraper. Cell suspension was 
transferred to a 1.5 ml Eppendorf tube and centrifuged at 4°C for 5 min at 1000 rpm. The 
supernatant was discarded and the cell pellet was suspended in ice-cold lysis buffer, incubated 
on ice for 1 h and centrifuged at 4°C for 10 min at 13,000 rpm. The supernatant represented 
the lysate and was used for protein estimation. For long term storage, the lysate was stored at  
- 80oC. 
b. Direct lysis protocol  
In short-term experiments with identical cell numbers per well, lysis was performed directly 
in the plate. For this, medium was aspirated and cells were washed with ice-cold PBS. 100µl 
of 1 x SDS-loading dye was added to each well and plates were left for 15 min on ice with 
intermittent agitation. After 15 min, lysate was collected and boiled and processed as a normal 
SDS sample.   
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6.2.2 Western blotting  
The protein concentration of cell lysate was determined by Bio-Rad DC Protein Assay kit, a 
colorimetric assay based on Lowry assay. The standard curve was generated by measuring 
absorbance values (750nm) of samples with known BSA concentrations (0.25 to 2 mg/ml). 
Each cell lysate was read in duplicates and protein concentration was determined by using the 
BSA standard curve. Protein samples were prepared by adding 5 x SDS buffer to the cell 
lysates and boiling at 95°C for 5 min. The samples were loaded and resolved on a 10% SDS-
polyacrylamide gel. The separated proteins were then electro-blotted on an activated 
Immobilon-P membrane (Millipore, Eschwege, Germany) by the wet transfer method. 
Thereafter, the membrane was incubated for 1 h in blocking buffer at RT, washed three times 
with TBS-T and then incubated overnight at 4°C with specific primary antibody. Excess 
primary antibody on the membrane was removed by washing three times with TBS-T. The 
membrane  was incubated with a peroxidase-labelled secondary antibody for 1 h at RT and 
then was washed three times with TBS-T. Immunoreactive protein bands were detected with 
ECL-plus system from Amersham (GE Healthcare Biotech, Freiburg, Germany). For studying 
the phosphorylation status of proteins of signalling pathways, the membrane was first probed 
for the phosphorylated form and then for the total protein. To probe the membrane a second 
time, the membrane was first stripped by incubating in stripping buffer for 20 min at 60°C and 
then the whole process from blocking step onward was repeated with another primary 
antibody. 
6.2.3 Immunoprecipitation 
50µl of protein-A agarose beads were processed by washing first twice in PBS and then twice 
with lysis buffer. 750µg of protein (cell lysate) together with 2µg of primary antibody was 
added to the washed beads (final volume was 750µl) and left overnight for incubation at 4°C 
on a rotating shaker. Next morning, tubes were centrifuged and supernatant was discarded. To 
remove proteins bound unspecifically, beads were washed thoroughly twice with lysis buffer, 
then two times with LiCl buffer and again twice with lysis buffer (to remove the excess salt). 
Thereafter, beads were suspended in 30µl of 2.5 x  SDS buffer, boiled at 95°C for 5 min to 
separate the protein complex from beads. The beads were subjected to centrifugation at 
10,000 rpm for 10 min and  supernatant was loaded and resolved on 10% SDS-
polyacrylamide gel.  
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6.2.4 Firefly luciferase reporter gene assay  
MELN cells are MCF7 cells stably transfected with ERE controlled firefly luciferase reporter 
gene (Balaguer et al., 2001). 3 x 105 MELN cells per well were plated in M3 in a 6-well plate. 
After 10 h treatment with compounds, cells were washed with PBS and were directly lysed in 
the plate by incubating with 150 µl/well of luciferase lysis reagent for 30 min on ice. Cell 
lysate was collected and centrifugation (10,000 × g, 10 min) was performed to separate cell 
debris from supernatant.  20 µl of the supernatant was mixed with 100µl of luciferase assay 
reagent (Promega, Mannheim, Germany) and luminescence was measured for 1 min at 
560 nm in a luminometer. The luciferase activity (cpm/mg protein) was calculated by 
normalizing luminescence (expressed in counts per minute) with the protein concentration of 
the lysate.     
6.3 Molecular biology 
6.3.1 RNA extraction from cultured cells 
3 x 105 MCF7 cells were seeded per well of a 6-well plate in M3. After 12 h cells were 
starved for 24 h in M4. Cells were stimulated with required compounds for 1 h, 3 h or 6 h. 
After treatment, cells were washed with PBS and incubated for 10 min with the lysis buffer 
from RNeasy kit (Qiagen, Hilden, Germany). For shearing genomic DNA, cell lysate was 
passed 5 times through a fine needle syringe (20 Gauge) and then transferred to Eppendorf 
tubes. From here on RNA purification was performed according to the instructions provided 
in the Manual of the RNeasy kit. RNA bound to the matrix of the column (provided in the kit) 
was eluted by adding 20 μl of nuclease-free water to the column. For maximum yield, elution 
was repeated and thus the total volume of RNA eluted was 40µl.  RNA concentration was 
measured by determining absorbance at 260nm in a Nanodrop device (Peqlab, Erlangen, 
Germany). RNA or DNA is considered pure if absorbance ratio (260nm/280nm) is between 
1.5 and 2.0. Therefore, only those RNA samples which had absorbance ratio between 1.5 and 
2.0 were considered for further processing. For long term storage, RNA samples were kept at 
-80°C. 
6.3.2 cDNA synthesis by reverse transcription 
500ng of total RNA was reverse transcribed to generate cDNA. oligo-dT primers were used 
for producing cDNA and the whole process was performed as suggested in the Manual of 
‘RevertAidTMH Minus First Strand cDNA Synthesis’ kit (Fermentas, St. Leon-Rot, Germany). 
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cDNA, thus synthesised, was purified with the QIAquick PCR purification kit (Qiagen). After 
elution from the matrix, cDNA concentration was measured by determining absorbance at 
260nm in Nanodrop device. Only cDNA samples which showed absorbance ratio 
(260nm/280nm) between 1.5 and 2.0 were considered for quantitative PCR. For long term 
storage, cDNA samples were kept at -20°C.  
6.3.3 Quantitative polymerase chain reaction 
Primers for quantitative PCR were designed using ‘Universal Probe Library’ website of 
‘Roche Diagnostics’. 50ng of cDNA was incubated with 500nM of SYBR Fwd primer and 
SYBR Rev primer. MgCl2 was added to obtain a final concentration of 25mM Mg2+ in the 
reaction. Reaction was started by adding 10 µl of iQ SYBR Green supermix (Bio-Rad, 
München, Germany). PCR amplification was performed following the manufacturer’s 
instructions on PTC-200 Peltier Thermal Cycler (MJ Research, Miami, FL, USA) and the MJ 
OpticonMonitor analysis software, version 3.1 (Bio Rad).  
6.4 Statistical analysis 
Immunoblots were quantitatively evaluated using ImageJ software (NIH, USA). Signal 
intensities of phospho-proteins were normalized to the corresponding protein signals. Data are 
presented as mean ± SD of at least three independent experiments. Significance of differences 
between groups was calculated by t-test. Proliferation assays (dose-response curves) were 
evaluated using a four-parametric log-logistic model (Ritz and Streibig, 2005) and t-tests in a 
multiple contrast testing approach (Hothorn et al., 2008). P-values below 0.05 were 
considered statistically significant. 
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ABBREVIATIONS 
  
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
AF1 Transcriptional Activation Function1 
AF2 Transcriptional Activation Function2 
APS  adaptor protein containing PH and SH2 domains  
ATP Adenosine Triphosphate 
BSA Bovine Serum Albumine 
cAMP cyclic AMP 
Cdk Cyclindependent kinase  
Cdk2 Cyclin dependent kinase 2  
cDNA complementary or copy DNA 
CNS Central Nervous System 
CO2 Carbon Dioxide  
COX2 Cyclooxygenase2 
cpm counts per minute 
CREB cAMP Response Element Binding protein 
cSrc Cellular homologue of vSrc 
DBD DNABinding Domain   
DCC DextranCoated Charcoal 
DCIS Ductal Carcinoma In Situ 
DHEA Dehydroepiandrosterone 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribonucleic Acid 
dsDNA doublestranded DNA 
dNTPs deoxynucleotides Triphosphate 
DTT Dithiothreitol  
ECL Enhanced Chemiluminescence 
EDTA Ethylen diaminetetraacetic Acid  
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
eIF2B eukaryotic Initiation Factor 2B 
ER Estrogen Receptor 
ERα Estrogen Receptor alpha 
ERβ Estrogen Receptor beta  
ERE Estrogen Response Element 
ERK Extracellular signalRelated Kinase  
ER ERα negative 
E2 17βEstradiol 
FBS Foetal Bovine Serum 
FCS Foetal Calf Serum 
FGFR Fibroblast Growth Factor Receptor 
Fos nuclear DNA binding protein (product of the cFos protooncogene) 
Fwd primer Forward primer 
GAPDH Glyceraldehyde3Phosphate Dehydrogenase 
Gab1 Grb2-associated binder-1  
GDP Guanosine diphosphate 
GF Growth Factor 
GFP Green Fluorescence Protein 
GLUT glucose transporter 
GMCC Protein kinases group including GSK, MAPK, Cdk and CTD kinases. 
GMP Guanosine Monophosphate 
Grb2  Growth factor receptor bound protein 2 
GSK3α/β Glycogen Synthase Kinase3alpha/beta 
h hour 
H & E Hematoxylin and Eosin 
HCl Hydrochloric acid 
Abbreviations   121 
HEPES  4(2Hydroxyethyl)1Piperazineethanesulfonic acid  
HEPES/KOH HEPES/Potassium hydroxide 
HER2 Human epidermal growth factor receptor 2 or ErbB2 
HRP Horseradish Peroxidase 
HRT Hormone Replacement Therapy  
IDC  Invasive Ductal Carcinoma 
IGF-I Insulin Like Growth Factor-I  
IGF-II Insulin Like Growth Factor-II 
IGF-IR Insulin Growth Factor –I Receptor 
IGFBP Insulin Growth Factor Binding Protein 
IgG Immunoglobulin G 
IHC Immunohistochemistry 
ILC Invasive Lobular Carcinoma 
IL6 Interleukin6 
IR Insulin Receptor 
IR-A  Insulin Receptor isoform lacking exon 11 
IR-B  Insulin Receptor isoform with full transcript 
IRS Insulin Receptor Substrate 
JNK cJun Nterminal kinase  
Jun nuclear DNA binding protein (product of the cJun protooncogene) 
KCl Potassium Chloride 
kDa kilo Dalton 
l litre 
LAR Luciferase Assay Reagent 
LBD Ligand Binding Domain  
LCIS  Lobular Carcinoma In Situ 
m milli 
M Molar 
MAPKAPK1 MAPKActivated Protein Kinase 1 or p90Rsk 
MAPK MitogenActivated Protein Kinase 
MEK MAPK/ERK kinase  
µ micro 
min minutes 
M6PR Mannose 6-Phosphate Receptor or IGF-II receptor 
MMTV Mouse Mammary Tumor Virus 
MNAR Modulator of Nongenomic Action of estrogen Receptor 
mRNA messenger RNA 
mTOR mammalian Target Of Rapamycin 
Myc protein inducing cell growth and encoded by the cMyc protooncogene 
MW molecular weight 
NaAc Sodium Acetate 
NaCl Sodium Chloride 
Na2CO3 Sodium Carbonate 
NaF Sodium Fluoride 
Na2HPO4 Disodiumhydrogenphosphate 
NaH2PO4 Sodium dihydrogen phosphate  
NaN3 Sodium azide 
NaOH Sodium hydroxide 
Na3VO4 Sodium orthovanadate 
NCAM Neural CellAdhesion Protein  
NCI National Cancer Institute (USA) 
NFAT  Nuclear Factor of Activating T cells 
NFκB Nuclear Factor kappa B 
NGF Nerve Growth Factor  
NIH National Institutes of Health (USA)  
NLS Nuclear Localization Signal 
NPH  Neutral Protamine Hagedorn 
nm nanometres  
O.D. Optical Density 
O/N Overnight 
PAGE Polyacrylamide Gel Electrophoresis  
PBS Phosphate Buffered Saline 
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PCR Polymerase Chain Reaction 
PDK1/2 3PhosphoinositideDependent Protein Kinase1/2  
PFA Paraformaldehyde 
PH domain Pleckstrin-homology domain 
PKA Protein Kinase A 
PKB Protein Kinase B or Akt 
PKC Protein Kinase C 
PI3K Phosphatidylinositol 3Kinase 
PIK3CA Gene encoding the PI3K Catalytic subunit (p110 Alpha) 
PTB domain Phosphotyrosine-binding domain 
PTK Protein Tyrosine Kinase 
PVDF Polyvinylidenfluoride 
p38 MAPK Mitogen Activated Protein Kinase p38 
Rev primer Reverse Primer  
RNA Ribonucleic acid 
RNAi RNA interference 
RNase Ribonuclease 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute cell culture medium 
Rsk Ribosomal S6 Kinase or MAPKAPK1 
RT Room Temperature 
RTK Receptor Tyrosine Kinase 
RTPCR Reverse Transcriptase Polymerase Chain Reaction 
SDS Sodium Dodecyl Sulfate 
sec seconds 
SEM Standard Error of the Mean 
Ser (S) Serine, amino acid 
Shc Src-homology-2-containing protein 
SH2 domain Src-homology-2 domain 
siRNA small interfering RNA 
SNPs SingleNucleotide Polymorphisms  
SYBR SYBR green (DNA intercalating dye) 
TAE Tris Acetate EDTA buffer 
TBS Trisbuffered saline 
TBS-T TBS-Tween 20 
TE TrisEDTA buffer 
TEMED N, N, N’, N’Tetramethyl ethylenediamine 
Tm melting Temperature 
Tris trishydroxymethylaminomethane 
U Unit of the enzyme activity 
UV Ultraviolet 
vSrc Oncoprotein encoded by Rous sarcoma virus 
v/v volume per volume 
w/v weight per volume 
 
Erklärung   123 
 
ERKLÄRUNG 
Hiermit erkläre ich, Ashish Shukla, daß ich die vorliegende Dissertation selbst angefertigt 
habe und keine anderen als die aufgeführten Hilfsmittel und angegebenen Quellen benutzt 
habe. Ich habe die vorliegende Arbeit an keiner anderen in- oder ausländischen Fakultät 
eingereicht. 
 
Heidelberg, 27. November 2008 
 
 
 
Ashish Shukla 
 
 
Acknowledgements   124 
ACKNOWLEDGEMENTS 
 
I thank Prof. Dr. Doris Mayer for this interesting project. Her guidance and knowledge has 
allowed me to enhance my scientific expertise and awareness. Due to her observational skills, 
I have become more careful scientist. 
   
I also thank my other PhD supervisors, namely Prof. Dr. Lutz Gissmann and Dr. Stephan 
Herzig for their interesting discussion regarding my project and its aims. Moreover, I thank 
Prof. Dr. Bernhard Dobberstein and Prof. Dr. Bernd Bukau to take part in my examination 
committee.  
 
I thank Dr. Milen Kirilov for his help in designing primers for quantitative PCR.  Along with 
him, I thank Dr. Jan Rodriguez for valuable help in analysing quantitative PCR data. I thank 
Nitin Patil for guiding me whenever I was stuck in carrying out molecular biology.   
 
I thank Alexander Hermani and Jean Grisouard for their help in troubleshooting, analysis of 
data and excellent scientific discussions. Regarding scientific discussions, I will also like to 
thank Anke Petzold, Katrin Hahn and Nibedita Gupta. 
 
I thank Raphael Bleiler and Katharina Becke for their valuable technical assistance. In this 
regard, special thanks to Gabriele Rincke. I thank Anke Petzold for her help with microscope. 
I thank Nibedita Gupta for her help with luciferase assay and immunoprecipitation.  
 
I thank all my lab colleagues, Biswajit Mukerjee, Bogdan Munteanu, Elif Cholak, Milan, 
Zlatko Radev for the pleasant working atmosphere. Special thanks to Gabriele Rincke for 
always correcting my Indian-German. 
 
I thank Kabeer, Rashmi, Nibedita and Shazia for helping me with thesis writing.  
 
PhD in DKFZ has been a nice opportunity to meet students from other fields. In this regard, I 
will like to thank Kiran Maß for helpful discussions and her valuable advices.   
 
During the PhD tenure, the Indian Students Association (ISA) of Heidelberg has often been 
my refuge, my platform to avoid nostalgic feelings and through it I had opportunity to meet 
Acknowledgements   125 
highly talented students. I will like to specially acknowledge Alok and Vijayan as the skits 
directed by them allowed me to realize my own creative self. I thank all my skit-colleagues 
(Alok, Arun, Deepitha, Kabeer, Kannabiran, Jonnah, Lucas, Meeta, Ram, Sadanand Sarvanan, 
Sashidhar, Shipa,and Vijayan) for the funny and artistic break from the monotony of daily 
life.  
 
My special thanks to Vanitha and Kabeer, two Homo sapiens who buffeted me from most of 
the emotional disturbances. I will also like to thank Nitin, Pooja and Hritvik, who have been a 
family to me in Heidelberg. I thank my roommates – Bhaskar, Prasad and Lakshmi (Mr. 
President) – for the great food and equally great discussions. I extend special thanks to 
Lakshmi for taking care of me whenever I was ill.  
 
Last but not least, I will like to thank other ISA members (Irfan, Kalai, Mohini, Nitin Patil, 
Prachiti, Ranjeet, Obul, Sowjanya, Suresh, Sharada) for making my stay lively and peaceful. 
 
 
 
 
Publications    126 
 
PEER-REVIEWED PUBLICATIONS  
Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H & Mayer D Analysis of 
signaling pathways related to cell proliferation stimulated by insulin analogs in human 
mammary epithelial cell lines. Endocr Relat Cancer (Manuscript under revision). 
Hermani A, Shukla A, Rincke G, Medunjanin S, Werner H & Mayer D Insulin-like growth 
factor binding protein-4 and -5 modulate ligand dependent estrogen receptor-α activation in 
breast cancer cells in an IGF independent manner. Endocrinology (Manuscript under 
revision). 
Mayer D, Shukla A & Enzmann H 2008 Proliferative effects of insulin analogues on 
mammary epithelial cells. Arch Physiol Biochem 114 38-44. 
Grisouard J, Medunjanin S, Hermani A, Shukla A & Mayer D 2007 Glycogen synthase 
kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for 
full transcriptional activity of the receptor. Mol Endocrinol 21 2427-2439. 
 
POSTERS PRESENTED 
Shukla A, Bleiler R, Becker K, Enzmann H & Mayer D 2008 Mitogenic potency of insulin 
analogues. 33rdFEBS-IUBMB Meeting, Athens, Greece.  
Grisouard J, Medunjanin S, Hermani A, Shukla A & Mayer D 2007 Glycogen synthase 
kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for 
full transcriptional activity of the receptor. ZMBH-FSPA Retreat, Altleiningen, Germany. 
Shukla A, Bleiler R, Becker K, Enzmann H & Mayer D 2008 Mitogenic potency of insulin 
analogues. 3rdDKFZ Alumni Meeting, Heidelberg, Germany.  
Shukla A, Bleiler R, Becker K, Enzmann H & Mayer D 2007 Effect of insulin analogues on 
human mammary cell lines. Deutsch-Indischer Workshop, Heidelberg, Germany. 
Shukla A, Bleiler R, Becker K & Mayer D 2007 Effect of insulin analogues on human 
mammary cell lines. Graduate Students Forum, Heidelberg, Germany  
Shukla A, Bleiler R & Mayer D 2006 Effect of insulin analogues on breast cancer cell lines. 
DKFZ PhD Retreat, Weil der Stadt, Germany. 
Curriculum vitae    127 
 
CURRICULUM VITAE  
PERSONAL INFORMATION 
First Name  Ashish 
Last Name Shukla 
Birth Date 26th February 1980 
E-mail  ashishshukla@email.com 
Nationality  Indian 
EDUCATION 
2005-2008 PhD German Cancer Research Centre (DKFZ)  
Heidelberg, Germany  
2003-2005  JRF Tata Institute of Fundamental Research 
Mumbai, India 
2001-2003 M.Sc. Jawaharlal Nehru University 
New Delhi, India 
1997-2001 B.Sc. Chhatrapati Shahu Ji Maharaj University, 
Kanpur, India 
RESEARCH EXPERIENCE 
Oct/2005 – Present Project title: 
Insulin analogues: Analysis of proliferative potency and characterization 
of receptors and signalling pathways activated in human mammary 
epithelial cells.  
Publications:  
Mayer D, Shukla A & Enzmann H 2008 Proliferative effects of insulin 
analogues on mammary epithelial cells. Arch Physiol Biochem 114 38-44. 
Grisouard J, Medunjanin S, Hermani A, Shukla A & Mayer D 2007 
Glycogen synthase kinase-3 protects estrogen receptor alpha from 
proteasomal degradation and is required for full transcriptional activity of 
the receptor. Mol Endocrinol 21 2427-2439. 
 
 
Curriculum vitae    128 
 
 
Sept/2003 – Sep/2004 Project title: 
To study the possible interaction of hRad51 and hRad52 with MCM 
complex. 
Publications:  
Shukla A, Navadgi VM, Mallikarjuna K & Rao BJ 2005 a cross-talk 
between recombination and replication proteins. Biochem Biophys Res 
Commun 329 1240-1245. 
Project title: 
To characterization binding property of hRad51 and hRad52 to DNA by 
in vitro approach. 
Publications:  
Navadgi VM, Shukla A, Vempati RK & Rao BJ 2006 DNA mediated 
disassembly of hRad51 and hRad52 proteins and recruitment of hRad51 
to ssDNA by hRad52. FEBS J 273 199-207. 
Navadgi VM, Shukla A & Rao BJ 2005 Effect of DNA sequence and 
nucleotide cofactors on hRad51 binding to ssDNA: role of hRad52 in 
recruitment. Biochem Biophys Res Commun 334 696-701. 
ACHIEVEMENTS Cleared twice (Dec. 2003 and Dec. 2002) All-India Junior Research 
Fellowship (JRF) exam held by Council of Scientific and Industrial 
Research (CSIR). 
 
GRE Score: 600/800 in vocabulary skills, 730/800 in quantitative skills 
and 3.5/6.0 in essay writing. 
 
TOEFL Score: 283/300. 
INTERESTS Sports: Chess, computer games especially Age of Empires, gilli-danda 
and kabbadi. 
Others: Cooking, reading novels, 
REFERENCES Personal references available upon request. 
 
  
